Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Shealy YF, Krauth CA, Montgomery JA (1962) J Org Chem 27:2150–2154
Playle AC (1976) Drugs of Today 12:20–23
Kazemifard G, Moattar F, Zia H (1979) Arch Pharm 312:573–577
WM
Loo TL, Householder GE, Gerulath AH et al. (1976) Cancer Treat Rep 60:149–152
Mizuno NS, Decker RW (1976) Biochem Pharmacol 25:2643–2647
Audette RCS, Connors TA, Mandel HG et al. (1973) Biochem Pharmacol 22:1855–1864
Lown JW, Singh R (1982) Biochem Pharmacol 31:1257–1266
Beal DD, Skibba JL, Whitnable KK et al. (1976) Cancer Res 36:2827–2831
Lonn U, Löhn S (1987) Cancer Res 47:26–30
Loo TL, Luce JK, Jardine H et al. (1968) Cancer Res 28:2448–2453
Skibba JL, Ramirez G, Beal DD (1969) Cancer Res 29:1944–1951
Breithaupt H, Dammann A, Aigner K (1982) Cancer Chemother Pharmacol 9:103–109
Benvenuto JA, Hall SW, Farquar D et al. (1979) Chromatogr Sci 10:377–395
Householder GE, Loo TL (1971) J Pharmacol Exp Ther 179:386–395
Comis RL (1976) Cancer Treat Rep 60:165–176
Bonadonna G, Zucali R, Monfardini S et al. (1975) Cancer 36:252–259
Bonadonna G, Valagussa P, Santoro A (1986) Ann Intern Med 104:739–746
Moore GE, Meiselbaugh D (1976) Cancer Treat Rep 60:219
Feaux de Lacroix W, Runne U, Hauk H et al. (1983) Cancer Treat Rep 67:779–784
Carey RW,Kunz VS (1987) Am J Hematol 25:119–121
OJ
Brockmann H, Lackner H (1964) Die Naturwissenschaften 16:384–385
Okawa K, Nakajima K, Tanaka T (1980) J Heterocycl Chem 17:1815–1816
WM
Frei E (1974) Cancer Chemother Rep 58:49–54
Schmoll H-J, Peters H-D, Fink U (1986) Kompendium internistische Onkologie, Teill. Springer, Berlin Heidelberg New York Tokyo
Heenen M, Preumont AM, Galand P (1973) Cancer Res 33:2.624–2.626
Ross WE, Glaubiger DL, Kohn KW (1979) Biochem Biophys Acta 562:41–50
Gause GF, Dudnik YV (1980) Antibiot Chemother 28:102–108
Neidle S, Abraham Z (1984) CRC Crit Rev Biochem 17:73–121
Sobell HM (1973) Progr Nucleic Acid Res Mol Biol 13:153–159
Chabner BA, Myers CE (1982) Clinical pharmacology of cancer chemotherapy. In: De Vita jr V, Hellmann S, Rosenberg SA (Hrsg.) Cancer. Principles and Practice of Oncology. Lipincott, Philadelphia Toronto, S. 156–197
Dabrowiak JC (1983) Life Sci 32:2.915–2.931
Giannini L, Bonadonna G (1988) Antitumor antibiotics. In: Bonadonna G, Robustelli delle Cuna G (Hrsg.) Handbook of Medical Oncology, Masson, Milano Parigi Barcelona Mesico, S. 359–360, 1.063
Reich E, Franklin RM, Shatkin AJ (1962) Proc Natl Acad Sci USA 48:1.238–1.245
Biedler JL Chang TD, Meyers MB, Peterson RH, Spengler BA (1983) Cancer Treat Rep 67:859–867
Kessel D (1986) Cancer Surv 5:109–127
Grossberg SE (1972) 2. N Engl J Med 287:79–85
Vermund H (1971) Acta Radiol Suppl Stockh 311:1–78
Goffinet DR, Bagshaw MA (1974) Cancer Treat Rev 1:15–26
Thiel HJ, Fietkau R, Sauer R (1988) Rec Res Cancer Res 108:205–226
Fromm M, Littman P, Raney RB, Nelson L, Handler S, Diamond G, Stanley C (1986) Cancer 57:2.070–2.076
Galbraith WM, Mellet LB (1975) Cancer Chemother Rep 59:1.061–1.069
Tattersall MHN, Sodergren JE, Sengupta SK, Trites DH, Modest EJ, Frei III E (1975) Clin Pharmacol Ther 17:701–708
Emmanuel IC (1969) B J Radiol 42:948–952
Jereb B (1971) Acta Radiol Ther Biol 10:417–426
Haas RJ, Devens K, Helmig M, Janka G, Klose H, Lampert F (1978) Onkologie 1:142–148
Meuret (1978) Dtsch Med Wochenschr 103:308–313
Tebbi CK, Gaeta J (1988) Pediatr Ann 17:283–300
Ebeling K, Bielek K (1978) Zentralbl Gynäkol 100:897–912
Edson M (1979) J Urol 122:763–765
Tscherne H, (1979) Wien Klin Wochenschr Suppl 103:1–21
Obrist R, Hartmann D, Obrecht JP (1978) Onkologie 1:20–22
Baas PC, Hoekstra HJ, Schraffordt-Koops H, Oosterhuis JW, Oldhoff J (1989) Arch Surg 124:373–376
Chakravorty NK (1979) Gerontology 25:151–158
Strian F, Maurach R (1980) Med Klin 75:478–484
Levantine A, Almeyda J (1974) B J Dermatol 90:239–242
Ferguson MK (1982) Surg Gynecol Obstet 154:421–429
Harris CC (1976) Cancer 37:1.014–1.023
Best JB, Morita M (1982) Teratogenesis Carcinog Mutagen 2:277–291
Mw
Barbieri RL, Lee H, Ryan KJ (1979) Fertil Steril 31:182–186
Shaw RW (1992) Lancet 340:1.267–1.271
Barbieri RL, Canick JA, Makris A, Davies IJ, Ryan KJ (1977) Fertil Steril 28:809–813
Barbieri RL (1990) Drugs 39:501–510
Hooper WD, Eadie MJ, Dickinson RG (1991) Biopharm Drug Dispos 12:577–582
Saltiel E, Garabendian-Ruffalo SM (1991) Clin Pharm 10:518–531
Deeny M, Hawthorn R, McKay-Hart D (1991) Postgrad Med J 67:450–454
Holt JP, Keller D (1984) Fertil Steril 41:70–74
Barbieri RL, Evans S, Kistner RW (1982) Fertil Steril 37:737–746
vB
White R, Schwan TJ (1976) J Pharm Sci 65:135
Clarke’s Isolation and Identification of Drugs (1986) The Pharmaceutical Press, London, S. 508
Kracmar J, Alvarez Sotolongo M, Kracmarova J (1978) Pharmazie 33:659–661 (UV)
Hollifield RD, Conklin JD (1973) J Pharm Sci 62:271
Lalande M, Mills P, Peterson RG (1988) J Chromatogr 430(1):187
Wuis EW, Grutters ACLM, Vree TB, van der Kleyn E (1982) J Chromatogr 231(1):401
DG
Cedarbaum JM, Schleifer LS (1990) Drugs for Parkinson’s disease, spasticity and acute muscle spasms. In: Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.), Goodman and Gillman’s the pharmacological basis of therapeutics, 8. Aufl., Pergamon Press, New York, S. 463–484
Greef K, Wirth KE (1987) Pharmakologische Beeinflussung der cholinergen Erregungsübertragung. Pharmakotherapeutische Anwendung von Parasympathomimetia, Parasympatholytika und peripheren Muskelrelaxantien. In: Forth W, Hentschler D, Rummel W (Hrsg.) Allgemeine und spezielle Pharmakologie und Toxikologie,5. Aufl., Bibliographisches Institut & F.A. Brockhaus, Mannheim, S. 103–121
Winkle van B (1976) Science 193:1130–1131
Putney SW, Bianchi CP (1973) Fed Proc 32 (part 1):772
Butterfield AC, Ellis KO (1973) Fed Proc 32 (part 1):772
Monster AW, Tamai Y, Mc Henry J, (1974) Arch Phys Med Rehabil 55:355–362
Hermann R, Mayer N, Mecomber SA (1972) Am J Physiol Med 51:296–311
Ellis KO, Castellion AW, Honkomp LJ et al. (1973) J Pharm Sci 62:948–951
Ward A, Caffman MO, Sorkin EM (1986) Drugs 32:130–168
Büch HP, Büch U (1987) Narkotika, Narkose. In: Forth W, Henschler D, Rummel W (Hrsg.) Allgemeine und spezielle Pharmakologie und Toxikologie, 5. Aufl., Bibliographisches Institut & F.A. Brockhaus, Mannheim, S. 1203–1219
Wislon RD, Dent TE, Traber DL, McCoy NR, Allen CR (1967) J Amer Med Ass 202:183
Dykes MHM (1975) J Amer Med Ass 231:862
Product information: Dantrium, Norwich-Eaton, 1985
Morrison DH (1983) Anesthesiology 59:265
Hollifield RS, Conklin JD (1973) J Pharm Sci 62:271
Meyler WJ, Vermeer GA, Agoston S, Wesseling H (1980) Excretion pattern of dantrolen sodium and metabolites in patients with and without cholecystectomy. Abstract No. 0796. Proceeding of the World Conference on Clinical Pharmacology and Therapeutics, London
Mar 29, S. 1232
NB
Mar 29, S. 1.086
vB
Orzech CE, Nash NG, Daley RD (1976) in Ana 5:87
Beilstein 13:536, EII 300, EIII, S. 1246
Gordon GR, Ghoul DC, Peters JH (1975) J Pharm Sci 64.1.205–1.210
Tomicek O (1948) Collect Czech Chem Commun 13:116–130
Wojahn H (1948) Süddtsch Apoth Ztg 88:395–96
Murray JF, Gordon GR, Gulledge CC, Peters JH (1975) J Chromatogr 107:67–72
Ot
Hastings RC, Franzblau SG (1988) Ann Rev Pharmacol Toxicol 28:231–245
Mandell GL, Sande MA (1990) Antimicrobial Agents. Drugs Used in the Chemotherapy of Tuberculosis and Leprosy. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (Hrsg.) The Pharmacological Basis of Therapeutics, 8. Aufl., Pergamon Press, New York Oxford Beijing Frankfurt Sao Paulo Sydney Tokyo Toronto, S.1.146–1.164
Venkatesan K (1989) Clin Pharmcokin 16:365–368
N.N.. (1988) Lancet II:487–488
Treatment of Leprosy, Mar 29, S. 551–552
Monographie Acedapsone, Mar 29, S.553
Monographie Dapsone, Mar 29, S. 558–560
Twose TM (1989) Dapsone and Sulphapyridine. In: Greaves MW, Shuster S (Hrsg.) Pharmacology of the Skin II. Handb Exp Pharmacol 87,II:543–552
Meyer H, Baumann HR, Leuenberger P, Sonntag R (1988) Drugs Used in Tuberculosis and Leprosy. In: Dukes MNG (Hrsg.) Meylers Side Effects of Drugs, 11. Aufl., Elsevier, Amsterdam New York Oxford, S. 633–650
Goldsmith P, Burton JL, Staughton RCD (1989) Immunosuppressive (Cytotoxic) and Immunostimulant Drugs. In: Greaves MW, Shuster S (Hrsg.) Pharmacology of the Skin II. Handb Exp Pharmac 87, II:307–327
Fernex M (1984) Internist 25:208–215
N.N. (1989) Arzneimittelbrief 23:1–4
Kastrup EK (1988) Drugs, Facts and Comparison. Lippincott, St. Louis, S. 1.589–1.591
Fränz J, Windorfer A (1990) Arzneimittel in Schwangerschaft und Stillzeit, 3. Aufl., Wissenschaftliche Verlagsgesellschaft, Stuttgart, S.59
N.N. (1989) Arznei-telegramm 10/89:91–92
Ry
Di Marco A, Acarmone F (1975) Adriamycin and its mechanism of action. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 11–24
Pigram WJ, Fuller W, Hamilton LD (1972) Nature (New Biol) 235:17–19
Chaires JB (1990) Biophys Chem 35:191–202
Schwartz HS (1975) Res Commun Chem Pathol Pharmacol 10:51–64
Casazza AM, Isetta AM, Giuliani M, Di Marco A (1975) Immunodepressive activity of daunomycin and adriamycin. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action, Adriamycin Review, European Press Medikon, Ghent, Belgium, S. 121–131
Maral RJ, Jouanne M (1981) Cancer Treat Rep 65(Suppl4):9–18
Peterson C, Paul C (1983) Pharmacokinetics of doxorubicin and daunorubicin. In: Hansen HH (Hrsg.) Anthracyclines and cancer therapy. Excerpta Medica, Elsevier Science Publishers BV, Amsterdam, S.7–12
Bachur NR, Riggs jr CE, Green MR, Langone JJ, Van Vunakis H, Levine L (1977) Clin Pharmacol Ther 21:70–77
Paul C, Liliemark J, Tidefelt U, Gahrton G, Peterson C (1989) Therapeutic Drug Monitoring 11:140–148
Lenaz L, Di Fronzo G, Molinari R (1975) Distribution of daunomycin and adriamycin in man. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 89–99
Speth PA, Linssen PCM, Termond EFS, Boeseman JBM, Wessels HMC, Haanen C (1989) Drug Metab Dispos 17:98–105
Noel G, Trouet A, Zenebergh A, Tulkens P (1975) Comparative cell pharmacokinetics of daunorubicin and adriamycin. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 99–105
Nooter K, Sonneveld P, Martens A, Hagenbeek A, Schultz F (1986) Eur J Clin Oncol 2:801–806
Benjamin RS, Riggs CE, Bachur NR (1977) Cancer Res 37:1.416–1.420
Huffman DH, Bachur NR (1972) Cancer Res 32:600
Le Bot MA, Bégué JM, Kernaleguen D, Robert J, Ratanasavanh D, Airiau J, Riche C, Guillouzo A (1988) Biochem Pharmacol 37:3.877–3.887
Goldin A, Johnson RK (1975) Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 7–54
Walters TR (1976) Med Clin North Am 60:987–1.000
Gale RP (1984) Ann Intern Med 101:702–705
Steuber CP (1981) Am J Pediatr Hematol Oncol 3:379–388
Von Hoff DD, Rozencweig M, Layard M, Slavik M, MuggiaFM(1977) Am J Med 62:200–208
Von Hoff DD, Layard M (1981) Cancer Treat Rep 65(Suppl4):19–23
Uzuka Y, Saito Y, Takahashi H, Komatu M, Ito T (1989) Rinshoe Ketsueki 30:980–987
Reszka K, Hartley JA, Lown JW (1990) Biophys Chem 35:313–323
Arena E, D’Alessandro N, Dusonchet L, Gebbia N, Gerbasi F, Rausa L (1973) J Antibiotics 26:338
Marzin D, Jasmin C, Maral R, Mathe G (1983) Eur J Cancer Clin Oncol 19:641–647
Mw
Robinson C (1980) Drugs of Today 16:371–373
WM
Haubrich DR, Gerber NH, Pflueger AB (1981) J Neurochem 37:476–482
Lohr J, Acara M (1990) J Pharmacol Exp Ther 252:154–158
Pepeu G, Freedman DX, Giarman NJ (1960) J Pharmacol Exp Ther 129:291–295
Rimland B (1988) J Child Neurol 3(Suppl):68–72
hr
Wenner W (1965) J Med Chem 8:125–126
LJ
Moe RA, Bates HM, Palkoski ZM, Banziger R (1964) Curr Ther 193:194–208
Luria HM, Freis ED (1965) Curr Ther Res 7:289–296
Adi FC, Eze CJ, Anwunah A (1975) Brit Med J 1:482–485
Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR (1977) Br Med J I:422–425
McMahon FG (1984) Peripheral adrenergic blocking agents. In: McMahon FG (Hrsg.) Management of essential hypertension: The new low-dose era, Futura Publishing Company, Inc, Mount Kisco New York, S. 457–497
Medina MA, Giachetti A, Shore PA (1969) Biochem Pharmacol 18:891–901
Allen JG, East PB, Francis JR, Haigh JL (1975) Drug Metab Dispos 3:332–337
Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL (1977) Lancet II:584–586
GW
Kle 82
Wenner W (1965) J Med Chem 8:125–126
Malcolm SL, Marten TR (1976) Analyt Chem 48:807–809
LJ
Blomquist AT, Hallam BF, Josey AD (1959) J Am Chem Soc 81:678–680
Clarke’s Isolation and Identification of Drugs (1986) The Pharmaceutical Press, London, S.510
DG
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Bickel H et al (1960) Helv Clim Acta 43: 2118
HU
Keberle H (1964) Ann N Y Acad Sci 119:758–768
Day JP (1986) Chemical aspects of aluminium chelation by desferrioxamine. In: Taylor A (Hrsg.) Aluminium and other trace elements in renal disease, Baillière Tindall, London, S. 184–192
Pippard MJ, Callender ST, Finch CA (1982) Blood 60:288–294
Allain P, Chaleil D, Mauras Y, Beaudeau G, Varin MC, Poignet JL, Ciancioni C, Ang KS, Cam G, Simon P (1987) Clin Chim Acta 170:331–338
Allain P, Mauras Y, Chaleil D, Simon P, Ang KS, Cam G, Le Mignon L, Simon M (1987) Br J Clin Pharmac 24:207–212
Stremmel W, Niederau C, Strohmeyer G (1988) Dtsch Med Wochenschr 113:1648–1650
Zoller WG, Hehlmann R (1986) Klin Wschr 64:417–422
Hümpfner A (1989) Aluminiumintoxikation bei Niereninsuffizienz, Zuckschwerdt, München, S. 63–68
Milliner DS, Nebeker HG, Ott SM (1984) Ann Intern Med 101:775–780
Gallant T, Boyden MH, Gallant LA, Carley H, Freedman MH (1987) Am J Med 83:1085–1090
Cases A, Kelly J, Sabater J, Campistol JM, Torras A, Montoliu J, Lopez I, Revert L (1988) Clin Nephrol 29:176–178
Gabutti V, Sandri A, Capalbo P, D’Oria A, Sacchetti L, Tricta F, Piga A (1989) Toxicity of desferrioxamine treatment. In: Kattamis C (Hrsg.) Iron overload and chelation in thalassaemia, Hans Huber Publishers, Toronto, S. 26–33
Walker JA, Sherman RA, Eisinger RP (1985) Am J Kidney Dis 6:254–256
Fk
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Mar 29, S. 1.359
vB
Beil Erg. Werk 4, Bd. 10, Teil 5, S.3478
Rj
Okolicsanyi L, Lirussi F, Strazzabosco M, Jemmolo R, Orlando R, Nassuato G, Muraca M, Crepaldi G (1986) Drugs 31:430–448
Bobowiec R, Studzinski T, Sikorska M (1990) Acta Physiol Polon 41:146–154
Boyer J, Klatskin G (1970) Gastroenterology 59:853–859
Bloomer J, Boyer J, Klatskin G (1973) Gastroenterology 65:929–935
Eulenburg F, Bode J (1976) Zeitschr Gastroenterologie 14:354–364
Maurer C (1971) Arzneim Forsch 21:1.375–1.379
Soloway R, Hofmann A, Thomas P, Schoenfield L, Klein P (1973) J Clin Invest 52:715–724
Hardison W (1971) J Lab Clin Med 77:811–820
Yousef I, Mignault D, Weber A, Tuchweber B (1990) Digestion 45:40–51
Roma M, Marinelli R, Rodriguez Garay E (1991) Biochem Pharmacol 42:1.775–1.781
Binder H (1981) Colonic secretion. In: Johnson L (Hrsg.) Physiology of the gastrointestinal tract, Raven Press, New York, S. 1.003–1.019
Hofmann A (1989) The enterohepatic circulation of bile acids in health and disease. In: Sleisenger M, Fordtran J (Hrsg.) Gastrointestinal disease, 4. Aufl., Vol.1, Saunders, Philadelphia, S. 144–161
Cowen A, Korman M, Hofmann A, Thomas P (1975) Gastroenterology 68:1.567–1.573
Yoneda M, Makino I, Tamasawa N, Takebe K, Sakuraba K, Goto J, Nambara T (1989) Amer J Gastroenterol 84:290–295
Adinolfi L, Utili R, Gaeta G, Abernathy C, Zimmerman H (1982) Hepatology 2: Abstract No. 121, S.703
Peters G, Witten D (1971) Minnesota Med 54:787–788
Lindholm A, Henricsson S, Dahlquist R (1990) Br J Clin Pharmacol 29:541–548
Vonk R, Scholtens E, Keulemans G, Meijer D (1978) Naunyn-Schmiedeberg’s Arch Pharmacol 302:1–9
Silverman S, Andrews A (1977) J Natl Cancer Inst 59:1.557–1.559
Cohen B, Raicht R, Deschner E, Takahashi M, Sarwal A, Fazzini E (1980) J Natl Cancer Inst 64:573–578
BJ
Blanc F, Nosny Y, Armgengaud M, Sankale M, Martin M, Charmot G, Nosny P (1961) Bull Soc Pathd Exotique (Paris) 54:29–38
Manson-Bahr PEC, Apted FIC (1982) Manson’s tropical diseases, 18. Aufl., Ballière Tindall, London, S. 132–140
Steck EA (1971) Walter Reed Army Institute of Research, Washington 1:3.132–3.137
Rees PH (1982) Drugs. In: Manson-Bahr PEC, Apted FIC (Hrsg.) Manson’s tropical diseases, 18. Aufl., Ballière Tindall, London, S. 610–636
Powell SJ, Wilmot AJ, MacLeod IN (1967) Ann Trop Med Parasitol 61:26–28
Merchant HC, Shikaripurkar NK (1964) Ind J Med Sci 18:200–209
Werner GT, Stickl H (1976) Med Klin 71:2.254–2.259
Al-Khateeb GH, Molan AL (1981) Chemotherapy 27:117–125
Fourage M, Dewulf M, Couvreur P, Roland M, Vranchx H (1989) J Microencapsul 6:29–34
Bienzle U, Ebert F, Dietrich M (1978) Tropenmed Parasitol 29:188–197
Aguirre Errasti C, Merino Angulo J, Flores Torres M, Rios A de los (1981) Med Clin (Barc.) 76:125–128
Farid Z, Trabolsi B, Boctor F, Hafez A (1986) J Inf Dis 154:920–921
Auer H, Aspoeck H, Picher O, Ploier R, Tulzer W (1981) Wien Klin Wochenschr 93:360–366
Muangmanee L, Aswapokee N, Jaroonvesama N, Viranuvatti V (1974) Southeast Asian J Trop Med Pub Hlth 5:581–585
Hernandez-Perez E (1980) Cutis 25:424–426
Salako LA (1972) J Pharm Pharmac 24:32–39
Webster LT jr (1985) Drugs used in the chemotherapy of protozoal infections amebiasis, giardiasis and trichomoniasis. In: Goodman and Gillman’s the pharmacological basis of therapeutics, 7. Aufl., McMillan, New York Toronto London, S. 1.049–1.057
Rollo IM (1980) Drugs used in the chemotherapy of amebiasis. In: Goodman and Gilman’s The pharmacological basis of therapeutics, 6. Aufl., McMillan, New York, S. 1.066–1.067
Salako LA (1974) W Afr J Pharmac Drug Res 1:13–17
Sharma S (1976) Indian J Med Sci 30:239–240
HA
Miyake A, Itoh K, Oka Y (1986) Chem Pharm Bull 34:2852–2858
MA
Salvetti A (1990) Drugs 40:800–828
MJ
Miyake A, Itoh K, Oka Y (1986) Chem Pharm Bull 34:2.852
Hiroyukil, Mikio Y, Yoshiru U (1985) Fukuoka Igaku Zasshi 76(9):441–450; CA (1986) 104:104902c
MA
Mar 29, S. 1396
vB
Mar 29, S. 728
vB
Keck J, Pueschmann S, Krueger G, Noll K (Thomae, Dr. Karl G.m.b.H.) (1972/74) Dt Pat Ger offen 2251891, zit. nach CA (1974) 81:25327
KU
Walther H, Meyer FP (1987) Klinische Pharmakologie antibakterieller Arzneimittel, Urban & Schwarzenberg, München Wien Baltimore, S. 245–262
Toon S, Rowland M (1979) J Pharm Pharmacol 31:43P
Münch R (1981) Schweiz Apoth Ztg 119:222–226
fm
McCormick JRD et al. (1957), J Am Chem Soc 79:4561–4563
Casy AF, Yasin A (1983), J Pharm Biomed Anal 1:281–292
Asleson GL, Frank CW (1975), J Am Chem Soc 97: 6246–6248
Am Cyanamid Co, USP 2878289 (1959), zit. nach CA (1959) 53:9584c
Gd
Clarke EGC (1974) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 21
Fox RH (1969) Paper Chromatography. In: Clarke EGC (Hrsg.) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 34
Curry AS (1969) Thin-layer Chromatography In: Clarke ECG (Hrsg.) Isolation and Identification of Drugs, The Pharmaceutical Press, London, S. 46
WM
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
McCormick JRD et al. (1957) Jam Chem Soc 79:4561–4562
Gd
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Hafely W, Kyburz E, Gerecke M, Möhler H (1985) Adv Drug Res 14:165–322
Greenblatt DJ, Shader RI (1974) Benzodiazepines in clinical practice, Raven Press, New York
Wm
Nardi D, Tajana A, Leonardo A, Pennini R, Portioli F,Magistretti MJ, Subissi A (1981) J Med Chem 24:727
Tajana A, Sibili C, Cappeletti R, Cova A, Nardi D (1986) Boll Chim Farm 125:7–20
PA
Mar 29, S.400
vB
Tajana A, Sibili C, Cappeletti R, Cova A, Nardi D (1986) Boll Chim Farm 125:7–20
PA
Van der Stelt C, Harms AF, Nauta WT (1961) J Med Pharm Chem 4:335–349
Beilsteins Handbuch der Organischen Chemie EV21/1,S.224
Moffat AC, Jackson AV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
Van der Stelt C, Funcke ABH, Tersteege HM, Nau taWT (1966) Arzneim Forsch 16:1342–1345
MP
Mar 29, S.451
EH
Austin WC, Potter MD, Taylor EP (1958) J Chem Soc:1.489–1.898
Aka T, Soda K, Adachi T, Kitano K, Ono S (1965) Jap Pat 5835 (’65), zit. nach CA 62:16213 f
Attwood D, Natarajan R (1979) J Pharm Pharmacol 32:460–462
Eigene Untersuchungen
Surmann JP, Glienke M (1988) Fresenius’ Z Anal Chem 331:630–633
Pinzauti S, La Porta E (1977) Analyst 102:938–942
hh
Kramer A, Wallhäußer KH (im Druck) Wirkungsspektrum und Anwendungseigenschaften häufig aus prophylaktischer Indikation angewendeter Antiseptika. In: Kramer A, Weuffen W, Gröschel D, Heeg P, Hingst V, Lippert H, Rotter M (Hrsg.) Klinische Anwendung von Antiseptika, Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo Hing Kong Barcelona
Tatra G (1972) Muench Med Wochenschr 114:773–776
Mühlbauer W (1972) Therapiewoche 22:1.416–1.417
Gjermo P, Baastad KL, Rölla G (1970) J Periodont Res 5:102–109
Raitano A (1981) Disinfettanti, Medico Farmaceutica, Milano
Kramer A, Rozsahegyi I, Weuffen W (1985) Chronische Vergiftungen durch Antiseptika. In: Kramer A, Berencsi G, Weuffen W (Hrsg.) Handbuch der Antiseptik, Bd. I/5, Toxische und allergische Nebenwirkungen von Antiseptika, Volk Und Gesundheit, Berlin, S.218
Ludewig R, Lohs KH (1988) Akute Vergiftungen, Fischer Verlag, Jena, S. 49–50
ak
Bláha L, Weichet J, Žváćek J, Šmolík S, Kakáć B (1960) Coll Czech Chem Commun 25:237–243
Klohs MW, Keller F, Williams RE, Kusserow GW (1955) J Am Chem Soc 77:4.084–4.087
Stoll A, Hoffmann A (1955) J Am Chem Soc 77:820–821
Neuss N, Boaz HE, Forbes JW (1955) J Am Chem Soc 77:4.087–4.090
Kle 82, S.272
LJ
Cicco C F (BOC Inc) Eur Pat Appl Ep 388,144 ( Cl. C07C41/22) 1990, US Appl 323,579 1985, zit. nach CA (1991) 114:121477s
Robin M L, Halpern D F, (BOC Inc) Eur Pat Appl Ep 341,004, zit. nach CA (1990) 112:178052n
QO
Mar 29, S.476
EH
Eger EI (1992) Anesth Anaig 75: Suppl 4, S3–S7
Rampil IJ, Lockhart SH, Zwass MS, Peterson N, Yasuda N, Eger EI, Weiskopf RB, Damask MC (1991) Anesthesiol 74:429–433
Ghouri AF, Bodner M, White PF (1991) Anesthesiol 74:419–424
Litt L, Lockhart S, Cohen Y, Yasuda N, Kim F, Freire B, Laster M, Peterson N, Taheri S, Chang LH (1991) Ann N Y Acad Sci 625:707–724
Smiley RM (1992) Anesth Anaig 75:Suppl 4, S38–S44
White PF (1992) Anesth Anaig 75: Suppl 4, S47–S53
Yasuda N, Lockhart SH, Eger EI; Weiskopf RB, Johnson BH, Freire BA, Fassoulaki A (1991) Anesthesiol 74:489–498
Koblin DD (1992) Anaesth Anaig 75:Suppl 4, S10–S16
Fassoulaki A, Lockhart SH, Freire BA, Yasuda N, Eger EI, Weiskopf RB, Johnson BH (1991) Anesthesiol 74:479–483
Zwass MS, Fisher DM, Welborn LG, Cote CJ, Davis PJ, Dinner M, Hannallah RS, Liu LM, Sarner J, McGill WA (1992) Anesthesiol 76:373–378
Wedel DJ, Iaizzo PA, Milde JH (1991) Anesthesiol 74:508–512
Sebel PS, Glass PS, Fletcher JE, Murphy MR, Gallagher C, Quill T (1992) Anesthesiol 76:52–59
vB
Kielholz P, Labhardt F, Battegay R, Rümmele W, Feer H (1963) Dt Med Wochenschr 88:1.617–1.624
Bickel MH (1968) Untersuchungen zur Biochemie und Pharmakologie der Thymoleptika. In: Jucker E (Hrsg.) Fortschritte der Arzneimittelforschung, Bd. 11, Birkhäuser Verlag, Basel Stuttgart, S. 121–225
Baldessarini RJ (1982) McLean Hosp J 7:1–27
Baldessarini RJ (1989) J Clin Psychiat 50:117–126
Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (Hrsg.) Goodman and Gilman’s The pharmacological basis of therapeutics, 8th edition, Macmillan, New York, S. 383–435
Shopsin B, Cassano GB, Conti L (1981) An overview of new “second generation” antidepressant compounds: research and treatment implications. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S.219–251
Richelson E, Pfenning M (1984) Eur J Pharmacol 104:277–286
Shein K, Smith SE (1978) Br J Pharmacol 62:567–571
Richelson E, Nelson A (1984) J Pharmacol Exp Ther 230:94–102
Sulser F (1983) Psychopharmacol Bull 19:300–304
Nielsen M, Braestrup C (1977) Naunyn-Schmiedeberg’s Arch Pharmacol 300:87–92
Mobley PL, Sulser F (1981) Down-regulation of the central noradrenergic receptor system by antidepressant therapies: biochemical and clinical aspects. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 31–51
MacMillan BA, Warnack W, German DC, Shore PA (1980) Eur J Pharmacol 61:239–246
Pi EH, Simpson GH, Cooper TB (1986) Am J Psychiat 143:1.174–1.176
Pollock BG, Perel JM (1989) Can J Psychiat 34:609–617
Ciraulo D, Barnhill JA, Jaffe JH (1988) Clin Pharmacol Ther 43:509–518
Ciraulo DA, Barnhill J, Boxenbaum H (1985) Am J Psychiat 142:1.373–1.374
Abernethy DR, Greenblatt DJ, Shader RI (1985) J Pharmacol Exp Ther 232:183–188
Steiner E, Spina E (1987) Clin Pharmacol Ther 42:278–282
Spina E, Steiner E, Ericsson Ö, Sjöquist F (1987) Clin Pharmacol Ther 41:314–319
Brøsen K, Otton SV, Gram LF (1986) Clin Pharmacol Ther 40:543–549
Brøsen K, Gram LF, Klysner R, Bech P (1986) Eur J Clin Pharmacol 30:43–49
Liebermann JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM (1985) Clin Pharmacol Ther 37:103–107
Sieberns S (1985) Therapiewoche 35:5.804–5.815
Spina E, Pacifici GM, van Bahr C, Rane A (1986) Acta Pharmacol Toxicol 5:277–281
RM
Kirkeby CJ, Risoe C (1984) Acta Chir Scand 150:91–92
De-Luca B, Cerciello A, Monda M (1982) Neuropharmacology 21:1.211–1.214
Helke CJ, Keller KJ, Gillis RA (1978) Eur J Pharmacol 52:47–55
Helke CJ, Keller KJ, Gillis RA (1979) Arch Int Pharmacodyn Ther 242:44–49
Marzo A, Ghirardi P, Brusoni B, Marchetti G (1978) Arch Int Pharmacodyn Ther 233:156–165
Ambrosioni E, Costa FV, Bracchetti D (1979) Int J Clin Pharmacol Biopharm 17:416–420
Bekke DM, Lehmann V, Lien E (1981) J Cardiovasc Pharmacol 3:1.015–1.025
Lö
Andersson KE (1988) Drugs of Today 24:509–528
Dinnendahl V, Fricke U (1987) Arzneistoff-Profile: Desmopressin, Govi-Verlag, Frankfurt/Main
js
Zeelen FJ (1990) Medicinal chemistry of steroids, Elsevier, Amsterdam Oxford New York Tokyo, S. 107–110
de Visser J, de Jager E, de Jongh HP, van de Vies J, Zeelen FJ (1975) Actaendocr Copenh 10 (Suppl 199):405–420
Widholm O, Alapapiessa U (1977) Contraception 15:1–13
Cyran W, Feldmann HM (1981) Gyne Heft 8, H.U.F.-Verlag, Essen
Oviol22, Oviol 28, Informationsschrift der Fa. Nourypharma, 1990
Dik M, Hönes S, Schindler AE, Donath EM (1986) Gynäkol Prax 10:265–275
Levrier M (1988) Therapiewoche 3:1.225–1.231
Wynants P (1986) Contraception 33:149–157
Käär K (1984) Scand J Clin Lab Invest 44:623–627
März W, Jung-Hoffmann C, Heidt F, Gross W, Kuhl H (1990) Contraception 41:245–250
Chez RA (1989) Am J Obstet Gynecol 160:1.296–1.300
Kuhnz W, Pfeffer M, Al-Yacoub G (1990) J Steroid Biochem 35:313–318
OM
Miller JA, Munro DD (1980) Drugs 19:119–134
Goa KL (1988) Drugs 36 S5:51–61
Pichl J, Schell H (1990) Z Hautkrankheiten 65:527–533
Tronnier H (1987) Aerztl Kosmetol 17:458–482
Leiferman KM, Schroeter A, Kirschner MK, Spelsberg TC(1983) J Inv Dermatol 81:355–360
Munck A, Mendel DB, Smith LI, Orti E (1990) Am Rev Respir Dis 141 S2:S2–10
Miesfeld RL (1990) Am Rev Respir Dis 141 S2:S11–17
Bowen DL, Fauci AS (1988) Adrenal corticosteroids. In: Gallin JI, Goldstein IM, Snyderman R (Hrsg.) Inflammation: basic principles and clinical correlates, Raven Press, New York, S. 877–897
Barry BW, Woodford R (1974) Br J Dermatol 91:323–338
Meyer E, Smith EW, Haigh JM, Kanfer I (1988) Arzneim Forsch 38:1840–1843
Laasko L (1981) Curr Ther Res 30:19
Niedner R (1989) Dtsch Aerztebl 86:1798–1803
Takeda K, Arase S, Takahashi S (1988) Drugs 36:15–23
Karl HJ (1980) Muench Med Wochenschr 122:1191–1194
GM
Munck A, Mendel DB, Smith LI, Orti E (1990) Am Rev Respir Dis 141 S2:S2–10
Schleimer RP (1985) Ann Rev Pharmacol Toxicol 25:381–412
Hahn HL (1990) Wirkungsmechanismen der Glukokortikoide bei Asthma, bronchialer Entzündungsreaktion und Hyperreaktivität. In: Nolte D (Hrsg.) Glukokortikoide bei obstruktiven Atemwegserkrankungen, de Gruyter, Berlin New York, S. 23–56
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Drugs 16:302–321
Alpermann HG, Sandow J, Vogel HG (1986) Z Hautkrkh61:S7–17
Hein R, Krieg T (1989) Z Hautkrkh 64 S1:13–17
Hornke I, Cavagna F, Christ O, Fehlhaber HW, Kellner HM, Sandow J (1980) Arzneim Forsch 30:47–51
Kim KH, Henderson NL (1989) Z Hautkrkh 64 Sl:19–22
Niedner R (1989) Dtsch Aerztebl 86:1.798–1.803
Miller JA, Munro DD (1990) Drugs 19:119–134
Takeda K, Arase S, Takahashi S (1988) Drugs 36 S5:15–23
Karl HK (1980) Muench Med Wochenschr 122:1.191–1.194
GM
Fieser LF, Rajagopalan S (1949) Am Soc 71:3935–3937
Fieser LF, Fieser M (1959) Steroids, Reinhold, New York
Beil Erg. Werk 3, Bd. 10, Teil 2, S. 1641
Gattermann-Wieland (1961) Praxis des organischen Chemikers, 40. Aufl., de Gruyter, Berlin, S. 361
Wieland H, Siebert W (1939) Z Physiol Chem 262:1
Garcia Valdes J, Cabrara Vazquez N (1987) Rev Cubana Farm 21:217–230, zit. nach CA 108 (14):118794p
Hag 4, S. 492
MI 11
Dictionary of Organic Compounds 5th ed 1982 and Supplements
Hag 2, S. 799
Hag 4, S. 492
Grinbaum R, Marchlewski L (1937) Bl Acad Polon 1937A:171–186
Stoffliste
Silberman H, Silberman-Martybcewa S (1946) J Biol Chem 165:359–362
Kaziro K, Shimada T (1938) Z Physiol Chem 254:57,58
Vold RD, McBain JW (1941) Am Soc 63:1296
Shimada T (1939) J Biochem Tokyo 29:41
Zhang Q, Qian L (1991) Tianran Chanwu Yanjiu Yu Kaifa 3:56–60, zit. nach CA 115 (18):189551n u M, Cheng Z, Hong M (1990) Zhongguo Yaoxue Zazhi 25:524–528, zit. nach CA 114 (16):149998m
Shen F, Fu D, Wen H (1990) Zhongguo Yaoxue Zazhi 25:457–459, zit. nach CA 114 (8):68913c
Yokota Y, Ishida M, Arisawa M, Murakuwi M, Ejiri Ch, Saito H (1988) Toyama-Ken Yakuji Kenkyusho Nenpo 16:103–113; zit. nach CA 114 (2):12281c Zhang Q, Li S, Cheng J, Yan K, Tian S (1990) Zhongguo Zhonggao Zazhi 15:360–362, zit nach CA 113 (26):237916t Li H, Zhou J, Wu G (1989) Yaowu Fenxi Zazhi 9:284–287, zit. nach CA 112 (2):11978g Ni K, Zhong G, Hong H (1989) Zhongguo Yaoke Daxue Xuebao 20:22–24, zit. nach CA 110 (22):199296u Li W, Wang J, Chen L, Hu Z (1981) Proc. Sino-West Ger. Symp. Chromatogr. 447–462, zit. nach CA 102 (10):89376x ark JD, Yoo SJ (1984) Saengyak Hakhoechi 15:139–146, zit. nach CA 102 (8):67461u
Wang Y, Wang Q, Guo Y, Cheng H (1989) Zhongguo Yaoxue Zazhi 24:732–734, zit. nach CA 113 (18): 158761k Ni K, Chang L, Chen F (1989) Zhongguo Yaoke Daxue Xuebao 20:100–102, zit. nach CA 112 (14):125307t Li J (1988) Yaoxue Tongbao 23:355–358, zit. nach CA 109 (22): 197298b Liu L, Xu D, Xie D (1987) 18:361–362, zit. nach CA 107 (20):183699e Han X, Han L (1986) Yaoxue Xuebao 21:864–867, zit.nach CA 106 (10):72990c
Wang Y, Yang Z (1989) Shenyang Yaoxueyuan Xuebao 6:157–163, zit. nach CA 111 (26):239621a
Tankano I, Yasuda I, Seto T, Hamano T, Akiyama K (1986) 37:73–78, zit. nach CA 106 (22):182736g
Maeda M, Tsuji A (1985) Analyst (London) 110:665–668, zit. nach CA 103 (20):171205v
Bottari E, Festa MR, Jasionowksa R (1988) Ann. Chim. (Rome), 78:261–271, zit. nach CA 109 (20): 177572h
Preti C, Tassi L, Tosi G (1985) Ann. Chim. (Rome) 75:201–206, zit. nach CA 103 (14):115391r
Johns MR, Chong R, Maddox IS (1982) Can. J. Microbiol. 28:1019–1021, zit. nach CA 97 (21):180067m (by Curvularia coicis) Ascher RH, Maddox IS, Chong R (1981) Eur. J. Appl. Microbiol. Biotechnol. 12:46–52, zit. nach CA 95 (5):40825r (by Clostridium bifermentans)
Neubert R, Fuerst W, Amlacher R, Haertl A (18. Juli 1991) DD 291927 A5, zit. nach CA 115 (20):214888n
Simon B, Menaste L (10. Okt. 1990) EP 391369 A2, zit. nach CA 114 (26):254013j
Luecke L, Fries G, Voigt G, Neubert R, Fuerst W, Slapke J, Schewe T (3. Okt. 1990) EP 389773 A2, zit. nach CA 114(24):235054g Ueda Y, Shimojo F, Myatake T, Ozoki M (22. Mai 1989) JP 01128926 A2, zit. nach CA 112 (2):11933p Behl ChR, Unowsky J (6. Okt. 1987) EP 87–114589, zit. nach CA 110 (14):121391b Ueda Y, Shimojo F, Miyatake T, Ozaki M (18. Nov. 1987) JP 62265226, zit. nach CA 108 (26):226860r Andonova V, Radeva K (1987) Farmatsiya (Sofia) 37:32–36, zit. nach CA 108 (14):118859n Wu Q, Wu Q (1986) Yaoxue tongbao 21:457–459, zit. nach CA 106 (12):90092r Lee SJ, Yang BR (1984) Han’guk Saenghwa Hakhoechi 17:456–461, zit. nach CA 102 (8):67335f
Fujita S (10. Juli 1989) Heisei JP 01174355 A2, zit. nach CA 112 (20):185809t Niazy EM, Molokhia AM, ElGorashi AS (1989) Int. J. Pharm. 56:181–185, zit. nach CA 112 (8):62492b
Hermens WAJJ, Hooymans PM, Verhoef JC, Merkus FWHH (1990) Pharm. Res. 7:144–146, zit. nach CA 112 (14):125099b Sekline K, Araki D, Suzuki Y (7. Jan. 1988) Showa JP 63002932 A2, zit. nach CA HO (2):13573d Hersey SJ, Kackson RT (1987) J. Pharm. Sci. 76:876–879, zit. nach CA 108 (8):62354a Duchateau GSMJE (1987) Pharm. Veekbl. 122:281–286, zit. nach CA 107 (4):28286z
Yokota T, Fukukura I, Yamaguchi M (13.Dez. 1988) Showa JP 6330530 A2, zit. nach CA 110 (18):160198p
Ritschel WA, Ritschel GB, Ritschel BEC, Luecker PW (1988) Methods Find. Exp. Clin. Pharmacol. 10:645–656, zit. nach CA 109 (26):236908x
Roemisch J, Heimburger N (11. Okt. 1990) DE 3911629 Al, zit. nach CA 114 (22):214406h Daddona PE, Davis HM, Fogler WE, Klug TL, Le-Donne NC, McKinney S (5. Mai 1989) WO 8903885 Al, zit. nach CA 112 (12):104896u
Rj
Funder JW, Feldman D, Edelman IS (1973) Endocrinol 92:994–1.004
Morris DJ, Souness GW (1990) Am J Physiol 258:F756–759
Marra CA, de Alaniz MJ (1990) Biochem Int 22:483–493
Janiak PC, Lewis SJ, Brody MJ (1990) Am J Physiol 259:R1.025–1.034
Gomez-Sanchez EP (1991) Am J Hypertens 4:374–381
Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin St, Ohnishi S (1991) Hypertension 17:806–813
Zappia A, Hwang BH, Wu JY (1990) Anat Rec 227:518–522
Milosovich SM, Hussain AA, Hussain M, Dittert L (1989) Prog Clin Biol Res 292:273–277
vB
Kadac B, Vejdelek ZJ, Photometric (1977), Bd.2, S.1096
Rh
Beil Erg. Werk 4, Bd. 9, Teil 3, S. 1760 Rh
Vb
Bergeron RJ, McManis JS (1987) J Org Chem 52:1.700–1.703
Yamashita K, Watanabe K, Koga R, Mizuguchi S, Hashimoto Y, Nakamura T, Umezawa H (1988) J Chromatogr 424:39–48
us
Hibasami H, Midorikawa Y, Gasaluck P, Yoshimura H, Masuji A, Takaji S, Nakashima K, Imai M (1991) Chemother 37:202–205
Dickneite G, Walter P, Schorlemmer HU, Sedlacek HH (1985) In: Ishigami J (Hrsg.), Rec Adv Chemotherp, Tokyo, Univ of Tokyo
Hibasami H, Tsukada T, Suzuki R, Takano K, Takaji S, Takeuchi T, Shirakawa S, Murata T, Nakashima K (1991) Anticancer Res 11:325–330
Dickneite G, Schorlemmer HU, Sedlacek HH, Falk W, Ulrichs K, Müller-Ruchholtz W (1987) Transplant Proc 19:1.301–1.304
Dickneite G, Schorlemmer HU, Racenberg J, Sedlacek HH (1989) Transplantat Proc 21:1.097–1.098
Kerr PG, Atkins RC (1989) Transplant 48:1.048–1.052
Takasu S, Sagakami K, Orita K (1989) Transplant Proc 21:1.081–1.084
Müller WE, Weissmann N, Maidhof A, Bachmann M, Schröder HC (1987) J Antibiot 40:1.028–1.035
Amemiya H, Suzuki S, Ota K, Takahashi K, Sonoda T, Ishibashi M, Omoto R, Koyama I, Dohi K, Fukuda Y, Fukao K (1990) Transplant 49:337–343
Okubo M, Inoue K, Umetani N, Sato N, Kamata K, Masaki Y, Uchiyama T, Yan XJ, Aoyagi T, Shirai T (1988) Kidney Int 34:467–473
Ishigaki Y, Sato T, Tonglin S, Hayashi K (1988) Ann N Y Acad Sci 540:551–553
Nemoto K, Abe F, Takita T, Nakamura T, Takeuchi T, Umezawa H (1987) J Antibiot 40:1.193–1.194
Muindi JF, Lee S-J, Baltzer L, Jakubowski A, Scher HI, Sprancmanis LA, Riley CM, Vander Velde D, Young CW(1991) Cancer Res 51:3.096–3.101
vB
East Germany Pat. 82731 (1971), zit. nach CA (1971) 77:19864
ms
Vaughan-Williams EM (1975) Pharmac Ther 31:115–138
Wruck C, Hofmann H, Sziegoleit W, Forster W (1982) Z Ges Inn Med 37:519–525
MollekenK,RugerK(1980) Z Ges Inn Med 35:296–299
EH
Cohen E in Ana 2, S. 174
Kadac B, Vejdelek ZJ (1977) Photometrie 1977, Verlag Chemie, Weinheim. Bd.2, S. 1.095
Kom
Rh
Kaiser H (1987) Thieme, Stuttgart New York
Hochhaus F, Möllmann H, Barth J (1990) Akt Rheumatol 15:66–69
Rohdewald P, Möllmann HW, Hochhaus G (1984) Atemw Lungenkrkh 10:484–489
Miesfeld RL (1990) Am Rev Respir Dis 141 S2:11–17
Munck A, Mendel DB, Smith LI, Orti E (1990) Am Rev Respir Dis 141 S2:2–10
Hahn HL (1990) Wirkungsmechanismen der Glukokortikoide bei Asthma, bronchialer Entzündungsreaktion und Hyperreaktivität. In: Nolte D (Hrsg.) Glukokortikoide bei obstruktiven Atemwegserkrankungen, de Gruyter, Berlin New York, S. 23–56
Schleimer RP (1990) Am Rev Respir Dis 141 S2:59–69
Bowen DL, Fauci AS (1988) Adrenal Corticosteroids. In: Gallin JI, Goldstein M, Snyderman R (Hrsg.) Inflammation: basic principles and clinical correlates, Raven Press, New York, S. 877–896
Nichols T, Nugent CA, Tyler FH (1967) J Clin Endocrinol 27:549
Loew D, Schuster O, Graul EH (1985) Therapiewoche 35:1106–1113
Melby JC (1977) Ann Rev Pharmacol Toxicol 17:511–527
Möllmann HW, Barth J, Schott D, Ulmer WT, Derendorf H, Hochhaus G (1989) Intensivmed 26:2–15
Hwang DG, Stern WH, Hwang PH, MacGowan-Smith LA (1989) Arch Ophthalmol 107:1375–1380
Watson D, Noble MJ, Dutton GN, Midgley JM, Healey TM (1988) Arch Ophthalmol 106:686–687
Kaiser H (1988) Akt Rheumatol 13:27–30
Tsuei SE, Moore RG, Ashley JJ, McBride WG (1979) J Pharm Biopharm 7:249–264
Laasko L (1981) Curr Ther Res 30:19
Miyabo S, Nakamura T, Kuwazima S, Kishida S (1981) Eur J Clin Pharmacol 20:277–282
Hornke I, Cavagna F, Christ O, Fehlhaber HW, Kellner HM, Sandow J (1980) Arzneim Forsch 30:47–51
Straub W (1987) Augenkrankheiten. In: Kaiser H (Hrsg.) Cortisonderivate in Klinik und Praxis, Thieme, Stuttgart New York, S. 216–225
Ortega E, Rodriguez C, Strand LJ, Segre E (1976) J Int Med Res 4:326–337
Fiegel G (1981) Med Welt 32:130–134
Karl HJ (1980) Muench Med Wochenschr 122:1191–1194
Jubiz W, Meikle AW (1979) Drugs 18:113–121
GM
Melby JC (1977) Ann Rev Pharmacol Toxicol 17:511–527
Kaiser H (1988) Akt Rheumatol 13:27–30
Clark JE, Lee HJ (1982) Curr Ther Res 32:761–781
Müller W (1981) Therapiewoche 31:6258–6265
GM/vB
Fresenius’ Z Anal Chem (1988) 389:778–780
Rh
Möllmann HW, Barth J, Schott D, Ulmer WT, Derendorf H, Hochhaus G (1989) Intensivmed 26:2–15
Jack D (1975) Atemw Lungenkrkh 1:S. 13–20
GM/vB
Möllmann HW, Barth J, Schott D, Ulmer WT, Derendorf H, Hochhaus G (1989) Intensivmed 26:2–15
Tsuei SE, Moore RG, Ashley JJ, McBride WG (1979) J Pharm Biopharm 7:249–264
Melby JC (1977) Ann Rev Pharmacol Toxicol 17:511–527
GM/vB
Harfst G, Katzung K, Sahihi A (1991) Rauschgift-Szene-Jargon von A-Z, Holger Harfst Verlag, Würzburg
Karrer P, Portmann P, Suter M (1948) Helv Chim Acta 31:1617–1623
Karrer P, Ehrhardt K (1951) Helv Chim Acta 34:2202–2210
Johns I B, Burch J M (1938) J Am Chem Soc 60:919–920
v Braun J, Friehmelt E (1933) Chem Ber 66:684–685
Wallis E S, Nagel S C (1931) J Am Chem Soc 53:2787–2791
Leithe W (1932) Chem Ber 65:660–666
Temmler (1939) Brit 508757
Magidson, Garkusha (1941) J Gen Chem (USSR) 11:339
Firmenschrift Knoll AG (1977): Pharma Chemikalien
NE
Dring LG, Smith RL, Williams RT (1970) Biochem J 116:425–435
Campbell DB (1969) Pharm Pharmac 21:129–130
Axelrod J (1970) Amphetamine: metabolism, physiological disposition and its effects on catecholamine storage. In: Costa E, Garattini S (Hrsg.) Amphetamines and related compounds, Raven Press, New York, S. 207–216 (enthält noch andere Artikel zu diesem Thema)
Lange KW (1990) Dtsch Med Wochenschr 115:1.244–1.250
Warneke L (1990) Can J Psychiat 35:3–10
hr
Harfst G, Katzung K, Sahihi A (1991) Rauschgift-Szene-Jargon von A-Z, Holger Harfst Verlag, Würzburg
Temmler (1939) Brit 508757
Magidson, Garkusha (1941) J Gen Chem (USSR) 11: 339
Firmenschrift Knoll AG (1977) Pharma Chemikalien
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
Kovar KA, Noy M, Pieper R (1982) Dtsch Apoth Ztg 122:3–22
NE
Walter LA, US Pat 3030371, zit. nach CA (1962) 57:9822i; Walter LA, US Pat 3061517, zit. nach CA (1963) 58:6744c
Beil Erg. Werk 5, Bd. 22, Teil 10, S.490
MP
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs (1986) The Pharmaceutical Press, London
MP
Walter LA, US Pat 3030371, zit. nach CA (1962) 57:9822i Walter LA, US Pat 3061517, zit. nach CA (1963) 58:6744c
Beil Erg. Werk 3/4, Bd. 22, Teil 6, S.4921.Brittain RT, D’Arcy PF, Hunt JH (1959) Nature 183:734–735
Fricke FL (1972) J Assoc Off Anal Chem 55:1162–1167
MP
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
MP
Mar 29, S.530
vB
Beregi Fr Pat M1658 (1963 an Science-Union, Anm. 04.04.1961), zit. nach CA (1963) 59:3831g
Wieduwilt H, Haendel KH, Jassmann E (1974) Ger (East) 108971 (12.10.74, Appl 172919 16.08.73), zit. nach CA (1975) 83(13):113915]
Beregi L, Hugon P, Le Douarec JC, Schmitt H (1965) USP 3198 834 (03.08.65, Appl 27.07.64 an Science Union), zit. nach CA (1965) 63:11425
NE
Mar 29, S.1.441
vB
Brit. Pat. 582156, zit. nach CA 41:2432i
DDR Pat. 45705, zit. nach CA 65:3757f
Beil Erg. Werk 4, Bd.4, Teil 1, S. 1652
Prosser AR, Sheppard AJ (1971) J Pharm Sci 60:909
Umagat H, Tscherne R (1980) Anal Chem 52:1368–1370
hh
Bäßler KH, Grühn E, Loew D, Pietrzik K (1992) Vitamin-Lexikon, Gustav Fischer Verlag, Stuttgart, New York
Buddecke E (1984) Grundriß der Biochemie, 7. Aufl., Gruyter Verlag, Berlin New York
Stryer L (1985) Biochemie, 3. Aufl., Friedrich Viehweg & Sohn, Braunschweig Wiesbaden
Friedrich W (1987) Pantothensäure. In: Friedrich W (Hrsg.) Handbuch der Vitamine, Urban und Schwarzenberg, München Wien Baltimore
Lang K (1976) Biochemie der Ernährung, Steinkopf Verlag, Darmstadt
Pietrzik K, Hornig D (1980) Int J Vit Nutr Res 50:283–293
Bamji MS (1981) Laboratory tests for the assessment of vitamin nutritional status. In: Briggs M (Hrsg.) Vitamin in Human Biology, CRC Press, Boca Raton
Fox HM (1984) Pantothenic Acid. In: Machlin LJ (Hrsg.) Handbook of Vitamins, Marcel Dekker, Inc., New York
Sauberlich HE, Skala JH, Dowdy RP (1974) The assessment of nutritional status, CRS Press, Inc., Cleveland, Ohio
Hanck A (1986) Pantothensäure. In: Spektrum Vitamine, Arzneimitteltherapie heute, Bd. 42, Aesopus Verlag, Zug, S. 97–102
Höhne E (1985) Pantothensäure/Panthenol. In: Vitamine, 2. Aufl., Otto Hoffmans Verlag GmbH, München
Spector R (1986) Fed Proc 45:37–39
Wagner M, Schubert V, Hötzel D (1972) Med Ernährung 13:25–29
Monographie Dexpanthenol, BAz (in Vorbereitung)
KP
Gloor M (1982) Pharmakologie dermatologischer Externa, Springer, Berlin Heidelberg New York, S. 27–28
Lochbühler H, Kaufmann W, Storz WL (1978) Therapiewoche 28:2665
Petzoldt D, Henkel W (1979) Ext Derm 3 (Suppl 1):29–34
Jacobsson S, Rothman U, Arturson G (1976) Scand J Plast Reconstr Surg 10:65–72
Paavolainen P, Sundell B (1976) Ann Chir Gynaec Fenn 65:313–317
Lassus A, Karvonen J, Juvakoski T (1977) Acta Derm Venerol 57:361–363
Matthews RW (1982) Brit Dent J 152:157–159
Gs
Handbook of Pharmaceutical Excipients (1986), American Pharmaceutical Association, Washington, USA, S. 93–94
BK
Fr. M 3683 (1965), zit. nach CA (1967) 66:55204n
Brit. 1,076,174, zit. nach CA (1966) 65:21691v
Schmitt J, Comoy P, Boitard J, Meingan JP, Le Meur J, Briot M (1966) Chim Therap 71–77, zit. nach CA (1966) 65:15255
Neth Appl 6:407,309, zit. nach CA(1965) 63:535
GU
Mar 29, S. 1.609
vB
Fr M3683 (1965), CA 66 (1967) 55204n
Brit 1,076,174, CA 68 (1968) 21691v
Schmitt J, Comoy P, Boitard J, Meingan JP, LeMeur J, Briot M (1966) Chim Ther 71–77; CA 65 (1966) 15255
Neth Appl 6,407,309, CA63 (1965) 535
Schnider O, Hellerbach J (1950) Helv Chim Acta 33:1437–1448
Schnider O, Grüssner A (1951) Helv Chim Acta 34:2211–2213
Weiss U, Rüll Th (1965) Bull Soc Chim France 12:3707–3714
Terui Y, Tori K, Maeda S, Sawa YK (1975) Tettrahedron Lett 33:2853–2856
Wainer IW, Tischler MA, Sheinin EB (1980) J Pharm Sci 69:459–461
Achari RG, Theimer EE (1977) J Chromatogr Sci 15:320–321
Park YH, Kuliberg MP, Hinsvark ON (1980) J Pharm Sci 73:24–29
Furlanut M, Cima L, Benetello P, Giusti P (1977) J Chromatogr 140:270–274
Barnhart JW, Massad EN (1979) J Chromatogr 163:390–395
Noirfalise A (1974) J Chromatogr 90:392–393
Häfliger O, Brossi A, Chopard-dit-Jean LH, Walter M, Schnider O (1956) Helv Chim Acta 39:2053–2061
KU
Marks W (1987) Pharmazeut Ztg 132:426–428
Benson WM, Stefko PL, Randell LO (1953) J Pharmacol Exp Ther 109:189–200
Eddy NB, Friebel H, Hahn KJ, Halbach H (1970) Bull WHO 40:169–178
Mortimer Ö, Lindström B, Laurell H, Bergmann U, Rane A (1989)-demethylated and didemethylated metabolites in man, Br J clin Pharmac 27:223–227
Silvasti M, Karttunen P, Tukiainen H, Kokkonen P, Hänninen U, Nykänen S (1987) Int J Clin Pharmacol Ther Tox 25:493–497
Hildebrand M, Seifert W, Reichenberger A (1989) Eur J Clin Pharmacol 36:315–318
Matthys H, Bleicher B, Bleicher U (1983) J Int Med Res 11:92–100
Matthys H, Erhard J, Rühle KH (1985) Schweiz Med Wschr 115:307–311
Flemming PhA (1986) Br J Med 293:597
Dodds A, Revai E (1967) Med J Aust 2:231
Schnider O, Grüssner A (1954) US Pat. 2676177; CA (1955) 49:6325a
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaantical Press, London
Farbegas JL, Margalet A (1975) J Pharm Sci 64:1005–1006
Barnhart JW, Massad EN (1979) J Chromatogr 163:390–395
Noirfalise A (1974) J Chromatogr 90:392–393
Park JH, Kuliberg MP, Hinsvark ON (1984) J Pharm Sci 73:24–29
KU
Janssen P A J (1956) J Am Chem Soc 78:3862
Kovar K A, Noy M, Pieper R (1982) Dtsch Apoth Ztg 122:3
Caddy B, Idowu R (1979) Analyst (London) 104:328
Rh
Arzneistoff-Profile: Basisinformation über arzneiliche Wirkstoffe (1990) Govi-Verlag, Frankfurt a. M.
Ghodse AH, Sheehan M, Taylor C, Edwards G (1985) Br Med J 290:425–428
Jurand A, Martin LV (1990) Teratology 42:45–54
Kintz P, Mangin P, Lugnier AA, Chaumont AJ (1990) J Anal Toxicol 14 (4):252–253
Kintz P, Tracqui A, Mangin P, Lugnier AA, Chaumont AJ (1989) J Anal Toxicol 13 (4):238–239
Lançon JP, Pechinot A, Athis PD, Pechinot M, Pointaire P, Obadia JF, Caillard B (1989) Ann Fr Anesth Réanim 8:488–492
Meignier M, Zaouter M, Ricard P, Charles-Guillard S, Heloury Y, Rogez JM, Pannier M (1990) Chir Pédiatr 31:341–344
Pagani I, Barzaghi N, Crema F, Perucca E, Ego D, Rovei V (1989) Fundam Clin Pharmacol 3 (l):27–35
KG
Anon (1972) Med Lett Drug Ther 14 (ll):37–40
Baratta RR (1976) Curr Ther Res 20:233–240
Bassendine MF, Woodhouse KW, Bennett M, James OF (1986) Gut 27 (4):444–449
Beaver WT (1984) Hum Toxicol 3 Suppl.:191S–220S
Bellville JW,Seed JC (1968) Clin Pharmacol Ther 9:428–434
Briggs GG, Freeman RK, Yaffe SJ (1986) Drugs in Pregnancy and Lactation, 2. Aufl., Williams, Wilkins, Baltimore, 537S.
Brosen K, Gram LF, Schou J, Larsen NE, Thayssen P (1985) Eur J Clin Pharmacol 29 (l):79–84
Claghorn JL, Schoolar JC (1966) JAMA 196:1.089–1.091
Daftery AV (1974) N Engl J Med 291:979–980
Flanagan RJ, Johnston A, White AST, Crome P (1989) Br J Clin Pharmacol 28:463–469
Ford JF, Kellett RJ (1977) Br Med J 2:674
Giacomini KM, Giacomini JC, Gibson TP, Levy G (1980) Clin Pharmacol Ther 28(3):417–424
Hansten PD, Horn JR (1990) Drug Interactions & Updates, 6. Aufl., Lea & Febiger, Philadelphia, London, 620S.
Jaffe JH, Martin WR (1990) Opioid Analgesics and Antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) The Pharmacological Basis of Therapeutics, Pergamon Press, New York, S. 485–521
Kunka RL, Venkataramanan R, Stern RM, Ladik CF (1984) Clin Pharm Ther 35:675–680
Kurz-Müller K, Zenz M (1991) Schmerz 5:233–242
Lee TH, Rees PJ (1977) Br Med J 2:296
Lupin AJ, Harley CH (1976) Can Med Assoc J 114:596
Musa MN, Lyons LL (1976) Curr Ther Res 19 (6):669–674
Owen M, Hillis LJ (1980) Med J Aust 1:617–618
Sewester CS (1990) Drug: Fact and comparison, Lippincott, Philadelphia
Tennant FS (1973) Arch Intern Med 132:191–194
Tyson HK (1974) J Pediatr 85 (5):684–685
Verebely K, Inturrisi CE (1974) Clin Pharmacol Ther 15:302–309
Wagner JG, Welling PG, Sedmann AJ (1972) Int J Clin Pharmacol 5:381–388
Waife SO, Gruber CM, Rodda BE, Nash JF (1976) Int J Clin Pharmacol Biopharm 13:177–181
Welling PG, Lyons LL, Tse FLS, Craig WA (1976) Clin Pharmacol Ther 19:559–565
Wiederholt IC, Genco M, Foley JM (1967) Neurology 17:703
McMahon RE, Shader RI (1973) Life Sci (II) 12:463–473
Abernethy DR, Greenblatt DJ, Steel K, Sullivan HR, Due SL, Marshall FJ (1982) Ann Intern Med 97:223–224
KG
Schnider O, Grüssner A (1951) Helv Chim Acta 34:2211–2217
Meyers AI, Bailey TR (1985) J Org Chem 51:872–875
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr323(2):191–225
Furlanut M, Cima L, Benetello G, Giusti P (1977) J Chromatogr 140 (3):270–274
KU
Nahm H, Siedel W (1963) Chem Ber 96:1–9
In: Pouchert CJ (Hrsg.) (1989) The Aldrich Library of FT-IR-Spectra, Bd. 1, Aldrich Chemical Co., Milwaukee, S. 254
In: Hansch C, Sammes PG, Taylor JB (Hrsg.) (1990) Comprehensive Medicinal Chemistry, Bd. 6, Pergamon Press Oxford, S. 438
Ba
Schwindler H (1968) Wien Med Wochenschr 118:98–100
Myant NB (1964) The thyroid and lipid metabolism. In: Paoletti R (Hrsg.) Lipid Pharmacology, Academic Press Inc, New York, S. 299–323
Kuschinsky G, Lüllmann H (1981) Kurzes Lehrbuch der Pharmakologie und Toxikologie, Georg Thieme Verlag, Stuttgart New York, S. 155
The Coronary Drug Project (1972) J Am Med Assoc 220:996–1.008
The Coronay Drug Project Research Group (1975) J Am Med Assoc 231:360–381
Tapley DF, Davidoff FF, Hatfield WB, Ross JE (1959) Am J Physiol 197:1.021–1.025
Klotz U (1984) Klinische Pharmakokinetik, Gustav Fischer Verlag, Stuttgart New York, S. 120
Weser JK, Sellers E (1971) N Engl J Med 285:547–558
Bj
Neudecker H, Scheiffele E (1971) Arzneim Forsch 21:432
HeintzB, Hamacher H (1983) Dtsch Apoth 123:417–420
Gübitz G, Juffmann F (1987) J Chromatogr 404:391–393
Richheimer SL, Schacher MS (1983) J Pharm Sci 72: 822–823
Wachholz E, Pfeifer S (1972) Pharmazie 27:43–46
Wachholz E, Pfeifer S (1972) Pharmazie 27:97–106
Hay ID, Annesley TM, Jiang NS, Gorman CA (1981) J Chromatogr 226:383–390
DAB 10, Monographie Levothyroxin-Natrium
Ba
Cohen MS (1987) Special aspects of perinatal and pediatric pharmacology. In: Katzung BG (Hrsg.) Basic and clinical pharmacology, Norwalk, Appleton Lange, S. 749–755
Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW (1984) N Engl J Med 310:1.213–1.217
Jamous MA, Hand CW, Moore RA, Teddy PJ, McQuay HJ (1986) Anesth Analg 65:1.290–1.294
Kaiko RF, Wallenstein SL, Rogers AG, Grabinski PY, Houde RW (1981) N Eng J Med 304:1.501–1.505
Kotob HI, Hand CW, Moore RA, Evans PJ, Wells J, Rubin AP, McQuay HJ (1986) Anesth Analg 65:718–722
Lee A, McKeown D, Brockway M, Bannister J, Wildsmith JA (1991) Anaesthesia 46 (6):447–450
Levine MN, Sackett DL, Bush H (1986) Arch Intern Med 146:353–356
McGrady EM, Brownhill DK, Davis AG (1989) Anaesthesia 44:400–403
Moore A, Bullingham R, McQuay H, Allen M, Baldwin D, Cole A (1984) Clin Pharmacol Ther 35:40–45
Product Information-Diamorphine hydrochloride BP for injection® (1989)
Robinson SL, Rowbotham DJ, Smith G (1991) Anaesthesia 46 (7):538–540
Sawynok J (1986) Can J Physiol Pharmacol 64:1–6
Smith ID, Klubien KE, Wood ML, Macrae DJ, Carli F (1991) Anaesthesia 46 (11):970–973
Stevens JD, Braithwaite P, Corke CF, Madej TH, Wheatley RG (1991) Anaesthesia 46 (4):256–259
Wallenstein SL, Houde RW, Portenoy R, Lapin J, Rogers A, Foley KM (1990) Pain 41 (1):5–13
Way WL, Way EL (1987) Opioid Analgesics and Antagonists. In: Katzung BG (Hrsg.) Basic and clinical pharmacology, Norwalk, Appleton Lange, S. 749–755
KG
Poochikian GK, Cradock JC, Davignon JP (1983) Int J Pharm 13:219
Beaumont I, Deeks T (1982) J Chromatogr 238:520
Wyatt DK, Grady LT (1982) in Florey K Anal Profiles of Drug Substances 10:357
Bernhauer D, Fuchs E, Neumann H (1983) Fresenius Z Anal Chem 316:357
Rogers GC, Davies MB, Allwood MC (1991) International Pharmacy Journal 5(2):70
Am
Sternbach LH (1978) Progr. Drug Res 22:229–266
Schütz H (1982) Benzodiazepines, Springer, Berlin Heidelberg New York
Sü
Haefely W, Pieri L, Polc P, Schaffner R (1981) General pharmacology and neuropharmacology of benzodiazepine derivatives. In: Hoffmeister F, Stille G (Hrsg.) Handbook of experimental pharmacology, Bd. 55/II, Springer-Verlag, Berlin, S. 13–262
Haefely W, Kyburz E, Gerecke M, Möhler H (1985) Adv in Drug Res 14:165–322
Müller WE (1987) The benzodiazepine receptor: drug only or a physiologically relevant part of our central nervous system? Cambridge University Press, Cambridge
Klotz U, Kanto J (1988) Clin Pharmacokin 14:1–12
O’Sullivan GF, Wade DN (1987) Clin Pharmacol Ther 42:254–259
Mandelli M, Tognoni G, Garattini S (1978) Clin Pharmacokin 3:72–91
Greenblatt DJ, Allen MD, Harmatz JS, Shader RI (1980) Clin Pharmacol Ther 27:301–312
Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) J Clin Invest 55:347–359
Greenblatt DJ, Shader RI (1974) Benzodiazepines in clinical practice, Raven-Press, New York
Müller WE (1990) Therapiewoche 40:3.170–3.175, 3.635–3.641
Stoeckel H, Lauven PM, Schwilden H, Murday H (1986) Benzodiazepine als Supplement in der Allgemeinanästhesie. In: Hippius H, Engel RR, Laakmann G (Hrsg.) Benzodiazepine, Rückblick und Ausblick, Springer-Verlag, Berlin Heidelberg New York, S.214–223
Kugler J, Leutner V (Hrsg.) (1987) Benzodiazepine in der Neurologie, Editiones Roche, Grenzach
Nathan PW (1970) J Neurol Sci 10:33–50
Woods JH, Katz JL, Winger G (1987) Pharmacol Rev 39:251–419
Winokur A, Rickels K, Greenblatt DJ, Snyder PJ, Schatz NJ (1980) Arch Gen Psychiatry 37:101–105
Tyrer P, Owen R, Dawling S (1983) Lancet 25:1.402–1.406
Klotz U (1984) Progr Clin Biochem Med 1:117–167
Wm
Kom
Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 467
ToplissJG, Sperber N, Rubin AA (1967) US Pat 3.345.365; zit. nach CA (1968) 68:78.318h
Ebel S (1977) Handbuch der Arzneimittelanalytik,Verlag Chemie Weinheim-New York, S.226
JakobsenP, Treppendahl S (1979) Tetrahedron 35:2151
Mannhold R, Rodenkirchen R, Bayer R, Haas W (1984) Arzneim Forsch 34:407
DaldrupT, Susanto F, Michalke P (1981) Fresenius Z Anal Chem 308:413
RE
Rubin AA, Roth FE, Taylor RM, Rosenkilde H (1962) J Pharmacol Exp Ther 136:344–352
Topliss JG, Konzelman LM, Shapiro EP, Sperber N, Roth FE (1964) J Med Chem 7:269–273
Topliss JG, Sherlock MH, Reimann H, Konzelman LM, Shapiro EP, Petterson BW, Schneider H, Sperber N (1963) J Med Chem 6:122–127
Koch-Weser K (1976) N Engl J Med 294:1.271–1.274
Scriabine A (1980) Diazoxide. In: Scriabine A (Hrsg.) Pharmacology of antihypertensive drugs, Raven Press, New York, S. 397–406
McMahon FG (1984) Diazoxide (Hyperstat). In: McMahon FG (Hrsg.) Management of essential Hypertension: The new low dose era. Futura Publishing Company, Inc, Mount Kisco New York, S. 506–522
Küchel O, Fishman ML, Liddle GW, Michelakis A (1967) An Intern Med 67:791–799
Finnerty FA (1974) Am Heart J 88:265–268
Dollery CT, Pentecost BL, Samaan NA (1962) Lancet II:735–737
Fang P, Macdonald I, Laver M, Hua A, Kincaid-Smitth P (1974) Med J Aust 2:621–624
Wohl AJ, Hausier LM, Roth FE (1968) Life Sci 7:381–387
Maxwell GM (1971) Nature 233:250
Quast U, Cook NS (1989) J Pharmacol Exp Ther 250:261–271
Taylor J, Green RG (1970) Europ J Pharmacol 12:385–387
Thirlwell MP, Green RD (1972) Am Heart J 83:512–517
Lang RE (1985) Vasodilatantien. In: Ganten D, Ritz E (Hrsg.) Lehrbuch der Hypertonie, Schattauer-Verlag, Stuttgart New York, S. 677–685
Sellers EM, Koch-Weser J (1973) Ann NY Acad Sci 226:319–332
Dayton PG, Pruitt AW, Faraj BA, Israili ZH (1975) Drug Metab Dispos 3:226–229
Pearson RM (1977) Clin Pharmacokin 2:198–204
Pruitt AW, Faraj BA, Dayton PG (1974) J Pharmacol Exp Ther 188:248–256
Finnerty FA, Kakaviatos N, Tuckman J (1963) Circulation 28:203–208
Black J (1968) Ann NY Acad Sci 150:194–203
Morris JA, Arce JJ et al (1977) Obstet Gynecol 49:675–680
Kumar GK, Dastoor FC, Robayo JR, Razzaque MA (1976) J Amer Med Ass 235:275–276
Combs JT, Grunt JA, Brande IK (1967) Pediatrics 40:90–92
Wales JK, Wolff F (1967) Lancet I:53–54
Lockwood CH, Nicholls DM, Troop VL, Lewis JA (1963) Am J Med Sci 246:312–318
Okun R, Russel RP, Wilson WR (1963) Arch Intern Med 112:120–126
Milner RDG, Chouksey SK (1972) Arch Dis Child 47:537–543
Huysmans FTM, Thien TA, Koene RAP (1982) Am Heart J 103:395–400
Aynsley-Green A, Illig R (1975) Lancet II:658–659
Sellers EM, Koch-Weser J (1970) Clin Pharmacol Ther 11:524–529
GW
Angaben der Fa. Pfizer
Gg
l.Noone P (1984) Drugs 27:548–578
Walther H, Meyer FP (1987) Klinische Pharmakologie antibakterieller Arzneimittel, Urban & Schwarzenberg, München Wien Baltimore, S.306
Rimoldi R, Curcio L, Sanfilippo A (1978) Pharmacokinetic study of dibekacin in humans. Current chemotherapy. Proc 10th Congr Chemother, Zürich 1977, Vol.2, S. 928
Bégué P, Safran C, Quiniou F, Michel P, Laget P (1984) Dev Pharmacol Ther 7 (Suppl. 1):116–120
Autret E, Borderon JC, Saliba E, Koki P, Ployet MJ, Gold F, Breteau M, Laugier J (1984) Dev Pharmacol Ther 7 (Suppl. 1):121–124
Furlanut M, D’Elia R, Granati B, Bruno R, Mainardi G, Tamassia V (1981) Pharmacokinetic study of dibekacin in full-term newborn infants. Current chemotherapy and immunotherapy. Proc 12th Congr Chemother, Florence 1981, Vol. 12, S. 813–814
Arancibia A, Chávez J, Ibarra R, Ruiz I, Icarte A, Thambo S, Chávez H (1987) Int J Clin Pharmacol Ther Toxicol 25:38–43
Campillo JA, Lanoa JM, Dominguez-Gil A, Rubio F, Martin A (1980) Eur J Clin Pharmacol 18:347–350
fm
Mar 29, S. 1.352
vB
Spezifikation der Fa. Luitpold-Pharma, München
FB
Wallhäußer KH (1988) Praxis der Sterilisation Desinfektion-Konservierung, 4. Aufl., Thieme Verlag, Stuttgart New York, S. 514
Beilfuß W, Bücklers L, Eigener U, Harke HP, Sturm U (1987) Phenole. In: Kramer A, Weuffen W, Krasilnikow AP, Gröschel D, Bulka E, Rehn D (Hrsg.) Handbuch der Antiseptik, Bd.II/3 Antibakterielle, antifungielle und antivirale Antiseptik-ausgewählte Wirkstoffe, Volk und Gesundheit, Berlin, S.292–293
Kramer A, Zbinden G, Stephan U, Koch St, Koch D, Junghans A (1985) Akute Toxizität von Antiseptika. In: Kramer A, Berencsi G, Weuffen W (Hrsg.) Handbuch der Antiseptik, Bd. I/5, Toxische und allergische Nebenwirkungen von Antiseptika, Volk und Gesundheit, Berlin, S. 113–210
Beilfuß W, Bücklers L, Eigener U, Harke HP, Sturm U (1987) Phenole. In: Kramer A, Weuffen W, Krasilnikow AP, Gröschel D, Bulka E, Rehn D (Hrsg.) Handbuch der Antiseptik, Bd.II/3, Antibakterielle, antifungielle und antivirale Antiseptik-ausgewählte Wirkstoffe, Volk und Gesundheit, Berlin, S. 320
ak
Todd A, Sorkin EM (1988) Drugs 35:244–285
Skoutakis VA, Carter CA, Mickle TR, Smith VH, Arkin CR, Alissandratos J, Petty DE (1988) Drug Intell Clin Pharm 22:850–859
Ku EC, Lee W, Kothari HV, Kimble EF, Liauw L, Tjan J (1985) Semin Arthritis Rheum 15 (Suppl 1):36–41
Ku EC, Lee W, Kothari HV, Scholer DW (1986) Am J Med 80 (Suppl4B):18–23
Vane JR (1987) Drugs 33 (Suppl1): 18–27
Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS(1980) Drugs 20:24–48
Burkhardt D, Ghosh P (1987) Semin Arthritis Rheum 17(Suppll):3–34
Martel-Pelletier J, Pelletier JP, Cloutier JM, Howell DS, Ghandur-Mnaymneh L, Woessner JF (1984) Arthritis Rheum 27:304–312
Woessner JF, Seize MG (1984) J Biol Chem 259:3.633–3.638
Walton EA, Upfold LI, Stephens RW, Ghosh P, Taylor TKF (1981) Semin Arthritis Rheum 11:73–74
Kruze D, Fehr K, Menninger H, Böni A (1976) Z Rheumatol 35:337–346
Minta JO, Williams MD (1985) J Rheumatol 12:751–757
Kalbhen DA (1984) Biochemically induced osteoarthritis in the chicken and rat. In: Munthe E, Bjelle A (Hrsg.) Effects of drugs on osteoarthritis, Huber-Verlag, Bern Stuttgart Vienna, S. 48–68
Hoedt-Schmidt S, Scheid A, Kalbhen DA (1989) Arzneim Forsch 39:1.212–1.219
McKenzie LS, Horsburgh BA, Ghosh P, Taylor TKF (1977) Ann Rheum Dis 36:369–373
John VA (1979) Rheumatol Rehabil (Suppl2):22–35
Kendall MJ, Thornhill DP, Willis JV (1979) Rheumatol Rehabil (Suppl2):38–45
Riess W, Stierlin H, Degen P, Faigle JW, Gérardin A, Moppert J, Sallmann A, Schmid K, Schweizer A, Theobald W, Wagner J (1978) Scand J Rheumatol 22 (Suppl):17–29
Morimoto K, Iwamoto Y, Katashima T, Takeeda T, Nakamoto Y, Morisaka K (1985) Pharm Res 4:166–170
Willis JV, Kendall MJ, Jack DB (1981) Eur J Clin Pharmacol 19:33–37
APr
Riess W, Schmid K, Botta L, Kobayashi K, Moppert J, Schneider W, Sioufi A, Strusberg A, Tomasi M (1986) Arzneim Forsch 36:1.092–1.096
Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG (1979) Eur J Clin Pharmacol 16:405–410
Willis JV, Kendall MJ, Jack DB (1980) Eur J Clin Pharmacol 18:415–418
Chamouard JM, Barce J, Urien S, Houin G, Tillement JP (1985) Biochem Pharmacol 34:1.675–1.700
Brune K, Dietzel K, Nürnberg B, Schneider HT (1987) Scand J Rheumatol 65 (Suppl): 135–140
Benson MD, Aldo-Benson M, Brandt KD (1985) Semin Arthritis Rheum 15 (Suppl 1):65–67
Stierlin H, Faigle JW, Colombi A (1978) Scand J Rheumatol 22 (Suppl) :30–35
Zimmerer J, Tittor W, Degen P (1982) Fortschr Med 100:683–688
Willis JV, Kendall MJ (1978) Scand J Rheumatol 22 (Suppl):36–41
Borghi C, Corno C, Palummeri E, Giorgi D (1986) Acta Pharmacol Toxicol 59 (Suppl5):101
Rainsford KD (1984) Trends Pharmacol Sci 5:156–159
O’Brien WM, Bagdy GF (1985) J Rheumatol 12:13–20, 347–353, 562–567, 785–790
Rainsford KD, Velo GP (Hrsg.) (1987) Side effects of anti-inflammatory drugs, Bd. I und II, MTP Press, Lancaster
Rainsford KD (1988) J Rheumatol 15 (Suppl 17):63–70
Small RE (1989) Clin Pharm 8:545–548
Fowler PD (1979) Rheumatol Rehabil 2:60–68
Koopmans PP, Thien T, Gribnau FWJ (1987) Eur J Clin Pharmacol 31:553–557
Kuhlmann J (1982) Akt Rheumatol 7:38–43
Reimann IW, Frölich JC (1981) Clin Pharmacol Ther 30:348–352
Danion JM, Schmidt M, Welsch M, Imbs JL, Singer L (1987) Encephale 13:255–260
Gabrielli A, Leoni P, Danieli G (1987) Br Med J 294:776
Daly HM, Boyle J, Roberts CJC, Scott GL (1986) Lancet 1:557
Harima Y, Maekawa T, Miyauchi Y, Tsutsui T, Sakabe T, Koshiro A (1987) Intensive Care Med 13:361–362
Netter P, Lambert H, Larcan A, Godbillon J, Gosset J (1984) Eur J Clin Pharmacol 26:535–536
Hs/KA
Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 532–533
Schmitt C, Vandenheuvel WJA, Walker RW, Plazonnet B (1979) J Pharm Sci 68:381–383
WE
Novello FC, Bell SC, Abrams ELA, Ziegler J, Sprague JM (1960) J Org Chem 25:965–970
Boissier JR, Dumont C, Lesbros J (1966) Therapie 21:331–340
Mar 29, S.985
Oß
Gloxhuber C, Offe HA, Rauenbusch E, Scholtan W, Schmid J (1965) Arzneim Forsch 15:322–330
Knott T, Lange A, Volkening R (1965) Arzneim Forsch 15:331–340
Sutherland R, Croydon EAP, Rolinson GN (1970/4) Br Med J:455–460
Gravenkemper CF, Bennett JV, Brodie JL, Kirby WMM (1965) Arch Intern Med 116:340–345
Thijssen HHW, Mattie H (1976) Antimicrob Agents Chemother 10:441–446
Thijssen HHW (1980) J Chromatog 183:339–345
Thijssen HHW (1979) J Antibiotics 32:1.033–1.037
Cole M, Kenig MD, Hewitt VA (1973) Antimicrob Agents Chemother 3:463–468
Onorato JM, Axelrod JL (1978) Arch Intern Med 89:497–500
Deboever G (1987) Amer J Gastroenterol 82:483
Tauris P, Jorgensen NF, Petersen CM, Albertsen K (1985) Acta Med Scand 217:567–569
Nauta EH, Mattie H (1976) Clin Pharmacol Ther 19:98–108
Daten der Firma Bayer (s. Fachinfo zu Dichlor-Stapenor®)
Barza M, Weinstein L (1976) Clin Pharamcokinet 1:297–308
Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M (1992) J Hepatol 15:154–161
CW
Gloxhuber C, Offe HA, Rauenbusch E, Scholtan W, Schmid J (1965) Arzneim Forsch 15:322
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Stoffe, Editio Cantor, Aulendorf
MuraiY, Nakagawa T, Okumura K, Uno T (1984) Chem Pharm Bull 32:3277–3280
GU
Link KP (1959) Circulation 19:97–109
Suttie JW (1987) Adv Exp Med Biol 214:3–16
Preusch PC, Smalley DM (1990) Free Radic Res Commun 8:401–415
Myszka DG, Swenson RP (1991) J Biol Chem 266:4.789–4.797
Liska DJ, Suttie JW (1988) Biochemistry 27:8.636–8.641
Rockwell S, Keyes SR, Sartorelli AC (1989) Cancer Chemother Pharmacol 24:349–353
Sartorelli AC (1988) Cancer Res 48:775–778
Mar 29, Anticoagulants, S. 338–349
Otagiri M, Miyoshi T, Yamamichi R, Maruyama T, Perrin JH (1991) Biochem Pharmacol 42:729–733
Majerus PW, Broze GJ, Miletich JP, Tollefsen DM (1990) Anticoagulant, Thrombolytic, and Antiplatelet Drugs. In: Goodman-Gilman A, Rall W, Nies AS, Tay lor P (Hrsg.) The Pharmacological Basis of Theapeutics, 8. Aufl., Pergamon Press, New York, S. 1.311–1.331
American College of Chest Physicians and the National Heart. Lung, Blood Institute. National Conference on antithrombotic therapy (1986) Chest 89 Suppl:1s-106s
Arfvidsson B, Lundgren F, Drott C, Schersten T, Lundholm K (1990) Am J Surg 159:556–560
Kretschmer G, Wenzl E, Huk I, Polterauer P, Ehringer H, Minar E, Schemper M (1987) Wien Klin Wochenschr 99:591–595
Levine MN, Hirsh J (1986) Semin Thromb Hemost 12:39–57
Griffin JP, D’Arcy PF, Speirs CJ (1988) Anticoagulants. In: A Manual of Adverse Drug Interactions. 4. Aufl., John Wright, London, S. 137–158
EH
Bohlmann F, Herbst P, Arndt C, Schönowsky H, Gleinig H (1961) Chem Ber 94:3193–3212
Bohlmann F, Mönch H, Blaskiewicz P (1967) Chem Ber 100:611–617
Breinlich J, Scharnagel K (1968) Arzneim Forsch 18:429–431
Mitteilung der Asta Pharma (1991) Frankfurt
RÜ
Bohlmann F, Herbst P, Arndt C, Schönowski H, Gleinig H (1961) Chem Ber 94:3193–3212
Bohlmann F, Mönch H, Blaskiewicz P (1967) Chem Ber 100:611–617
Mitteilung der Asta Pharma (1991), Frankfurt
RÜ
Tilford M et al (1947) J Am Chem Soc 69:2903–2905
Kopp M, Tchouber B (1952) Bull Soc Chim France 1952:84–89
Yoshida Y, Iwashige M (1955) Pharm Bull (Tokyo) 3:417–425
Verrier M (1959) Bull Soc Chim France 1959:1863–1865
Mills III T, Roberson J C (1987) Instrumental Data for Drug Analysis, 2. Aufl., Bd. 1 Elsevier, New York-Amsterdam-London, S.654–655
Meffin P J, Moore G, Thomas J (1973) Anal Chem 45:1964–1966
Gb
Kilbinger H, Stein A (1988) B J Pharmacol 94:1.270–1.274
Nilvebrant L, Sparf B (1986) Eur J Pharmacol 123:133–143
Freedman SB, Beer MS, Harley EA (1988) Eur J Pharmacol 156:133–142
Delmendo RE, Michel AD, Whiting RL (1989) Br J Pharmacol 96:457–464
Anticholinergics/Spasmodics. In: Drug Information for the health care professional (USPDI) (1990) Bd. IA, The United States Pharmacopeial Convention, Rockville Maryland (USA), S. 312–332
Smith JM (1980) J Cln Psychiatry 41:351–354
Greenblatt DJ, Shrader RI (1973) N Engl J Med 288:1.215–1.219
Mar 29, S. 530
Noronha-Blob L, Lowe VC, Peterson JS, Hanson RC (1989) J Pharmac Exp Ther 249:843–851
RJ
Dibbern HW, Wirlitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
Mills III T, Roberson IC (1987) Instrumental Data for Drug Analysis, 2. Aufl., Bd. 1, Elsevier, New York Amsterdam London
SchmidtF (1968) Arch Pharm (Weinheim) 301:940–942
MeffinPJ, Moore G, Thomas J (1973) Anal Chem 45:1964–1966
Oza SP, Dave MP, Vakil HN (1991) Indian Drugs 28:198–200
Shingbal DM, Barad UG (1985) Indian Drugs 22:609–610
Raggi MA, Cavrini V, Di Pietra AM (1985) J Pharm Biomed Anal 3:287–291
Hanna GM (1984) J Assoc Off Anal Chem 67:222–224
Jane I, Mc Kinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225
Gb
Hübner M, Ponsold K, Oettel M, Freund R (1980) Arzneimittelforschung/Drug Res 30:401–406
OettelM,Kurischko A (1980) Contraception 21:61–75
Oettel M, Komor A, Goncharov NP, Kurischko A, Strecke J, Schubert K (1980) Contraception 21:537–549
Freund H, Hesse G, Oettel M (1980) Contraception 21:641–650
Majumdar SS, Chaudhary J, Sharma RK, Das RP (1990) Contraception 41:641–649
Hobe G, Hillesheim HG, Schumann W, Ritter P, Claussen C (1983) Exper Clin Endocrinol 81:158–167
Hobe G, Klinger G, Reddersen G, Erdmann A, Klinger G (1986) Pharmazie 41:772–774
Klinger G, Carol W (1985) Wiss. Beiträge der Friedrich-Schiller-Universität, Jena, IV. Jenaer Symp. Horm. Kontrazeption, S. 125–141
Klinger G, Carol W (1989) Wiss. Beiträge der Friedrich-Schiller-Universität, Jena, IV. Jenaer Symp. Horm. Kontrazeption, S. 30–51
Klinger G (1989) Wiss. Beiträge der Friedrich-Schiller-Universität, Jena, IV Jenaer Symp. Horm. Kontrazeption, S. 141–144
Hillesheim HG, Hoffmann H (1983) Exper Clin Endocrinol 81:175–178
Hoffmann H, Hillesheim HG, Güttner J, Stade K, Merbt EM, Holle K (1983) Exper Clin Endocrinol 81:179–196
OM
Clarke CGC (Hrsg.) (1969/1975) Isolation and Identification of Drugs, Pharmaceutical Press, London
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, London
PA
Testa E, Fontanella L, Christiani G, Gallo G (1959), J Org Chem 24:1928–1936
NE
Mar 29, S.531
vB
Charpentier P (Rhone Poulenc) Fr Pat 986, 718 (ert. 1951); CA50:7880d (1956)
Clarke CGC (1969/1975), Isolation and Identification of Drugs, Pharmaceutical Press, London
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, London
PA
Maxim R (1929) Bull Soc Chim Romania 11:29–32
Mc Cabe ET et al. (1954) J Org Chem 19:493–496
Moffat AC (hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, London
eigene Messungen
Wu A et al. (1979) J High Resolut Chromat Commun 2:558–562
QO
Kushner S et al (1948) J Org Chem 13:144
sb/Ni
Denham DA (1986) Nematode infections in man, extraintestinal infections. In: Campbell WC, Rew RS (Eds.) Chemotherapy of parasitic diseases, Plenum Press, New York London, p. 277–286
Bossche H van den (1981) Ann Soc Belg Med Trop 61:287–296
Hawking F, Sewell P, Thruston JP (1950) Br J Pharmacol 5:217–238
Mehlhorn H, Steinhorst U, Lindenblatt B, Grüntzig J, Thomas H (1981) Zentralbl Bakteriol Hyg I Abb Orig A 251:263–272
Kobayashi J, Matsuda H, Fujita K, Sakai T, Shinoda K (1969) Jpn J Parasitol 18:563–574
Piessens WF, Beldekas M (1979) Nature 282:845–847
Beckenridge A, Awadzi K, Back DJ, Edwards G, Gilles H, Orme M, Ward S (1984) Biochem Soc Trans 12:90–95
Roberson EL (1988) Chemotherapy of parasitic diseases. In: Booth NH, McDonald LE (Eds.) Veterinary Pharmacology and Therapeutics, Iowa State University Press, Ames, S. 877–968
Adam D, Christ W (1987) Antiinfektiöse Therapie. In: Forth W, Henschler D, Rummel W (Hrsg.) Allgemeine und spezielle Pharmakologie und Toxikologie, Wissenschaftsverlag, Mannheim Wien Zürich, S. 580–715
Rote Liste (1989)
Andrews P (1985) Anthelmintics, Ullmanns’s encyclopedia of industrial chemistry, VCH Verlagsgesellschaft 2:329–342
ha
Baveja SK, Rao KVR (1981) Analyst 106:726
Allen GD, Goodchild TH, Weatherly BC (1979) J Chromatogr 164:521
BulbuleMV, Kasture A, Wadodkar SG (1981) Indian Drugs 19:27, zit. nach CA (1982) 96:129.876b
sb/Ni
Handbook of Pharmaceutical Excipients (1986), American Pharmaceutical Association, Washington, USA, S.105
BK
Korn 2, S. 1.442
Eb/kp
Westerholm B (1980) Pharmac Ther 10:337–349
Beral V,Colwell L(1980) Br Med J 281:1.098–1.106
Fachinformation Merbentul, Merrel Dow Pharma GmbH, Juni 1990
Haspels AA (1972) IPFF med Bull 6:3–7
Oettel M (1975) Pharmazie 30:42–47
Konturri M, Sotaniemi E, Ahlqvist J (1972) Scand J Urol Nephrol 6:289–294
Herbst AL, Cole P, Colton T, Robboy SJ, Scully RE (1977) Am J Obstet Gynec 119:713–720
Oelschläger H, Rothley D, Dunzendorfer U (1984) Arzneim Forsch/Drug Res 34:1.333–1.336
Mar 29, S. 1.433–1.435
Brandes LJ, Hermonat MW (1983) Cancer Res 43:2.831–2.835
Griffiths K, Peeling WB, Harper ME, D Avies P, PierrePoint CG (1981) Prostatic cancer: rational for hormonal therapy. in: Stoll BA (Hrsg.) Hormonal management of endocrine-related cancer, Lloyd-Luke, London, S. 131–147
Schneider MR, Humm A, Graf AH (1990) J Cancer Res Clin Oncol 116:159–167
Forth W, Henschler D, Rummel W (1987) Allgemeine und spezielle Pharmakologie und Toxikologie, 5. Aufl., Bibliographisches Institut & FA. Brockhaus AG, S.416
Oettel M (1971) Mh Vet med 26:670–672
Vangils APG, Tham RTO, Falke THM, Peters AAW (1990) Am J Roentgenol 153:1.235–1.238
Sharp GB, Cole P (1990) Am J Obstet Gynecol 162:994–999
Thorp JM, Fowler WC, Donehoo R, Sawicki C, Bowes WA (1990) Obstet Gynecol 76:828–832
Liehr JG (1990) Mut Res 238:269–276
Hailing A, Forsberg JG (1990) J Reprod Fert 88:399–405
Sharp GB, Cole P (1990) Am J Obstet Gynecol 162:994–1.001
De Sario A, Vagnarelli P, De Carli L (1990) Mut Res 243:127–131
Walker BE (1990) J Natl Cancer Inst 82:50–54
Bergsjo P, Brodtkorb C (1974) Acta Obstet Gynec Scand 53:77–80
OM
Oda T, Murai T, Sato Y (1988) Chem Parm Bull 36:1534–1539
Inamori Y (1985) Chem Pharm Bull 33:4478–4483
McLachlan JA (1982) Cancer Res 42:3040–3045
JM/Mo/Wc
Kuznetsov SG, El’tsov AV (1962) Zh Obshch Khim 32:511–515, zit. nach CA (1963) 58:470b
Hoffmann C (1965) Fr M 3406, zit. nach CA (1965) 63:13163a
gs
Hoffmann C (1965) Fr M 3406, CA (1965) 63:1.3163a
Kuznetsov SG, El’tsov AV (1962) Zh Obshch Khim 32:511–515, CA (1963) 58:470b
van Wijngaarden I, Soujdin W (1972) Arzneim-Forsch 22:513–516
Eisner M, Ferrat E (1976) Arzneim-Forsch 26:1.642–1.644
van Nueten JM, Janssen PAJ (1972) Arzneim-Forsch 22:518–520
Bianchi C, Goi A (1977) Arzneim-Forsch 27:1.040–1.043
Niemegeers CJE, Lenaerts FM, Janssen PAJ (1972) Arzneim-Forsch 22:516–518
Stransky M, Schwarzenbach FH (1979) Therap Umschau 36:267–270
Schenker H (1976) Schweiz med Wschr 106:1.650–1.653
Rubens R, Verhaegen H, Brugmans J, Schuermans V (1972) Arzneim-Forsch 22:513–516
Awouters F, Niemegeers CJE, Janssen PAJ (1983) Ann Rev Pharmacol Toxicol 23:279–301
Mar 29, S. 1.087
Heykants J, Brugmans J, Verhaegen H (1972) Arzneim-Forsch 22:529–531
Heykants J, Lewi PJ, Janssen PAJ (1972) Arzneim-Forsch 22:520–526
PK
Janel, Mc Kinnon A, Flanagan RJ (1985) J Chromatogr 323(2):191–225
WP
Mar29,S.662
vB
Barquin A, Jose J (1982), S.31
Mitteilungen der Fa. Upjohn, 6148 Heppenheim
Van de Vaart FY, Hultshoff A, Indemans AWM (1983) Pharm Weekbl Sci Ed 5:113–118
Heintz B, Kalusa R (1978) Dtsch Apoth Ztg 118:1.000–1.006
Kirschmann Y, Poet R, Bush K, Petrie G (1980) J Chromatogr 190:481–485
Shaw MC, Van der Wielen AJ (1984) J Pharm Sci 73:1.606–1.608
As
Miller JA, Munro DD (1980) Drugs 19:119–134
Goa KL (1988) Drugs 36 S5:51–61
Pichl J, Schell H (1990) Z Hautkrankheiten 65:527–533
Tronnier H (1987) Aerztl Kosmetol 17:458–482
Leiferman KM, Schroeter A, Kirschner MK, Speisberg TC (1983) J Invest Dermatol 81:355–360
Munck A, Mendel DB, Smith LI, Orti E (1990) Am Rev Respir Dis 141 S2:S2–10
Bowen DL, Fauci AS (1988) Adrenal corticosteroids. In: Gallin JI, Goldstein IM, Snyderman R (Hrsg.) Inflammation: basic principles and clinical correlates, Raven Press, New York, S. 877–896
Bluefarb SM, Howard FJ, Leibsohn E, Schlagel CA (1976) J Int Med Res 454
Turi JS, Danielson D, Wolterson JW (1979) J Pharm Sci 68:375
Niedner R (1989) Dtsch Aerztebl 86:1798–1803
Teller E (1983) Dtsch Dermatol 31:56–62
Eichenberger-de Beer H (1982) Schweiz Rundsch Med 32:1266–1268
Chan MM, Hall JH, Kirschenbaum MB, Klein L, Leibsohn E, Peng VT, Roth H, Savin RC, Schlagel CA (1977) Curr Ther Res 22:297
Squires JP, Masson EL (1981) J Int Med Res 9:79
GM
Kapp JF, Koch H, Casals-Stenzel J, Töpert M, Gerhards E (1976) Arzneim Forsch 26:1.463–1.475
Reckers R, Wendt H (1976) Arzneim Forsch 26:1.499–1.504
Miller JA, Munro DD (1990) Drugs 19:119–134
Goa KL (1988) Drugs 36 S5:51–61
Pichl J, Schell H (1990) Z Hautkrankheiten 65:527–533
Tronnier H (1987) Aerztl Kosmetol 17:458–482
Leiferman KM, Schroeter A, Kirschner MK, Speisberg TC (1983) J Invest Dermatol 81:355–360
Munck A, Mendel DB, Smith LI, Orti E (1990) Am Rev Respir Dis 141 S2:S2–10
Lavker RM, Schechter NM, Lazarus GS (1986) Br J Dermatol 115 S31:101–107
Hahn HL (1990) Wirkungsmechanismen der Glukokortikoide bei Asthma, bronchialer Entzündungsreaktion und Hyperreaktivität. In: Nolte D (Hrsg.) Glukokortikoide bei obstruktiven Atemwegserkrankungen, de Gruyter, Berlin New York, S. 23–56
Schleimer RP (1990) Am Rev Respir Dis 141 S2:59–69
Täuber U (1976) Arzneim Forsch 26:1.479–1.483
Täuber U (1983) Arzneim Forsch 33:1.503–1.507
Täuber U, Amin M, Fuchs P, Speck U (1976) Arzneim Forsch 26:1.492–1.494
Täuber U, Toda T (1976) Arzneim Forsch 26:1.484–1.487
Mützel W (1976) Arzneim Forsch 26:1.487–1.492
Langen ML (1979) Clinical Ther 2:124–133
Kesczkes K, Teasdale P, Wiseman RA, Mugglestone CJM (1978) Br J Dermatol 99:417–420
Reckers R, Wendt H (1976) Arzneim Forsch 26:1.504–1.509
Takeda K, Arase S, Takahashi S (1988) Drugs 36 S5:15–23
GM
Cotton M, Hux R in Florey 14:491
Ruyle, William V, Sarett, Lewis H: Matzuk, Alexander S; African 67 01, 021
Rh
Stone CA, Van Arman CG, Lotti VJ, Minsker DH, Risley EA, Bagdon WZ, Bokelman DL, Zensen RD, Mendlowski B, Tak CL, Peck HM, Zwickey RE, McKinney SE (1977) Br J Clin Pharmacol 4:19S–29S
Forbes JA, Calderazzo JP, Bowser MW, Foor VM, Shackleford RW, Beaver WT (1982) Z Clin Pharmacol 22:89–96
Honig WJ, Van Ochten J (1986) J Clin Pharmacol 26:700–705
DeVroey P (1978) Curr Med Res Opin 5:544–547
Brodgen RN, Heel RC, Pakes GE, Speight TM, Avery GS (1980) Drugs 19:84–106
Majerus PW, Stanford N (1977) Br J Clin Pharmacol 4:15S–18S
Forrest M, Brooks PM (1988) Basilliére’s Clinical Rheumatology 2:275–294
Schultz P, Perrier CV, Ferber-Perret F, Vanden Heuvel WZA, Steelman SL (1979) J Int Med Res 7:61–68
Smit Sibinga CT, Tempero KF, Breault GO (1976) Effect of flunisal, a novel salicylate, on platelet function and blood coagulation. In: Grayson Z, Zingg W (ed.) Microcirculation. Vol.1, Plenum Press, London, New York, S. 211–212
Smit Sibinga CT (1977) Br J Clin Pharmacol 4:37S–38S
Green D, Davies RO, Holmes GI, Kohl H, Lee RB, Reynolds N, Schmid FR, Ts’ao C (1981) Clin Pharmacol Ther 30:378–384
Green D, Davies RO, Holmes GI, Kohl H, Lee RB, Reynolds N, Schmid FR, Ts’ao C (1983) Pharmacotherapy 3:65S–69S
Tempero KF, Cirillo VJ, Steelman SL (1977) Br J Clin Pharmacol 4:31 S-36S
Tempero KF, Cirillo VJ, Steelman SL (1978) The clinical pharmacology of diflunisal. In: Diflunisal in clinical practice. Proceedings of a special symposium at 14th Congress of Rheumatology, Futura Publishing, New York, S. 23–39
Dresse A, Gerard MK, Lays A, Tempero KF, Verhaest L(1978) Pharm Acta Helv 53:177–181
Nuernberg B, Koehler G, Brune K (1991) Clin Pharmacokin 20:81–89
Verbeeck R, Tjandramaga TB, Mullie A, Verbesselt R, DeSchepper PJ (1979) Br J Clin Pharmacol 7:519–522
Tobert JA, DeSchepper P, Tjandramaga TB, Mullie A, Buntiux AP, Meisinger MAP, Huber PB, Hall TLP, Yeh KC (1981) Clin Pharmacol Ther 30:385–389
Verbeeck R, Tjandramaga TB, Mullie A, Verbesselt R, Verbeckmoes R, DeSchepper PJ (1979a) Br J Clin Pharmacol 7:273–282
Tocco DJ, Breault GO, Zacchei AG, Steelman SL, Perrier CU (1975) Drug Metab Disposition 3:453–466
DeSchepper PJ, Mullie A, Tjandramaga TB, Verbeeck R, Verbeckmoes R (1977) Br J Clin Pharmacol 4:645P
Steelman SL, Breault GO, Tocco DJ, Besselaar GH, Tempero KF, Lutterbeck PM, Perrier CU, Gribman FW, Hinseimann M (1975) Clin Pharmacol Ther 17: 245
Buck ME, Paintin DB (1978) Curr Med Res Opin 5:548–549
Goutallier D, Dedeyre J, Bock F (1978) A doubleblind study comparing the efficacy and safety of diflunisal and of glafenine in the relief of postoperative pain. In: Diflunisal in clinical practice. Proceedings of a special symposium at 14th Congress of Rheumatology, Futura Publishing, New York, S. 119–129
Ackermann K, Braun HD (1978) Diflunisal in the treatment of postoperative pain in oral surgery. In: Diflunisal in clinical practice. Proceedings of a special symposium at 14th Congress of Rheumatology, Futura Publishing, New York, S. 143–148
Peterson JK (1979) Int J Oral Surgery 8:102–113
Peterson JK (1978) Diflunisal in the treatment of postoperative pain in oral surgery. In: Diflunisal in clinical practice. Proceedings of a special symposium at 14th Congress of Rheumatology, Futura Publishing, New York, S. 133–142
Jaegemann V (1979) Diflunisal compared with placebo in acute untreated lumbago. In: Diflunisal. Royal Society of Medicine, International Congress and Symposium Series, No 6, Academic Press/Royal Society of Medicine, London, S. 45–19
Cirillo VJ, Bahous I, Franchimont P, Baumgartner H, Van Gemert J, Lutterbeck PM, Hwang I, Tempero KF (1978) Clin Trials J 15:40–48
Bahous I, Lutterbeck PM, Tempero KF (1978) Clin Ther(SupplA)l:10–19
Lee P, Davis P, Prat A (1985) J Rheumatol 12:544–548
Poe TE, Limpert GH, Winkler GJ (1989) J Fam Pract 28:104–105
Huskisson EC (1979) Practitioner 222:415–418
McLean CA, Begley CG, Harris RA (1986) Aust NZ J Med 16:811–812
Rider JA (1983) Pharmacotherapy 3:61S–64S
O’Brien WM, Bagby GF (1985) J Rheumatol 12:785–790
Warren JS (1978) Br Med J 2:736–737
Chan LK, Winearls CG, Oliver DO, Dunnill MS (1980) Br Med J 1:84–85
Steelman SL, Cirillo VJ, Tempero KF (1978) Curr Med Res Opin 5:506–514
Serlin MJ, Mossman S, Sibeon RG, Breckenridge AM (1980) Clin Pharmacol Ther 28:493–498
Upadhayay HP, Gupta SK (1978) Br Med J 2:640
Me
Zeliha I, Türkan Y (1986) Planta Med 53:43–46
Kiliani H (1892) Arch Pharm 230:250
Rittel W, Hunger A, Reichstein T (1952) Helv Chim Acta 35:434
AG
Bloch R, Steimer C, Spach MO, Schwartz J (1978) Coeur Med Interne 17:403–409
Bloch R, Steimer C, Schwartz J (1981) Rev Med Interne 2:349–355
Chiche P, Baligadoo S, Lamelle P, Borgard JP (1976) Coeur Med Interne 15:249–262
Scholz H (1989) Herzinsuffizienz. In: Fülgraff G, Palm D (Hrsg.) Pharmakotherapie, Klinische Pharmakologie, 7. Aufl., Gustav Fischer Verlag, Stuttgart, S.42–57
Lö
Brown L, Cheung HTA, Thomas R, Watson TR, Nemorin JLE (1981) J Chem Soc Perkin Trans 1:1779–1781
Kedde DL (1947) Pharm Weekbl 82:741
Keller CC (1895) Ber Dtsch Pharm Ges 5:275
Kiliani H (1899) Arch Pharm 237:446
AG
Braunwald E, Bloodwell RD, Goldberg LJ (1961) J Clin Invest 40:52–60
Mason DT (1974) Ann Int Med 80:520–530
Covell JW, Braunwald E, Ross J Jr (1966) J Clin Invest 45:1.535–1.543
Bailey JC, Anderson GJ, Fisch C (1973) Am J Cardiol 32:202–208
Higgins CB, Vatner SF, Braunwald E (1973) Pharm Rev 25:119–155
Hordorf HJ, Spotnitz A, Mary-Rabine L, Edie RN, Rosen MR (1978) Circulation 57:223–229
Weidmann S (1974) Ann Rev Physiol 36:155–169
Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG (1989) Circulation 80:65–77
Haasis R, Larbig D (1975) Dtsch Med Wochenschr 100:1.768–1.773
Amelie JP, Storstein L, Heldaas O (1979) J Cardiovasc Pharmacol 1:529–540
Aronson JK (1983) Clin Sci 64:253–258
Scholz H (1984) J Am Coll Cardiol 4:389–397
Kim D, Cragoe EJ Jr, Smith TW (1987) Circ Res 60:185–193
Allen DG, Blinks JR (1978) Nature (London) 273:509–513
Eisner DA, Lederer WJ (1985) Am J Physiol 248:C189–C202
Fabiato A, Fabiato F (1975) J Physiol (London) 249:469–495
Smith TW, Butler VP Jr, Haber E (1982) N Engl J Med 307:1.357–1.362
Mulrow CD, Feussner JR, Velez R (1984) Ann Int Med 101:113–117
Parmly WW (1989) J Am Coll Cardiol 13:771–785
Chai CY, Hsu PL, Wana SC (1973) Neuropharmacol 12:1.187–1.193
Mooradian AD (1988) Clin Pharmacokinet 15:165–179
Belz GG,PfledererW (1975) Basic Res Cardiol 70:142
Kuemmerle HP (1989) Klinische Pharmakologie. Datenhandbuch für Klinik und Praxis, ecomed-verlagsgesellschaft mbH, Landsberg München Zürich
Lö
BAz, Nr. 22a vom 03.02.1988
GS
Brown L, Cheung HTA, Thomas R, Watson TR, Nemorin JLE (1981) J Chem Soc Perkin Trans 1:1.779–1.781
Kedde DL (1947) Pharm Weekbl 82:741
Keller CC (1895) Ber Dtsch Pharm Ges 5:275
Kiliani H (1899) Arch Pharm 237:446
Baljet H (1918) Schweiz Apoth Ztg 56:71,84
AG
Aronson JK,Gaham-Smith DG (1976) Br J Clin Pharmacol 3:639–648
Larbig D, Haasis R, Kochsiek K (1978) Die Glykosidkonzentration und ihre klinsche Bedeutung: Neue Erkenntnisse für die Digitalistherapie durch radioimmunologische Bestimmung von Lanata-Glykosiden, forum cardiologicum 15:Studienreihe Boehringer-Mannheim
Mooradian AD (1988) Clin Pharmacokinet 15:165–179
Ferrer MJ, Conroy RJ, Harvey RM (1960) Circulation 21:372–385
Scholz H (1984) J Am Coll Cardiol 4:389–397
Buschauer A (1989) Pharm Ztg Wiss 134:3–16
Kuemmerle HP (1989) Klinische Pharmakologie, Datenhandbuch für Klinik und Praxis, ecomed-verlagsgesellschaft mbH, Landsberg München Zürich
Doherty JE, Parkins WH (1962) Am Heart J 63:528–536
Kuhlmann I, Rietbrock N, Schnieders B (1979) J Cardiovasc Pharmacol 1:219–234
Brurion PF, Morgan LM, Stevenson HM, Fletcher E (1969) Brit Heart J 31:633–640
Allonen H, Andersson KE, Gisalo E, Kanto I, Stomblad LG, Wettrell G (1977) Acta Pharmacol Toxicol (Kbh) 41:193–201
Peters U, Falk LC, Kaiman SM (1978) Arch Intern Med 138:1.074–1.076
Zilly W, Richter E, Rietbrock N (1975) Clin Pharmacol Ther 17:302–309
Aronson JK (1978) Brit J Clin Pharmacol 5:55–64
Johnston GD (1989) Drugs 37:577–582
Steiness E (1978) Clin Pharmacol Ther 23:511–514
Leahey EB jr, Reiffei JA, Heissenbuthe RH, Drusin RE, Lovejoy WP, Bigger T jr (1979) Arch Intern Med 139:519–521
Lö
Sharp ME (1986) Can Soc Forensic Sci J 19:83–101
Kopp M, Tchouber B (1952) Bull Soc Chim Fr :84–86
gs
Mar 29, S. 531
EH
Drew HDK, Hatt HH, J Chem Soc (1937) 16; Haworth RD, Robinson S, J Chem Soc (1948) 777; Ciba DBP 847.748 (1949) Zentralbl. (1953) 53 85, U.S.Pat. 2484 785 (1949) CA (1950) 44:2573i
hh
Tripod J, Meier R (1954) Arch int Pharmacodyn 99:104–125
Bein HJ, Gross F, Tripod J, Meier R (1953) Schweiz Med Wochenschr. 83:336–340
Kolloch R (1983) Vasodilatatoren. In: Stumpe KO (Hrsg.) Therapie mit Antihypertensiva, Springer-Verlag, Berlin Heidelberg New York Tokyo, S. 55–105
Esselier AF, Luscher W, Morandi L (1053) Schweiz Med Wochenschr 83:28–37
Schaub F, Nager F, Schrithin W, Völlm K, Hany A (1964) Schweiz Med Wochenschr 94:769–775
Van Zwieten PA (1968) Arzneim Forsch 18:79–84
Koch-Weser J (1974) Arch Int Med 133:1.017–1.027
Reimann IW, Ratge D, Wisser H, Fröhlich JC (1985) Clin Exp Pharmacol Physiol 12:79–89
Gross F (1977) Drugs acting on arteriolar smooth muscle (vasodilator drugs). In. Gross F (Hrsg.) Antihypertensive Agents, Springer-Verlag, Berlin Heidelberg New York, S. 397–476
Struyker-Boudier HAJ, Van Essen H, Smits JFM (1983) Eur J Pharmacol 95:151–159
Heidland A, Heidbreder E (1985) Therapie des hypertensiven Notfalls und der malignen Hypertonie. In: Ganten D, Ritz E (Hrsg.) Lehrbuch der Hypertonie, Schattauer Verlag, Stuttgart New York, S. 705–725
Schroeder T, Sillesen H (1987) Eur J Clin Invest 17(3):214–217
Reubi FC (1950) Proc Soc exp Biol (N.Y.) 73:102–103
Fries ED (1953) Circulation 8:199–204
Heidbreder E, Heidland A (1985) Behandlung der Hypertonie bei chronischer Niereninsuffizienz. In. Ganten D, Ritz E (Hrsg.) Lehrbuch der Hypertonie, Schattauer Verlag, Stuttgart New York, S. 726–742
Curtis JR (1979) Drugs 18(5):377–391
Shultz PJ, Raij L (1989) Br J Clin Pharmacol 28(2):151S–157S
Fachinformation Nepresol/Nepresol forte CIBA Pharma, Feb 1991, Editio Cantor Verlag, Aulendorf
Schneider T, Siegmund W, Zschiesche M, Kallwellis R, Scherber A (1988) Pharmazie 43(1):33–36
Palm D, Hellenbrecht D (1987) Pharmakologie des noradrenergen und adrenergen Systems. In: Forth W, Henschler D, Rummel W (Hrsg.) Allgemeine und spezielle Pharmakologie und Toxikologie, BI Wissenschaftsverlag, Mannheim Wien Zürich, S. 124–168
Franke G, Pietsch P, Schneider T, Siegmund W, Grabow D, Schutz H (1986) Biol Res Pregnancy Perinatol 7(1)30–33
Ashe RG, Moodley J, Richards AM, Philpott RH (1987) S Afr Med J 71(6):354–356
Jamieson MJ, Shepherd AMM (1987) Vasodilators: first or second choice therapy? In: Drayer JIM, Lowenthal DT, Weber MA (Hrsg.) Drug Therapy in Hpertension, Marcel Dekker, Inc., New York Basel, S. 163–190
Salvadeo A, Villa G, Segagni S, Piazza W, Criscuolo D (1981) Int J Clin Pharmacol Ther Toxicol 19(8):372–376
Mauro F (1990) Listing of antihypertensive medications. In: Ganten D, Mulrow PJ (Hrsg.) Handbook of Experimental Pharmacology, Bd. 93, Pharmacology of Antihypertensive Therapeutics, Springer-Verlag, Berlin Heidelberg, S. 861–874
Pariente EA, Pessayre D, Bernuau J, Degott C, Benhamou JP (1983) Digestion 27:47–52
Baumgartner R, Siegmund W, Frengler JD (1988) Z Klin Med 43(2):87–89
GW
Hartke K, Mutschier E (Hrsg.) (1986) Kommentar zum Deutschen Arzneibuch 9.Ausg., Bd. 1 bis 3, Wissenschaftliche Verlagsgesellschaft, Stuttgart
Skita A, Franck HH (1911) Chem Ber 44:2861–2865
Budĕšinský, Protiva A (1961) Synthetische Arzneimittel, Akademie Verlag, Berlin, S. 192
Stein A (1955) Pharmazie 10:180–186
Ehrhart G, Ruschig H (1972) Arzneimittel, 2. Aufl., Verlag Chemie, Weinheim, S. 118
Takagi Y, Ueda J (1936) J Pharm Soc Jpn 56:44–56
Bobbitt JM, Weiss U, Hanessian DD (1959) J Org Chem 24:1582–1584
Okuda S, Yamaguchi S, Kawazoe Y, Tsuda K (1964) Chem Pharm Bull 12:104–112
Caroll JI, Moreland ChG, Brine GA, Kepler JA (1976) J Org Chem 41:996–1001
Gb
Friebel H, Reichle C, Graevenitz A v (1955) Naunyn-Schmiedeberg’s Arch Exper Path Pharmak 224:384–400
Haas, H (1955) Dtsch Apoth Ztg 95:1143–1148; 1171–1175
Haas H (1955) Naunyn-Schmiedeberg’s Arch Exper Path Pharmak 225:442–452
Seymour RA, Rawlins MD, Rowell FJ (1982) Lancet 1:1425
Vaughan DP, Beckett AH (1973) J Pharm Pharmacol 25 (Suppl.):104P–108P
Johnson MA, Woodcock AA, Geddes DM (1983) Br Med J 286:675–677
Supinski G, Dimarco A, Bark H, Chapman K, Clary S, Altose M (1990) Am Rev Respir Dis 141:1516–1521
Rowell FJ, Seymour RA, Rawlins MD (1983) Eur J Clin Pharmacol 25:419–424
Marks P, Ashraf H, Root TR (1978) Brit Med J i:1594
Kurz H (1989) Antitussiva und Expektoranzien, Wissenschaftliche Verlagsgesellschaft, Stuttgart
SZ
Wieland H, Koralek E (1923) Liebigs Ann Chem 433:267–271
Gb
Stein A, (1955) Pharmazie 10:180–186
Dibbern HW, Wirlitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Crone TA, Purdie N (1981) Anal Chem 53:17–21
Okuda S, Yamaguchi S, Kawazoe Y, Tsuda K (1964) Chem Pharm Bull 12:104–112
Carroll FI, Moreland ChG, Brine GA, Kepler JA (1976) J Org Chem 41:996–1001
Pesez M (1935) J Pharm Chim 21:542–544
Philippi I, Auterhoff H (1976) Dtsch Apoth Ztg 116:206–206
Böhme H, Hocke H (1960) Arch Pharm 293:342
Sakano I, Kokubo S (1989) Anal Sci 5:623–624
Jane I, McKinnon A, Flanagan RJ (1985) J Chromatogr 323:191–225
Gb
Goldstein M, Lew JY, Hata F, Liebermann A (1978) Gerontology (Basel) 24(Suppl. l):76–85
Markstein R (1983) Eur J Pharmacol 86:145–155
Weil C (1989) Hydergin-Pharmakologische und klinische Befunde, Springer-Verlag, Berlin Heidelberg New York, S. 137–147
KC
Stoll A, Hoffmann A (1943) Helv Chim Acta 26:2070–2081
SH
Markstein R (1983) Eur J Pharmcol 86:145–155
Müller-Schweinitzer E (1982) Naunyn-Schmiedebergs Arch Pharmacol 318:225–233
Rothlin E (1947) Bull Schweiz Akad Med Wiss 2:246–273
Spagnolis A, Tognoni G (1983) Drugs 26:44–69
Rachmann A, Kellmann L, Kriegelstein J (1984) J Cerebral Blood Flow Metab 4:610–614
Kiechel JR (1979) J Pharmacol (Paris) 10:533–565
Mailland F, Poli A, Zottino G (1984) Curr Ther Res 42:857–861
KC
Stoll A, Hoffmann A (1943), Helv 26:2070, 2080
Sandoz, USP 2507832 (1946)
Cousse H et al. (1972), Bull Soc Chim Fr, S.3131
Dibbern HW (1984), UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Verlag Editio Cantor, Aulendorf
SH
Stoll A, Hofmann A (1943) Helv Chim Acta 26:2070–2081
Yamatodani, Abe (1959) J Agri Chem Soc Japan 33:1036, zit. nach CA (1958) 52:2878
SH
Müller-Schweinitzer E, Weidmann H (1978) Basic pharmacological properties. In: Berde B, Schild HO (Hrsg.) Ergot Alkaloids and Realted Compounds, Handb Exp Pharmacol, Bd. 49, Springer-Verlag, Berlin Heidelberg New York, S. 87–232
Eckert H, Kiechel JR, Rosenthaler J, Schmidt R, Schreier B (1978) Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In: Berde B, Schild HO (Hrsg.) Ergot Alkaloids and Related Compounds, Handb Exp Pharmacol, Bd. 49, Springer-Verlag, Berlin Heidelberg New York, S. 719–803
Weil C (1989) Hydergin-Pharmakologische und klinische Befunde, Springer-Verlag, Berlin Heidelberg New York, S. 143–147
KC
Stoll A, Hoffmann A (1943), Helv Chim, Acta 26:2070 ff.
HÄ/pb
Rall TW (1990) Oxytocin, prostaglandins, ergot alkaloids and other drugs; tocolytic agents. In: Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) The pharmacological basis of therapeutics, 8. Aufl., Pergamon Press, New York Oxford Beijing Frankfurt Sao Paulo Sydney Tokyo Toronto, S. 933–953
Glusa E, Markwardt F (1984) Pharmacology 29:336–342
Müller-Schweinitzer E (1984) Naunyn-Schmiedeberg’s Arch Pharmacol 327:299–303
Mellander S, Nordenfelt I (1970) Clin Sci 39:183–201
Andersen AR, Tfelt-Hansen P, Lassen NA (1987) Stroke 18:120–123
Nordenfelt I, Mellander S (1976) Cardiology 61(Suppl.l):316–321
Barthel W, Großmann K (1982) Int J Clin Pharmacol Ther Tox 20:458–464
Partsch H (1981) Med Welt 32:1.668–1.671
Eichlisberger R, Huber P, Jäger K (1989) Vasa 18:221–226
Barthel W (1984) Z Ges Inn Med 39:417–428
Müller-Schweinitzer E (1984) Int J Clin Pharmacol Ther Tox 22:677–682
Aeilig WH, Nüesch E (1977) Int J Clin Pharmacol Ther Tox 15:106–112
Bobik A, Jennings G, Skews H, Esler M, McLean A (1981) Clin Pharmacol Ther 30:673–679
Schran HF, Tse FLS (1985) Int J Clin Pharmacol Ther Tox 23:1–4
Little PJ, Jennings GL, Skews H, Bobik A (1982) Br J Clin Pharmacol 13:785–790
Olver IN, Jennings GL, Bobik A, Esler M (1980) Br Med J 2:275–276
Wyss PA, Rosenthaler J, Nüesch E, Aellig WH (1991) Eur J Clin Pharmacol 41:597–602
Hilke H, Kanto J, Kleimola T, Mäntylä R (1978) Int J Clin Pharmacol Ther Tox 16:277–278
Kanto J, Allonen H, Koski K, Koulu M, Lammintausta R, Mäntylä R, Kleimola T, Siirtola T (1981) Int J Clin Pharmacol Ther Tox 19:127–130
Hilke H, Kanto J, Mäntylä R, Kleimola T, Syvälahti E (1978) Acta Anaesthesiol Scand 22:215–220
Aellig WH (1984) Eur J Clin Pharmacol 26:239–242
Jennings G, Esler M, Holmes R (1979) Br Med J 2:307–308
de Marées H, Welzel D, de Marées A, Klotz U, Tiedjen KU, Knaup G (1986) Eur J Clin Pharmacol 30:685–689
Müller-Schweinitzer E (1984) Eur J Clin Pharmacol 26:699–705
Labayle D, Chalas J, Lavène D, Humbert M, Azria M, Lindenbaum A, Chaput JC (1982) Gastroenterol Clin Biol 6:129–134
Dumont M, De Couët G, Le Bigot JF, Erlinger S (1985) J Pharmacol Exp Ther 234:239–243
Heuser B, Middendorf E (1985) Fortschr Med 103:966–970
Wörz R (1986) Fortschr Med 104:838–842
Thulesius O, Berlin E (1986) Int J Clin Pharmacol Ther Tox 24:465–467
Goeschen K, Jäger A, Saling E (1984) Geburtshilfe Frauenheilkde 44:351–355
Comerota AJ, White JV (1986) Chest 89(Suppl.):389S–395S
Kakkar VV, Stamatakis JD, Bentley PG, Lawrence D, de Haas HA, Ward VP (1979) JAMA 241:39–41
Gent M, Roberts RS (1986) Chest 89(Suppl.):396S–400S
Wolf H, Welzel D, Kaiser H, Majer M, Schäfer D, Husfeldt KJ, Voigt J, Sunder-Plassmann L (1988) Arzneim Forsch 38:1.516–1.519
Emory CE, Cuddy PG (1987) Drug Intell Clin Pharm 21:427–431
Barthel W, Glusa E, Koth W (1987) Int J Clin Pharmacol Ther Tox 25:63–69
GE/BW
Dibbern H W (1978), UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Ergebnisse der Firma Boehringer Ingelheim
HÄ/pb
Mitteilung der Firma Boehringer Ingelheim
HÄ/pb
v. Békésy N (1940) Biochem Zschr 303,368
SH
Flückinger E, Balthasar HU (1967) Arzneim Forsch 17:6–9
Aeilig WH, Berde B (1969) Br J Pharmacol 36:561–570
Berde B, Stürmer E (1978) Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO (Hrsg.) Handbook of Experimental Pharmacology, Springer-Verlag, Berlin Heidelberg New York, S. 1–28
Rothlin E (1947) Bull Schweiz Akad Med Wiss 2:249–273
Rothlin E, Brügger J (1945) Helv Physiol Pharmacol Acta 3:C43–C44
Fregman BG, Gläser AH (1964) J Pharm Pharmacol 16:744–750
Pacha W, Salzmann R (1970) Br J Pharmacol 38:439P–440P
Rothlin E, Cerletti A (1949) Verh Dt Ges Kreislauf-Forsch 15:158–185
Whitney B (1965) J Pharm Pharmacol 17:465–473
Cripps H, Dearnaley DP (1972) J Physiol (London) 227:647–664
Gillespie JS, Kirkepar SM (1965) J Physiol (Lond) 176: 205–227
Wennmalm A (1971) Acta Physiol Scand 82:532–538
Clark BJ, Bucher T, Weite R (1984) Kardiovaskuläre Wirkungen von Co-Dergocrin. In: Bergener M, Grobecker H (Hrsg.) Hypertonie im Alter: Normvariante oder Krankheit? F.K. Schattauer Verlag, Stuttgart New York, S. 155–165
Mchedlishvili GI, Ormotsadze LG (1974) Pat Fiziol éksp Ther 5:79–81
Karlsberg P, Elliott HW, Adams JE (1963) Neurology (Minneap) 13:772–778
Gaddum JH;, Paasonen MK (1955) Br J Pharmacol 10:474–483
Duret RL (1951) Acta Clin Belg 6:85–106
Marques MG, Rato JA (1954) Cardiologica (Basel) 24:196–206
Clark BJ, Chu DH, Aellig WH (1978) Actions on the heart and circulation. In: Berde B, Schild HO (Hrsg.) Ergot Alkaloids and related Compounds, Handb Exp Pharmacol, Bd. 49, Springer-Verlag, Berlin Heidelberg New York, S. 321–420
Müller-Schweinitzer E (1982) Naunyn-Schmiedebergs Arch Pharmacol 318:225–233
Memo M, Saghedu G, Cappuba MO, Spano PF (1985) Life Sci 36:1.515–1.522
Georges D, Lallemand A, Coustenoble J, Loria J (1977) Thérapie 32:173–180
Siegl H (1985) J Pharmacol (Paris) 16(Suppl.III):129–144 (Engl ed 113–127)
Jubert-Gruart J, Suner F, Gairin J, Fabrega MT, Oiler M (1975) VIIº Symposium Internacional “Insuficienca Circulatoria Cerebral”, Sandoz S.A.E., Barcelona, S. 83–108
Markstein R, Wagner H (1975) FEBS Letters 55:255–257
Iwangoff P, Enz A, Chappuis A (1975) Int Res Commun System Med Sci 3:403
Depoorter H, Loew DM, Vigouret JM (1975) Triangle 14:73–79
Loew DM, Depoortere H, Bürki HR (1976) Arzneim Forsch 26:1.080–1.083
Loew DM, Vigouret JM, Jaton AL (1976) Postgrad Med J 52(Suppl.I):40–46
Wang SC, Glaviano VV (1954) J Pharmacol Exp Ther 111:329–334
Loew DM, Vigouret JM, Jaton AL (1979) Topics Gerontol 15:85–103
Cerletti A, Emmenegger H, Enz A, Iwangoff P, MeierRuge W, Musil J (1973) Effects of ergot DH-alkaloids on the metabolism and function of the brain. An approach based on studies with DH-ergonine. In: Genazzani E, Herken H (Hrsg.) Central Nervous System-Studies on Metabolic Regulation and Function, Springer-Verlag, Berlin Heidelberg New York, S.201–212
Roubicek J, Geiger CH, Abt K (1972) J Am Geriatr Soc 20:222–229
Meier-Ruge W, Enz A, Gygax P, Hunziker O, Iwangoff P, Reichelmeier K (1975) Experimantal pathology in basic research of the ageing brain. In: Gershon S, Raskin A (Hrsg.) Genesis and Treatment of Physiologic Disorders in the Elderly, Raven Press, New York, S. 55–126
Emmenegger H, Meier-Ruge W (1968) Pharmacology (Basel) 1:65–78
Van den Driessche J, Allain H, Bentué-Ferrer D, Feuillu A, Pape D, Milon D, Reymann JM, Sublet Y (1985) J Pharmacol (Paris) 16(Suppl. III):99–113 (Engl ed 85–99
Weil C (1989) Hydergin-Pharmakologische und klinische Befunde, Springer-Verlag, Berlin Heidelberg New York London Paris Tokyo, S. 137–147
Zoglio MA, Maulding HV (1970) J Pharm Sci 59:215–218
Meier-Ruge W, Schieweck C, Iwangoff P (1973) Int Res Comm Service Med Sci 7–10–3
Rothlin E (1947) Schweiz Med Wochenschr 77:1.161–1.163
Luntschli HJ, Goetz RH(1948) Am Heart J 35:873–894
Loew DM, Weil C (1982) Gerontology 18:54–74
Venn RD (1978) Clinical pharmacology of ergot alkaloids in senile cerebral insufficiency. In: Berde B, Schild HO (Hrsg.) Handbook of Experimental Pharmacology, Bd.49, Springer-Verlag, Berlin Heidelberg New York, S. 533–566
Oswald WD, Lang E (1980) Muench Med Wochenschr 122:59–62
Fanchamps A (1983) Controlled studies with dihydroergotoxin in senile cerebral insufficiency. In: Agnoli A, Crepaldi C, Spano PF, Trabucchi M (Hrsg.) Aging Brain and Ergot Alkaloids, Aging, Bd.23, Raven Press, New York, S. 311–322
Hamot HB, Patin JR, Singer JM (1984) Psychopharmacol Bull 20:142–150
Biel LM, Seus R, Struppler A (1976) Med Klin 71:2.177–2.184
Manolidis L, Themelis C, Tsiptsios I, Tsaligolpoulos M (1982) Galenos 24:1.095–1.108
Arranz Munecas T, Ganoza Garcia C, Forcadell Puyo F(1979) Inform Psychat 77:250–258
Hajioff J, Wallace MG (1982) Br J Clin Pract (Suppl.16):43–46
Gouret C, Raynaud GJ (1976) J Pharmacol (Paris) 7:161–175
Kappert A (1949) Helv Med Acta Ser A 16(Suppl.22):66–67
Von Storch TJC (1938) J Am Med Ass 111:293–300
KC
Peck RL, Hoffhine CE, Folkers K (1946) J Am Chem Soc 68:1390
Bartz QR, Controulis J, Crooks HM, Rebstock MC (1946) J Am Chem Soc 68:2163
Fried J, Wintersteiner O (1947) J Am Chem Soc 69:79
Ikeda H (1956) Proc Jap Acad 32, 48 und 53, zit. nach CA (1956) 50:13765
Moffat AC (Hrsg.) Clarkes Isolation and Identification of Drugs (1986) The Pharmaceutical Press, London
Bock K, Pedersen C, Heding H (1974) J Antibiot 27: 139–140
GU
Mar 29, S.216
vB
Ikeda H (1956) Proc Jap Acad 31, 48 und 53, zit. nach (1956) CA 50:13765
Moffat AC (Hrsgb.) Clarkes Isolation and Identification of Drugs (1986) The Pharmaceutical Press, London
Bock K, Pedersen C, Heding H (1974) J Antibiotics 27:139–140
Bartz QR, Controulis J, Crooks HM, Rebstock MC (1946) J Am Chem Soc 68:2163
GU
Brockhaus ABC Chemie, Bd.2 (1971) VEB F.A. Brockhaus Verlag, Leipzig
Westerhof P, Buisman JAK (1956) Recueil Trav. Pays-Bas 15:453
Mills III T, Roberson JC (1987) Instrumental data for drug analysis, 2. Aufl., Vol 1, Elsevier, New York, Amsterdam, London
Berman E, Luz Z, Mazur Y, Sheves M (1977) J Org Chem 42:3325
WO
Suda T, Hallick RB, DeLuca HF, Schnoes HK (1970) Biochemistry 9:1.651–1.657
Hallick RB, DeLuca HF (1972) J Biol Chem 247:91–97
Bosch R, Thijssen JHH, Duursma SA (1987) J Steroid Biochem 27:829–836
Pierides AM (1981) Drugs 21:241–256
Harrison HE, Lifshitz F, Blizzard RM (1967) N Engl J Med 276:894–900
Taylor A, Bikle DD, Norman ME (1988) J Clin Endocrinol Metab 67:198–202
bm
Roth HJ (1959) Arch Pharm 292:234–238
Jeske J, Jakimowska K, Kakolewski J, Stochla K, Trawkowski J (1961) Acta Polon Pharm 18:335
Patent Pol 59,071 (Cl.C07d),15 Mar 1970, Appl. 02 May 1967, zit. nach CA 73:45544d
Farbenfabriken Bayer & Co Elberfeld (1905–1907) Friedländer 8:1136–1137
Ott R (1958) Sci Pharm 26:217–224
Stuchlik M, Csiba J, Krasnec L (1967) Cesk Farm 16(4):187–189, zit. nach CA 67:67530z
Stuchlik M, Csiba J, Krasnec L (1969) Cesk Farm 18(2):91–92, zit. nach CA 71:24754r
Schunack W, Mutschier E, Rochelmeyer H (1965) Dtsch Apoth Ztg 44:1551–1552
Raber H (1964) Sci Pharm 32(2):122–127
Raber H (1967) Sci Pharm 35:220–224
LD
Mar 29, S. 1526
EH
Mar 29, S.662
vB
Mar 29, S.685
vB
Buczkowski Z, Gryff-Keller A, Zajaczkowska E (1972) Rocz Chem 46:1047–1057
Salman S, Bayradkar N (1983) Eczacilik Bul 25:30–33
Hartvig P, Handl W (1975) Acta Pharm Suecica 12:349–360
Vessmann J, Hartvig P, Strömberg S (1970) Acta Pharm Suecica 7:373–388
Hartvig P, Sundin H, Vessmann J (1972) Acta Pharm Suecica 9:269–282
gs
Buczkowski Z, Gryff-Keller A, Zajaczkowska E (1972) Rocz Chem 46:1047–1057
Egli RA, Tanner S (1979) Fresenius Z Anal Chem 295:398–401
gs
Patent Toyo Rayon Co. Fr. 1, 542, 199, v. 11.10. 1968, zit. nach CA (1969) 71:80.716s
Patent S.Wakamatsu, S.Hosaka Japan 6908, 207 v. 17.4. 1969, zit. nach CA (1969) 71:90.852x
Patent K.Maruyama, T.Kominami, T.Watanabe Japan v. 7.2. 1970, zit. nach CA (1970) 73:3.479f
Eryshev BY (1978) Zh. Khim. 1973, zit. nach CA (1979) 90:103.350b
NP
Husain S, Pratop G, Rao NR (1989) J. Chromatogr 475: 426–31, zit. nach CA (1990) 112:90.948y
NP
Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 494
EGIS Gyogyszergyar (1990) Jap Kokai Tokkyo Koho JP 02,221,266,zit. nach CA (1991) 114:81.898w
EGIS Gyogyszergyar (1990) Jap Kokai Tokkyo Koho JP 02,221,265, zit. nach CA (1991) 114:81.899x
Amos K, Auterhoff H (1979) Dtsch Apoth Ztg 119:1440
RE
Fogari R (1980) G Ital Cardiol 10:1.675–1.678
Taddei L, L’Abbate A (1985) Pharmacology 31:82–87
Cargini A, Condorelli E, Ceconi C, Curello S, Albertini A, Ferrari R (1987) Pharmacol Res Commun 19:341–357
Gupta JB, Seth SD, Singh U, Vyas DS (1989) Int Cardiol 23:165–171
Okluma M, Kanji K, Ushikubi F, Ishibashi T, Uchino H (1989) Arzneim Forsch 39:898–950
Nakagawa Y, Gudenzi M, Mustafa SJ (1986) Eur J Pharmacol 122:51–58
Nakagawa Y, Gudenza M ,Mustafa SJ (1986) Pharmacology 33:148–156
Tonini M, Perucca E, Manzo L, Marcoli M, D’ Angelo L, Saltarelli P, Onori L (1983) J Pharm Pharmacol 35:434–439
Yamauchi Y, Ikuta J, Shimizu S, Nakamura M (1990) Nippon Yakurigaku Zasshi 95:239–246
Poggesi L, Masotti G, Serneri GG, Carnovali M (1988) J Clin Pharmacol 28:43–47
Ibba GV, Terrosu P, Franceschino V, Contini GM (1986) Int J Cardiol 11:337–347
Saito D, Kusachi S, Magashima H, Haraoka S (1982) Arzneim Forsch 32:1.029–1.032
Kokayashi A, Ogawa K, Yamazaki N (1980) Jpn Heart J 21:85–94
Sambhi MP, Kannan R, Thananopavarn C, Ookhtens M, Gudenzi M (1989) J Pharm Sci 78:281–284
Lö
Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia 2. Aufl., Noyes Publications, Park Ridge, New Jersey USA, S. 494
EGIS Gyogyszergyar (1990) Jpn Kokai Tokkyo Koho JP 02,221,266, zit. nach CA (1991) 114:81898w
EGIS Gyogyszergyar (1990) Jpn Kokai Tokkyo Koho JP 02, 221, 265, zit. nach CA (1991) 114:81899x
Amos K, Auterhoff H (1979) Dtsch Apoth Ztg 119: 1440
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor Aulendorf; Spektr.-Nr. 1.419
Schriewer H, Rauen HM (1972) Arzneim Forsch 22:1455
Mannhold R, Rodenkirchen R, Bayer R, Haas W (1984) Arzneim Forsch 34:407
Daldrup T, Susanto F, Michalke P (1981) Fresenius’ Z Anal Chem 308:413
Sadana GS, Kunhipurayil PS, Sane RT (1986) Indian Drugs 23:427, zit. nach CA (1986) 105:12243f
RE
Kle82
sb
Webster LT (1985) Drugs used in the chemotherapy of protozoal infections, amebiasis, giardiasis, and trichomomiasis. In: Goodman and Gillman’s the pharmacological basis of therapeutics, 7. Aufl., McMillan Publ, New York, S. 1.050–1.051
Woodruff AW, Bell S (1960) Trans R Soc Trop Med Hyg 54:389–395
Khalil, HM, Fawzy AFA, Sarwat MA (1987) J Egypt Soc Parasitol 17:417–425
Nigam P, Dubey AL, Jain AK, Bajpeyi HS, Kala RP, Goyal BM (1978) Clinician 42:309–316
Shaldon S (1960) Trans R Soc Trop Med Hyg 54:469–470
Marsden PD (1960) Trans R Soc Trop Med Hyg 54:396–399
Ata AH, El-Haieg HO, Aboul Magd LA, Mansour AH (1984) J Egypt Soc Parasitol 14:213–218
Pehrson P, Bengston E (1983) Trans R Soc Trop Med Hyg 77:845–846
Pain AK, McKendrick GW (1979) J Infection 1:87–89
Salaki JS, Shirey JL, Strickland GT (1979) Am J Trop Med Hyg 28:190–193
Mason PR, Patterson BA (1987) Am J Trop Med Hyg 37:277–282
Viens P, Beal CC, Doucet J, Pichard JJ, Leonarth T, Musto K, N’Diri AG, Pothier MA (1972) Mèdecine d’Afrique Noire 19:541–547
Agrawal A, Pandey VC, Sagar P (1989) Zbl Bakt 271:244–248
Ey IL (1977) Ethiopian Medical J 15:101–105
Foll CV (1957) J Trop Med Hyg 60:216–217
HA
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Verlag Editio Cantor, Aulendorf
SH
Chaffman M, Brogden RN (1985) Drugs 29:387–454
Buckley MMT, Grant SM, Goa KL, McTavish D, Sorkin EM (1990) Drugs 39:757–806
Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle, John Wiley & Sons, Inc. New York
Nayler W (1990) Calcium-Antagonisten, Springer-Verlag, Berlin Heidelberg New York
Kazda S, Knorr A (1990) Calcium antagonists. In: Ganten D, Mulrow PJ (Hrsg.) Handbook of Experimental Pharmacology, Bd.93, Pharmacology of Antihypertenive Therapeutics, Springer-Verlag, Berlin Heidelberg New York, S. 301–375
Hermann P, Morselli PL (1985) Acta Pharmacol Toxicol 57(Suppl.II):12–20
Smith MS, Verghese CP, Shand DG, Pritchett ELC (1983) Am J Cardiol 51:1.369–1.374
Kölle EV, Ochs HR, Vollmer KO (1983) Arzneim Forsch 33:972–977
Morselli PL, Rovei V, Mitchard M, Durand A, Gomeni R, Larribaud J (1979) Pharmacokinetics and metabo lism of diltiazem in man (observation on healthy volunteers and angina pectoris patients). In: Bing RJ (Hrsg.) New drug therapy with a calcium antagonist; Diltiazem Hakone Symposium 78, Excerpta Medica, Amsterdam-Princeton, S.152–167
Bloedow DC, Piepho RW, Nies AS, Gal J (1980) Pharmacologist 22:3–13
Schwartz JB, Abernethy DR, Egan JM, Mitchel JR (1985) Circulation 72:50–56
js
Dibbern HW (1978), UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Verlag Editio Cantor, Aulendorf
Japan Med Gaz (1974) 11(1),12
SH
FR M5878 (1968), zit. nach CA 71:13145s
Quevauviller A, Foussard-Blanpin O, Garcet S, Levrier-Pottier J, Huyen-Vu-Ngnoc, Besancon M, Muller P (1967) Arch Int Pharmacodyn Ther 166:398–416
Ba
Mar 29, S.422
vB
Da Re P, Verlicchi L, Setnikar I (1960) Arzneim Forsch 10:800–802.
My/Ms
Vieira da Silva MJJ, Carvalho Nogueira MT, Leite Inacio MM, Marques Leal A (1965) Rev Port Farm 15:295–300
Moffat AC (Hrsg.) Clarke’s Isolation and Identification of Drugs, 2. Ed. (1986) The Pharmaceutical Press, London
My/Ms
Cusic JW (1949) Science 109:574–Cusic JW US Pat 2499058, zit. nach CA (1950) 44:4926g-Cusic JW US Pat 2534813, zit. nach CA (1951) 45:4268h
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
MP
Rochae Silva M, Antonio A (1978) Handbuch der Experimentellen Pharmakologie, Bd. 18/2, S. 417
Scarone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ (1990) Biopharmaceutics and drug dispos 11:185–189
Faingold CL (1978) Handbuch der Experimentellen Pharmakologie, Bd. 18/2, S.567
Pyykko I, Magnusson M, Schalén L, Enbom H (1988) Acta Otolaryngol 455(Suppl.):77–81
hr
Aaseth J (1983) Human Toxicol 2:257–272
Berlin M, Lewander T (1965) Acta Pharmacol Toxicol 22:1–7
Eybl V, Sýkora J, Mertl F (1965) Naunyn-Schmiedebergs Arch Exp Path Pharmak 252:79–84
Gabard B (1976) Arch Toxicol 35:15–24
Cherian MG, Vostal JJ (1973) Fed Proc 32:261
Giesen J, Koelzer P (1949) Ärztl Forsch 3:133–143
Hook G (1953) Zschr Haut Geschlkrankh 14:357–364
Wexler J, Eagle H, Tatum HJ, Magnuson HJ, Watson EB (1946) J Clin Invest 25:467–473
Carleton AB, Peters RA, Stocken LA, Thompson RHS, Williams DI, Storey IDE, Levvy GA, Chance AC (1946) J Clin Invest 25:497–527
Longcope WT, Luetscher JA, Calkins E, Grob D, Bush SW, Eisenberg H (1946) J Clin Invest 25:557–567
Orzechowski G (1964) Pharmaz Rundsch 6:41–46
Sulzberger MB, Baer RL, Kanof A (1946) J Clin Invest 25:474–479
Modell W, Gold H, Cattell M (1946) J Clin Invest 25:480–487
Fk
Ger. Offen.2, 933, 027 (1981)
Bystryakov VP, Lanin SN, Arzamastsev AP (1991) Khim Farm Zh 25:81–84
Ryabykh L, Trokhimchuck VV, Farmatsiya (Moscow) (1983) 32(3):63–66
Nazarenko VA, Rybalka VB, Medinets VI, Lepeshkin VI (1984) Zh Anal Khim 39:1.449–1.454
Rh
Wronski, Mieczyslaw (1986) Chem. Anal. (Warsaw) 31:561–566
Rh
Aaseth J (1983) Hum Toxicol 2:257–272
Aposhian HV (1983) Ann Rev Pharmacol Toxicol 23:193–215
Wiedemann P, Fichtl B, Szinicz L (1982) Biopharm Drug Dispos 3:267–274
Gabard B (1978) Arch Toxicol 39:289–298
Reuther H, Wildenauer DB, Weger N (1982) Chem Biol Interact 42:179–194
Wildenauer DB, Reuther H, Weger N (1982) Chem Biol Interact 42:165–177
Maiorino RM, Barry TJ, Aposhian HV (1987) Anal Biochem 160:217–226
Planas-Bohne F, Gabard B, Schäffer EH (1980) Arzneim Forsch 30:1291–1294
Domingo JL, Ortega A, Bosque MA, Corbella J (1990) Life Sci 46:1287–1296
Nadig J, Knutti R, Hany A (1985) Schweiz Med Wschr 115:507–511
Lund ME, Banner WJ, Clarkson TW, Berlin M (1984) J Toxicol Clin Toxicol 22:31–49
Campbell JR, Clarkson TW, Omar MD (1986) J Am Med Ass 256:3127–3130
Goebel HH, Schmidt PF, Bohl J, Tettenborn B, Kramer G, Gutmann L (1990) J Neuropath Exp Neurol 49:137–149
Iffland R, Bösche G (1987) Monatsschr Kinderheilkd 135:227–230
Chisolm JJ, Thomas DJ (1985) J Pharmacol Exp Ther 235:665–669
Donner A, Hruby K, Pirich K, Kahls P, Schwarzacher K, Meisinger V (1987) Vet Hum Toxicol 29:37
Donner A, Meisinger V, Scholtz I, Pirich K, Hruby K (1986) Toxicol Lett 31(Suppl.):154
Walshe JM (1985) Br Med J 290:673–674
Aaseth J, Halse J, Falch J (1986) Acta Pharmacol Toxicol (Copenh) 59(Suppl.7):471–474
Playford RJ, Matthews CH, Campbell MJ, Delves HT, Hla KK, Hodgson HJ, Calam J (1990) Gut 31:359–360
Bertram HP (1977) Arch Pharmacol 297(Suppl.2), R 19, No 75
Mant TGK (1985) Hum Toxicol 4:346
Schiele R, Schaller KH, Weltle D (1989) Arbeitsmed Sozialmed Präventivmed 24:249–251
Fk
Mar 29, S. 360
vB
Senoh S, Mita I (1952) J Pharm Soc Japan 72:1096–1098
Takamatsu H (1956) J Pharm Soc Japan 76:1227–1229
Parham WE, Hunter WT, Hanson R, Lahr T (1952) J Am Chem Soc 74:5646–5648
Abou El-Ella D (1983) Master Thesis, Universität Kairo
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
NE
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Senoh S, Mita I (1952) J Pharm Soc Japan 72:1096–1098
Takamatsu H (1956) J Pharm Soc Japan 76:1227–1229
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
NE
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie Verlag, Berlin, Nr. 2142
vB
Mannich C, Lesser B, Silten F (1932) Ber 65:378–385
TR
Fromherz K (1930) Naunyn-Schmiedeberg’s Arch Pharmacol 158:369–380
Dietrichs H (1931) Naunyn-Schmiedeberg’s Arch Pharmacol 161:206–213
Geßner O, Klenke J, Wurbs FR (1932) Naunyn-Schmiedeberg’s Arch Pharmacol 168:447–472
Schaumann O (1938) Naunyn-Schmiedeberg’s Arch Pharmacol 190:30–51
Hansson E (1971) Absorption, Distribution, Metabolism and Excretion of Local Anesthetics. In: International Encyclopedia of Pharmacology and Therpeutics, Section 8, Vol.1, Pergamon Press, Oxford New York Toronto Sydney Braunschweig, S. 239–260
FM
Von Seemann K (1957) US Pat 2.778.824; CA (1957) 51:10.591h
Kuhnert-Brandstaetter M, Geiler M, Wurian I (1928) Sci Pharm 50(4):324–331
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
Jane I, McKinnon A, Flanagan Rj (1985) J Chromatogr 323(2):191–225
KU
Eyer P, Kiese M, Lipowsky G, Weger N (1974) Chem Biol Interact 8:41–59
Weger N (1983) Fundam Appl Toxicol 3:387–396
Eyer P, Kiese M (1976) Chem Biol Interact 14:165–178
Eyer P (1977) Naunyn-Schmiedebergs Arch Pharmacol (Suppl II) 297:R 21, No 83
Eyer P (1978) Biotransformation of 4-dimethylaminophenol in the erythrocyte: Covalent binding and interaction with glutathione. In: Fouts JR, Gut J (Hrsg.) Industrial and environmental xenobiotics, Excerpta Medica, Amsterdam, S. 290
Jansco P, Szinicz L, Eyer P (1981) Arch Toxicol 47:39–45
Weger N (1968) Arch Toxikol 24:49–50
Kiese M, Weger N (1969) Eur J Pharmacol 7:97–105
Kiese M, Schöber JG, Weger N (1968) Naunyn-Schmiedebergs Arch Exp Path Pharmak 260:152–153
Kiese M, Szinicz L, Thiel N, Weger N (1975) Arch Toxicol 34:337–340
Elbers R, Kampffmeyer HG, Rabes H (1980) Xenobiotica 10:621–632
Szinicz L, Weger N, Schneiderhan W, Kiese M (1979) Arch Toxicol 42:63–73
Szinicz L, Weger N (1980) Xenobiotica 10:611–620
Klimmek R, Fladerer H, Weger N (1979) Arch Toxicol 43:121–133
Klimmek R, Fladerer H, Szinicz L, Weger N, Kiese M (1979) Arch Toxicol 42:75–84
Fk
Dauderer M (1981) Fortschr Med 99:1.590–1.597
Rk
Ebel S (1988) in Ebel S, Dorner W (Hrsg) Parat-Jahrbuch Chemielabor, S. 127
Eb/Jö
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
DG
Standardzulassung Nr. 6399.99.99
Standardzulassung Nr. 6399.98.98
HU
Mar 29, S. 1.325
vB
Standardzulassung Nr. 6399.99.99
Standardzulassung Nr. 6399.98.98
FA/BK
Huebner CF, Donoghue E, Wenk P, Sury E, Nelson IA (1960) J Am Chem Soc 82:2077–2078
Schmid HJ, Hunger A, Hoffman K (1956) Helv Chim Acta 39:607–618
Siek FJ, Osiewcz RJ, Bath RJ (1976) J Forensic Sci 21:525–551
Buchmann M, Kesselring UW (1978) Pharm Acta Helv 53:261
Beilsteins Handbuch der Organischen Chemie E V 22/11, 123 (System-Nr. 3.399), Springer Verlag, Berlin
MB
Reinhardt D, Borchard U (1982) Klin Wochenschr 60:983–990
Schlicker E, Schunack W, Göthert M (1990) Naunyn Schmiedebergs Arch Pharmacol 342:497–501
Malinowska B, Schlicker E (1991) Eur J Pharmacol 205:307–310
Schlicker E, Lümmen G, Behling A, Göthert M (1992) Agents Actions, Special Conference Issue:C339–C342
Nicholson AN (1991) Br J Pharamcol 104:270–276
Kubo N, Shirakawa O, Kuno T, Tanaka C (1987) Japan J Pharmacol 43:277–282
Sautel M, Towart R, Theraulaz-Lacroix M, Weitsch AF (1992) Agents Actions, Special Conference Issue:C428–C430
Thermann M, Lorenz W, Schmal A, Schingale F, Dormann P, Hamelmann H (1977) Agents and Actions 7/1:97–101
Thermann M, Lorenz W, Schmal A, Schingale F, Dormann P, Hamelmann H (1975) Agents and Actions 5/5:450–454
Lui WL, Tainsh KR, Towart R, Pearce FL (1992) Agents Actions Special Conference Issue, C302–C304
Aniol M, Riesener KP, Eichelberg D, Schmutzler W (submitted) Compararive studies of H1-antihistamines in human adenoidal mast cells (HAMC)
Leuschner F, Neumann BW, Brunnauer H, Rehn D (1992) Agents Actions, Special Conference Issue:C431–C433
Rehn D,Geißler H, Schuster O, Lukas H, Hennings G (1990) Fundam Clin Pharmacol 4:673–683
Rehn D, Geißler H, Schönbrunn U, Lukas H, Hen nings G (1990) Eur J Clin Pharmacol 39:137–141
Lorenz W, Doenicke A (1985) NER Allergy Proc 6:174–194
Lorenz W, Stinner B, Dietz W, Koller M, Rothmund M, Dick W (1992) Agents Actions, Special Conference Issue:C213–C218
Hersteller-Angaben (unveröffentlicht)
Arnera V, Wermeille M, Wellman M, Llull JB, Althaus A, Balant LP (1990) Arzneim Forsch/Drug Res 40:1.346–1.348
Radler S, Blaschke G (1991) J Chromatogr 567:229–239
May KL, Nelemans FA (1966) Acta Allergologica 21:337–342
Holzhüter H (1979) Archiv f Arzneitherap 1:74–77
Horak F, Jäger S, Andresen I (1991) Schweiz med Wschr 121 Suppl 40/II:13
Poisson A, Brunei CM (1984) Gaz Med Fr 91:65–70
Adt M, Baumert JH, Reimann HJ (1992) Brit J Anaesth 68:155–160
Tryba M, Zenz M, Thole H (1992) Agents Actions, Special Conference Issue:C238–C241
Lorenz W, Doenicke A, Schöning B, Röher D, Ohmann C, Grote B, Schmal A (1985) Prospektive Studien mit Histamin H1-und H2-Rezeptorantagonisten. In: Doenicke A, Lorenz W (Hrsg.) Histamin und Histamin-Rezeptor-Antagonisten, Springer, Berlin Heidelberg, S. 253–291
Lee A, Lader M, Kitler ME (1988) Human Psychopharmacol 3:111–117
Bieber T, Ring J (1987) Med Klin 82:683–686
Menzel K (1981) Dtsch Ärtzebl 34:1591–1596
Niederle J (1968) Dtsch Med Wschr 93:1005–1013
Würmli K (1973) Pharm Acta Helv 48:4, 200–222
sw
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Buchmann M, Kesselring UW (1978) Pharm Acta Helv 53:261–272
MP
Cheney LC, Wheatley WB, Speeter ME, Byrd WM, Fitzgibbon WE, Minor WF, Binkley SB (1952) J Org Chem 17:770–777
Walton E, Ofner P, Thorp RH (1949) J Chem Soc:648–655
Wheatley WB, Minor WF, Byrd WM, Fitzgibbon WE, Speeter ME, Cheney LC, Binkley SB (1954) J Org Chem 19:794–801
Loomans J, Demoen P (1962) Mededel Vlaamse Chem Ver 24:54–64
Picco S, Villa F (1970) Boll Chim Farm 109:17–20
gs
Cheney LC, Wheatley WB, Speeter ME, Byrd WM, Fitzgibbon WE, Minor WF, Binkley SB (1952) J Org Chem 17:770–777
Montequi R, Serrano J (1961) Anal Real Acad Farm 27:165–172
gs
Bauer F (1955) Z Tropenmed Parasitol 6:129–150
Raether W, Seidenath H (1971) Z Tropenmed Parasitol 22:66–81
Janssens PG, DeMuynck A (1977) Annales de la Societe Beige de Medecine Tropicale 57:589–592
Boch J, Supperer R (1983) Veterinärmedizinische Parasitologic, 3. Aufl., Paul Parey, Berlin Hamburg
Raether W, Hajdu P, Seidenath H, Damm D (1972) Z Tropenmed 23:418–427
Raether W, Hajdu P, Seidenath H, Damm D (1974) Tropenmed Parasiol 25:42–48
Rogers DJ (1985) Acta Tropica 42:5–23
Janssens PG, De Muynck A (1977) Ann Soc beige Mèd Soc 57:589–592
Janssens PG, Wery M, van Meirvenne N (1984) Current knowledge and prospects in the field of african trypanosomiasis. In: Boch J (Hrsg.) Tropenmedizin, Parasitologic Medizin in Entwiclungsländern ed. Diesfeld HJ Peter Lang Verlag, Frankfurt Bern New York, 11:21–37
Bailey NM (1968) Trans Roy Soc Trop Med Hyg 62:122
McDougald LR, Roberson EL (1988) Antiprotozoan drugs. In: Booth NH, McDonald LE (Hrsg.) Veterinary Pharmacology and Therapeutics, 6. Aufl., Iowa State University Press, Ames/Iowa, S. 950–968
Kuttler KL (1988) Chemotherapy of Babesiosis. In: Ristic M (Hrsg.) Babesiosis of domestic animals and man, CRC Press, Boca Raton, Florida, S. 227–243
Ruebush II TK, Rubin RH, Wolpow ER, Cassaday PB, Schultz MG (1979) Am J Trop Med Hyg 28:184–189
Newton BA (1973) Symposia Brit Soc Parasitology 11:29–51
Newton BA, Le Page RWF (1968) Trans R Soc Trop Med Hyg 62:131–132
Balana-Fouce R, Ordonez D, Alunda JM (1989) Mol Biochem Parasitol 35:43–50
Aliu YO, Oedegaard S (1985) J Pharmacokinet Biopharm 13:173–184
Aliu YO, Oedegaard S, Soegnen E (1984) Acta Vet Scand 25:593–596
Gilbert RJ, Newton BA (1982) Vet Rec 111:397
Kellner HM, Eckert HG, Volz MH (1985) Trop Med Parasitol 36:199–204
Anika SM, Onyeyili PA (1989) Trop Med Parasitol 40:419–421
Gilbert RJ (1983) Br J Pharmacol 80:133–139
Naudé TW, Basson PA, Pienaar JG (1970) Onderstepoort J Vet Res 37:173–184
Newton BA, Gilbert RJ (1982) Agrochem: Fate Food Environ Proc Int Symp 1982:255–265
Rakhmatullin EK (1989) Veterinariya (Moskau) 6:52–53
Rakhmatullin EK, Tsvetkova NI (1989) Veterinariya (Moskau) 9:60–61
Akanji MA, Ngaha EO (1989) Pharmacol Toxicol (Kopenhagen) 64:272–275
HA
Gysin H, Margot A (JR Geigy AG) Brit 713, 278 (1954); US Pat 27544343 (1956), zit. nach CA (1956) 50:1092 h
Gasser R (1953) Z Naturforschung 86:225–232
Moffat AC (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, Pharmaceutical Press, London
Stan HJ et al. (1977) Z Anal Chem 287:271–285
QO
Ero M (1974) Organophosphorus Pesticides: Organic and Biological Chemistry. Chapt. V, CRC Press, Cleveland
Food and Agriculture Organization and World Health Organization (1965) Expert Committee on Pesticide Residues, FAO Meeting Report No. PL/1965/10/1:77–83
Food and Agriculture Organization and World Health Organization (1967) Evaluation of some pesticide residues in food, FAO Meeting Report No. PL: CP/15:229–231
Food and Agriculture Organization and World Health Organization (1975) WHO Expert Committee on Pesticide Residues, WHO Techn Report Ser No. 574:11–12
Davies DB, Holub BJ (1980) Arch Environ contam Toxicol 9:637–650
Hussain MA, Oloffs OC, Blatherwick FJ, Gaunce AP, Mackenzie CGJ (1981) J Environ Sci Health 316:1–19
Boch J, Supperer, R (1983) Veterinärmed. Parasitol., Verlag Paul Parey
Ungemach FR (1991) Antiparasitika, in “Grundlagen der Pharmakotherapie bei Haus-und Nutztieren”, Hrsg. Löscher W, Ungemach FR, Kroker R, Verlag Paul Parey
Rajendra W, Oloffs PC, Banister EW (1986) Drug Chem Toxicol 9:117–131
Stalberg E, Hilton-Brown P, Kolmondin-Hedman B, Holmstedt B, Augustinsson KB (1978) Scand J Work Environ Health 4:255
Iverson F, Grant DL, Lacroix J (1975) Bull Environ Contam Toxicol 13 (5):611–618
Raffo A (1987) Obiettivi Documenti Veterinari 10:21–26
Hart RJ, Cavey WA, Ryan KJ, Moore B, Strong MB (1979) Wool Technology Sheep Breeding 27:23–27
Kirkwood AC, Quick MP (1981) Vet Rec 108:279–280
Niemand HG, Niemand S, Wendel E (1979) Kleintierpraxis 24:173–175
Rust MK, Reierson DA (1989) J Med Entomol 26:301–305
Braye G, Ndatho AK, Ansay M (1986) Ann Med Vet 130:85–89
Anthony J, Banister E, Oloffs PC (1986) Bull Environ Contam Toxicol 37:501–507
Misawa M, Doull J, Kitos PA, Uyeki EM (1981) Toxicol Appl Pharmacol 57:20–29
rk
Sojka SA, Wolfe RA (1978) Anal Chem 50(4):585–587
Neumüller AO (1985) Römpp’s Chemielexikon, Bd. 4, 8. Aufl., Franckh’sche Verlagshandlung, Stuttgart
QO
Schrör K (1984) Prostaglandine und verwandte Verbindungen, Georg Thieme Verlag Stuttgart New York, S.8,80
Corey EJ, Weinshenker NM, Schaaf TK, Huber W (1969) J Am Chem Soc 91:5675–5677
Corey EJ, Varma RK (1971) Ibid 93:7.319
BudavariS, The Merck Index (1989) 11. Aufl.Merck & Co. Inc., Rahway New Jersey
BindraJS, Bindra R (1973) Prostaglandins. In: Jukker E (Hrsg.) Fortschritte in der Arzneimittelforschung, Bd. 17, Birkhäuser Verlag, Basel Stuttgart, S. 410–487; eidem (1977) Prostaglandin Synthesis, Academic Press, New-York
Pike JE, Lincoln FH, Schneider WP (1969) J Org Chem 34:3552–3557
Schneider WP, Murray HC (1973) J Org Chem 38:397–398
Morozowich W, Douglas SL (1975) Prostaglandins 10:19–23
Leovey EMK, Anderson NH (1975) J Amer Chem Soc 97:4148–4150
Lukacs G, Piriou F, Gero SD, Van Dorp D, Hagaman E, Wenkert E (1973) Tetrahedron Lett 515–518
Salmon JA, Flower RJ (1982) Methods in Enzymology 86:477–482
Eick H (1985) Beitrag zur Analytik und Trennung von synthetischen Prostaglandinen und Begleitsubstanzen, Diplomarbeit, FB Pharmazie der Humboldt-Universität zu Berlin, S. 21
Rudzik R, Terragno A, Tacket R (1984) J Chromatogr 308:31–34
Hatsumi M, Kimata SI, Hirosawa K (1982) Ibid 253:271–274
Ikenoya S, Hiroshima O, Ohmae M, Kawabe K (1980) Chem Pharm Bull 28:2941–2945
Gb
Oettel M (1982) Pharmakologie der Fortpflanzung. In: Bentz H (Hrsg.) Veterinärmedizinische Pharmakologie, Gustav Fischer Verlag, Jena
Standardinformationen für Krankenhausapotheker über Minprostin® der Fa. Upjohn, Oktober 1987
Forth W, Henschler D, Rummel W (Hrsg.) (1987) Allgemeine und spezielle Pharmakologie und Toxikologie, Bibliographisches Institut & FA. Brockhaus, Mannheim Wien Zürich
Caldwell BV, Anderson GG, Hobbins JC, Speroff L (1972) F prostaglandin levels in women receiving PGF2α for therapeutic abortion. In: Bergström S, Green K, Samuelsson B (Hrsg.) Prostaglandin in Fertility Control, 2nd WHO-Symposium, Karolinska Institute, Stockholm, S. 182
Green K (1972) Analysis of prostaglandin F2α.-In: Bergström S, Green K, Samuelsson B (Hrsg.) Prostaglandin in Fertility Control, 2nd WHO-Symposium, Karolinska Institute, Stockholm, S. 182
Beazley JM (1972) J Obstet Gynaecol Br Commonw 79:800–807
Nishibori T, Matsuoka Y (1971) Iyakuhin Kenkuyu 2:397
Green K, Hansson E, Samuelsson B (1967) Prog Biochem Pharmacol 3:85–90
Persaud TN (1978) Exp Pathol 15:46–53
Puri CP (1975) Contraception 12:697–702
Pace-Asciak C, Wolfe LS, Gilett PG, Kinch RA (1972) Prostaglandins 1:469–475
Kindahl H, Ganström E (1983) Acta Obstet Gynecol Scand Suppl 113:15–22
Raz A (1972) Biochem J 130:631–640
Simmons KR, Moses SC, Perkins BL (1979) J Dairy Science 62:1.443–1.449
Grandström E, Samuelsson B (1971) J Biol Chem 246:7.470–7.475
Grandström E, Samuelsson B (1969) J Am Chem Soc 91:12–18
Grandström E (1972) Eur J Biochem 27:462–470
Brash AR (1976) Biochem Med 16:77–82
Jose P (1976) Brit J Clin Pharmacol 3:342P
Samuelsson B (1971) Ann NY Acad Sci 180:138–142
Tagaki S (1976) Prostaglandins 12:565–573
Zahradnik HP (1977) Geburtsh Frauenheilk 37:493–500
Corson SL (1977) Am J Obstet Gynecol 129:918–925
Jacobs MM (1980) Obstetrics & Gynecology 55:665–672
Adrinopoulos GC (1983) Am J Obstet Gynecol 147:217–222
Smith ID, Temple DM, Shearman RP (1975) Prostaglandins 10:41–50
Brash AR, Conolly ME (1978) Prostaglandins 15:983–987
Weinstein L, Drögemüller W, Greer B (1976) Obstet & Gynecol 48:469–474
Shaala S, Khowessah M, El-Damarawy H (1977) Prostaglandins 14:523–530
Laudanski T, Akerlund M (1980) Br J Obstet & Gynecol 87:132–140
Karim SMM, Sharma SD (1972) J Obstet Gynaecol Br Commonw 78:251–260
OM
Schrör K (1984) Prostaglandine und verwandte Verbindungen, Georg Thieme Verlag, Stuttgart New York, S.8
Corey EJ, Schaaf TK, Huber W, Koelliker U, Weinshenker NM (1970) J Amer Chem Soc 92:397–398
Buckingham J (Hrsg.) (1982) Dictionary of Organic Compounds, 5. Aufl., Chapman and Hall, New-York-London-Toronto, S. 1994
Gennaro AR (Hrsg.) (1990) Remington’s Pharmaceutical Sciences, 18. Aufl., Mack Publishing Company, Easton Penns., S. 944–945
Terragno A, Rydzik R, Terragno NA (1981) Prostaglandins 21:101–103
Uekema K, Hirayama F, Yamasaki S, Otagiri M, Ikeda K (1977) Chem Lett S. 1389–1392
Uekema K, Hirayama F, Tanaka H, Takamatsu K (1978) Chem Pharm Bull 26:3779–3784
ChenSML, Schaub RE, Grudzinska V (1978) J Org Chem 43:3450–3454
NakamuraN, Kiyoshi S (1978) Tetrahedron Lett,S. 1549–1552
Lukacs G, Piriou F, Gero SD, van Dorp D, Hagaman E,Wenkert E (1973) ibid., S.515–518
Takeguchi C, Kohno E, Sih Ch J (1971) Biochemistry 10:2372–2373
Eick H (1985) Beitrag zur Analytik und Trennung von synthetischen Prostaglandinen und Begleitsubstanzen, Diplomarbeit, FB Pharmazie der Humboldt-Universität zu Berlin
Siegenthaler C (1989) Pharm Acta Helv 64:345–347
Monkhouse DC, van Campen L, Aguiar AJ (1973) J Pharm Sci 62:576–580
Gb
Forth W, Henschler D, Rummel W (Hrsg.) (1987) Allgemeine und spezielle Pharmakologie und Toxikologie, 5. Aufl., Bibliographisches Institut & F.A. Brockhaus, Mannheim Wien Zürich
Standardinformation für Krankenhausapotheker über Minprostin E2 der Fa. Upjohn, Oktober 1987
Raz A (1972) Biochem J 130:631–640
Gordon D (1977) Prostaglandins 13:399–403
Samuelsson B (1987) Ann NY Acad Sci 180:138–142
Hamberg M, Samuelsson B (1969) J Am Chem Soc 91:2.177
Goeschen K (1984) Prostaglandins 28:209–215
Gordon-Wright AP, Elder MG (1979) Prostaglandins 18:153–159
Reichel R, Husslein P, Göschen K (1985) Wiener klin Wschr 97:500–507
Husslein P, Reichel R, Goeschen K, Rasche M, Sinzinger H (1984) Prostaglandins 28:209–218
Nishiburi T, Matsuoka Y, Matsumoto T (1974) Pharmacometrics 8:797–803
Nagata I, Furuya K, Imaizumi E, Seki K, Makimura N, Kato K (1988) Gynecol Obstet Invest 26:21–29
Noah ML, De Coster JM, Frase TJ, Orr JD (1987) Acta Obstet Gynecol Scand 66:3–12
Bung P, Baer S, Djahhaschahi D, Huch R, Huch A, Huber JF, Extermann P, Beguin F, Delaloye JF, Germond M, Bossart H, De Grandi P, Pfisterer A, Ehrsam A, Haller U (1986) Geburtsh u Frauenheilk 46:93–99
Goeschen K (1989) Am J Perinat 6:181–188
Rath W (1989) Gyne Aug:242–249
Hackett GA, Reginald P, Paintin DB (1989) Br J Obstet Gynaecol 96:1.432–1.439
High WB (1988) Bone 8:363–369
OM
Zemplen G, Bognar R (1943) Ber Dtsch Chem Ges 76:452
Lorette NB (1951) J Org Chem 16:930
Horowitz M (1956) J Org Chem 21:1184–1185
Briggs LH, Cambie RC, Holdgate RH, Seelye RN (1960) J Chem Soc 2:1955–1956
Nieto JL, Gutierrez AM (1986) Spectroscop Letters 19:427–434
Geiiman A (1962) Chemistry of Flavonoid Compounds, Pergamon Press, Oxford London New York Paris, S. 325
Neu R (1956) Z Anal Chem 151:328–332
Neu R (1957) Mikrochim Acta, 2. Heft:196
Casteel HW, Wender SH (1953) Anal Chem 25:508–509
Vande CK, Geiger H, Van Sumere CF (1982) J Chrom 240(l):81–94
MA
Duperay B (1982) J Proceedings of Int. Symp. on venous Disorders of lower limbs. Florence (Italy) March 1982
Heusser J, Osswald W (1977) Arch Pharmacol Toxicol III:33–40
Boudet C, Peyrin L (1986) Arch Int Pharmacodyn Ther 283:312–320
Godfraind T (1988) Inter Angio 7 (Suppl.2):17–19
Casley-Smith JR, Casley-Smith RJ (1985) Agent Actions 17:14–20
Damon M, Flandre O, Michel F, Pedrix L, Labrid C, Crastes De Paulet A (1987) Arzneim Forsch 37:1149–1153
Michel F, Mecklein L, Rey R, Crastes de Paulet A (1985) In: Farkas L, Gabor M, Kallay F (Hrsg.) Flavonoids and Bioflavonoids, Elsevier Amsterdam S. 389–401
Vargaftig BB (1988) Inter Angio 7 (Suppl.2):7–9
Witte S (1988) Thromb Res 52:111–117
Huget AI, Máñez S, Alcaraz J (1990) Z Naturforsch 45e:19–24
Lonchampt M, Guardiola B, Sicot N, Bertrand M, Perdrix L, Duhault J (1989) Arzneim Forsch 39:882–885
Mora A, Payá M, Rios JL, Alcaraz MJ (1990) Biochem Pharmacol 40:793–797
Marescaux J, Maamer M, Trenque T, Evrard S, Mutter D, Furderer C (1987) Phlebologie 40:1043–1055
Cospite M, Dominici A (1989) Inter Angio 8(Suppl.4):61–65
Muschietti B (1978) Schweiz Rundschau Med (Praxis) 67:125–128
Tajana H, Boccasanta P, Micheletto G, Orio A (1988) Min Med 79:387–390
GA
Hess K, Frahm H (1938) Chem Ber 71:2627–2636
Pouchert ChJ (1970) The Aldrich Library of Infrared Spectra
Pouchert ChJ, Campbell JR (1974) The Aldrich Library of NMR Spectra
Et
Lespagnol A, Cuingnet E (1960), Ann Pharm Fr 18:445
Hutzinger O, Heacock RA (1969), Can J Chem 47:2003–2007
Cantin D, Alary J, Coer A (1975), Analysis 3:241–245
Ba
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Rider TH (1930) J Am Chem Soc 52:1528–1530
TR
Mar 29, S. 1.215
vB
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 557
Kuhnert-Brandstätter M, Geiler M, Wurian I (1982) Sci Pharm 50:324–331
Solomonova SG, Turkevich NM, Kurinaya NV (1973) Farm Zh (Kiev) 28:56–58, zit. nach CA 79:35.196b
Clarke EGC (1969) Isolation and Identification of Drugs, Vol. 1, The Pharmaceutical Press, London, S. 315
Daenens P, Van Boven M (1971) J Chromatogr 57:319–321
Hunter K (1985) J Chromatogr 321:255–272
Houglum JE, Larson RD, Neal RM (1989) J Chromatogr 481:458–460
us
Goeber B et al. (1972) Pharmazie 27:222,230–232
Dankowa X et al. (1951) Zh Obshsh Kim 21:570,571, engl. Ausgabe S. 631,632
SH
Schild HO (1947) Br J Pharmacol 2:191–206
von Schlichtegroll A (1957) Arzneim Forsch 7:237–252
Wells JH, Morris HC, Dragstedt CA (1946) Proc Soc expBiol(N.Y) 61:104–106
Winder CV, Daiser ME, Anderson MM, Glassco EM (1946) J Pharmacol Exp Ther 87:121–131
Rekker RF, Timmerman H, Harms AF, Nauta WT (1971) Arzneim Forsch 21:688–961
Weidmann H, Petersen PV (1953) J Pharmacol Exp Ther 108:201–216
Moscati RM, Moore GP (1990) Ann Emerg Med 19:12–25
Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartseil SC (1992) Ann Emerg Med 21:237–242
Packman EW, Ciccone PE, Wilson J, Masurat T (1991) Int J Clin Pharmacol Ther Toxicol 29:218–222
Omote K, Namiki A, Iwasaki H, Ujike Y (1991) Can J Anaesth 38:210–212
Tsavaris N, Zamanis N, Zinelis A, Tsoutsos E, Mylonakis N, Baccoyannis C, Valilis P, Sarafidou M, Kosmidis P (1991) J Pain Symptom Manag 6:461–465
Berman BA (1990) J Allergy Clin Immunol 86:1004–1008
Gengo FM, Manning C (1990) J Allergy Clin Immunol 86:1034–1039
Montgomery LC, Deuster PA (1992) Med Sci Sports Exerc 24:383–388
Scavone JM, Luna BG, Harmatz JS, von Moltke L, Greenblatt DJ (1990) Biopharm Drug Dispos 11:185–189
Simons KJ, Watson WT, Martin TJ, Chen XY, Simons FE (1990) J Clin Pharmacol (1990) 30:665–671
Mar 29, Diphenhydramine, S. 452–453
Glazko AJ, Dill WA, Young RM, Smith TC, Ogilrie RI (1974) Clin Pharmacol Ther 16:1066–1087
Wagner JG (1977) J Pharmacokinet Biopharm 5:161–182
Saxen I (1974) Lancet 1:407–408
Editorial (1979) Br med J 1:459
Borkenstein M, Haidvogl M (1978) J Pediatr 92:167–168
sw
Dibbern HW (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Verlag Editio Cantor Aulendorf
Andrews AC, Lyons TD, O’Brien TD (1962) J Chem Soc, 1776
de Roos AM, Recker RF, Nauta WT (1970) Arzneim Forsch 20:1763
Goeber B et al. (1972) Pharmazie 27:222,230–232
Knobloch E et al. (1954) Collect Czech Chem commun 19:976,980, zit. nach CA (1955) 49:2425e
Gruhzit OM, Fisken RA (1947) J Pharmacol Exp Ther 89:277
SH
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 558–559
Janssen PAJ (4.8.1959) U.S.Patent 2898340, zit. nach CA (1960) 54:2367a
Stead AH, Gill R, Wright T, Gibbs JP, Moffat AC (1982) Analyst 107:1106–1168
Jane I, Mc Kinnon A, Flanagan RJ (1985) J Chromatogr323(2):191–225
WP
Awouters F, Niemegeers CJE, Janssen PAJ (1983) Ann Rev Pharmacol Toxicol 23:279–301
Bianchi C, Goi A (1977) Arzneim-Forsch 27:1.040–1.043
Niemegeers CJE, McGuire JL, Heykants J, Janssen PAJ (1979) J Pharmacol Exp Ther 210:327–333
Rubens R, Verhaegen H, Brugmans J, Schuermans V (1972) Arzneim-Forsch 22:513–516
Dajani EZ, Roge EA, Bertermann RE (1975) Eur J Pharmacol 34:105–113
Ylitalo P, Svinhufvud U, Anttila P, Laasonen L, Gothoni G (1975) Arzneim-Forsch 25:1.081–1.082
Valiulis E, Long JF (1973) Physiologist 16:475
Zavecz JH, Jackson TE, Limp GL, Yellin TO (1982) Eur J Pharmacol 78:375–377
Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) (1990) Goodman and Gilman’s The pharmacological basis of therapeutics, 8. Aufl., Pergamon, New York, S.507
van Wijngaarden I, Soujdin W (1972) Arzneim-Forsch 22:513–516
Heykants J, Brugmans J, Verhaegen H (1972) Arzneim-Forsch 22:529–531
Karim A, Ranney RE, Evensen KL, Clark ML (1972) Clin Pharmacol Ther 13:407–419
Karim A, Garden G, Trager W (1971) J Pharmacol Exp Ther 177:546–555
Mar 29, S. 1.087
Harford WV, Krejs GJ, Santa Ana CA, Fordtran JS (1980) Gastroenterol 78:440–443
Palmer KR, Corbett CL, Holdsworth CD (1980) Gastroenterol 79:1.272–1.275
Glatt MM, Lewis DM, Wilson TS (1973) Br J Addict 65:237–243
Ammon HPT (Hrsg.) (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 386–388
Gilman AG, Rall TW, Nies AS, Taylor P (Hrsg.) (1990) Goodman and Gilman’s The pharmacological basis of therapeutics, 8. Aufl., Pergamon, New York, S. 925
Curtis JA, Goel KM (1979) Arch Dis Child 54:222–225
Ahmad S (1980) JAMA 243:1.036
Ammon HPT (Hrsg.) (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 575
Ammon HPT (Hrsg.) (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 91
McGuire JL, Awouters F, Niemegeers CJE (1978) Arch Int Pharmacodyn Ther 236:51–59
Wasserman GS, Green VA, Wise GW (1975) Am Farn Physician 11:93–97
Anonymus (Leading Article) (1973) Br Med J II:678–679
Figiel LS; Figiel SJ (1973) Am J Gastroenterol 59:267–270
Rubinstein JS (1979) West J Med 131:148–150
PK
Mills III T, Roberson JC (1987) Instrumental Data for Drug Analysis 2. Aufl., Elsevier Science Publishing Co, New York, S. 762–763
Jalal IM, Sa’sa SI, Abusaleh AH, Khalil H (1985) Anal Lett 18:2551–2568
WP
Schuler WA (1951) DBP 934890 (Promonta), zit. nach CA (1958) 52:20065I
Beil Erg.Werk 3/4, Bd.21, Teil 1,S.42III/IV21/l,S.42
Testa B, Murset-Rossetti L (1978) Helv Chim Acta 61:2530–2537
MP
Lung MA, Wang JC (1987) Rhinology 25:95–100
Mattes J (1979) Psychopharmacol Bull 15:5–6
Mar 29, Diphenylpyraline, S.454
EH
Siek TJ, (1974) J Forensic Sci 19:193–214
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, The Pharmaceutical Press, London
MP
Mar 29, S. 1.459
vB
Barrelet C, Saner H, Surber W, Ursprung R, Wagner Jauregg T (1959) Ind Chim Beige Suppl 2:428–431, zit. nach CA (1960) 54:3758i
Imai Z, Natori M, Saito K, Miyagi Y, Shinohara K (1966) Japan 71006:417, zit. nach CA (1971) 75:63236a
Daldrup T, Susanto F, Michalke P (1981) Fresenius Z Anal Chem 308:413–427
Attali B, Vogel Z (1990) Brain Res 517(1–2): 182–188
Chesis PL, Griffeth LK, Mathias CJ, Welch MJ (1990) J Nucl Med 31(2):192–201
Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AK (1991) J Cereb Blood Flow Metab ll(l):1–9
Dissanayake VU, Hughes J, Hunter JC (1991) Mol Pharmacol 40:93–100
Herman BH, Holtzman SG (1984) Life Sci 34(1):1–12
Jones AK, Luthra SK, Maziere B, Pike VW, Loc’h C, Crouzel C, Syrota A, Jones T (1988) J Neurosci Methods 23 (2): 121–129
Jones AK, Qi LY, Fujirawa T, Luthra SK, Ashburner J, Bloomfield P, Cunningham VJ, Itoh M, Fukuda H, Jones T (1991) Neurosci Lett 126:25–28
Leander JD, Hynes MD (1983) Eur J Pharmacol 87(4):481–484
Sadzot B, Mayberg HS, Frost JJ (1990) Neurophysiol Clin20(5):323–334
Skorupska M, Langwinski R (1989) Pol J Pharmacol Pharm41(5):401–411
KG
US 2575344 (1951), CA (1952) 46:1722
Roth HJ (1959) Arch Pharm 292:234–8
Holy A (1978) Cool Czechoslov Chem Commun 43:2054–61
Bram G, Bensaid Y, Combet-Farnoux C, Galons H, Miocque M (1985) Pharmazie 41:431
Holy A, Vanecek M (1979) Coll Czechoslov Chem Commun 44:2550–5
Brandstätter M, Grimm H (1956) Mikrochim Acta 1175–82
In Dibbern HW (Hrsg) (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor Aulendorf
In: Moffat AC (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press London
In: Pouchert CJ (Hrsg) The Aldrich Library of FT-IR Spectra, Aldrich Chemical Co., Inc., Milwaukee 1989, Bd2S.711
In: Hansch C, Sammes PG, Taylor JB (Hrsg) Comprehensive Medicinal Chemistry, Pergamon Press Oxford 1990, Bd. 6 S. 477
Paterson N (1982) J Chromatogr. 232:450–5
Aldrich-Chemie GmbH, Katalog/Handbuch 1990–91
Simons KJ, Simons FER (1979) J Pharm Sci 68:1327–8
NP
Maney RV, Jones JW, Gross EG, Korns HM (1946) J Am Pharm Ass 35:266–272
Boardman LE (1980) Br J Pharmacol 70:120p–121p
Kukovetz WR, Pöch G, Holzmann S (1983) Arzneim Forsch 33:1450–1454
Levine ER (1965) Am Allergy 23:403–413
Simons FER, Biermann CW, Sprenkle AC, Simons KJ (1975) Pediadrics 56 (Suppl.):916–918
Furukawa CT, Shapiro GG, Weliky I, Pierson WE, Biermann CW (1982) J Allergy Clin Immunol 69:136
Stablein JJ, Samaan SS, Bukantz SC, Lockey RF (1983) Eur J Clin Pharmacol 25:281–283
SZ/KC
Holy A, Vanecek M (1979) Coll Czechoslov Chem Commun 44:2550–2555
Ba
Klosa J (1955) Arch Pharm 288:301–303
DE 924085 (1953), zit. nach CA (1958) 52:2101
Ba
Kráčmar J, KráčmarovaJ, Bokovikova TN, Čičiro VE, Néstérova GA, Suranova AV, Trius NV (1989) Pharmazie 44(11):768–771
Moffat AC (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S.562–563
ImaiK,InukaiN,IshidaT, OzasaT,KawaharaS, Murakami M (1976) Yakugaku Zasshi 96(5):593–599, zit. nach CA (1976) 85:108.603t
Zoest AR, Wanwimolruk S, Watson JE, Hung CT (1991) J Liq Chromatogr 14:1967–1975
Tuncel M, Yazan Y, Dogrukol D, Atkosar Z (1991) Anal Lett 24:1837–1846
BararyMH, El-Sayed MAH, Abdel-Hay MH (1989) Anal Lett 22:1643–1664
Kigasawa K, Shimizu H, Hayashida S, Ohkubo K (1984) Yakugaku Zasshi 104:1191–1197, zit. nach CA (1984) 102:137.650f
WP
Fitzgerald GA (1987) N Engl J Med 316:1.247–1.257
Harker LA, Kadatz RA (1983) Thromb Res Suppl 4:39–46
Rivey MP, Alexander MR, Taylor JM (1984) Drug Intell Clin Pharm 18:869–880
Marcus ML, Chilian WM, Kanatsuka H, Dellsperger KC, Eastham CL, Lamping KG (1990) Circulation 82:1–7
Luthje J (1989) Blut 59:367–374
Young JD, Jarvis SM (1983) Biosci Rep 3:309–322
Chesebro JH, Adams PVC,FusterV (1986) J Am Coll Cardiol 8(Suppl. B):41B–56B
Frishman WH, Miller KP (1986) Curr Probl Cardiol 11:69–136
Weiss HJ (1980) Circulation 62 (6 Pt 2):V41–V43
Rowe GG, Folts JD (1990) Clin Cardiol 13:165–170
Iskandrian AS, Heo J, Askenase A, Segal BL, Auerbach N(1988) Am Heart J 115:432–443
Nienaber CA, Spielmann RP (1988) Dtsch Med Wochenschr 113:1.029–1.033
Younis LT, Chaitman BR (1990) Clin Cardiol 13:3–10
LÖ
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London, S. 565–566
Jane I, Mc Kinnon A, Flanagan RJ (1985) J Chromatogr 323(2):191–225
PatelRB, Gandhi TP, Patel VC, Patel SK, Gilbert RN 1983 Indian J Pharm Sci 45(3):129–130
Vasiliades JW (1979) Clin Chem 25:1900–1904
WP
Vaughan Williams EM (1975) Pharmac Ther B1:115–138
Kus T, Sasyniuk BI (1975) J Pharmacokinet Biopharm 4:231–242
Birkhead JS, Vaughan Williams EM (1977) Br Heart J 39:657–660
Baines MW, Davies JE, Kellett DN, Munt PL (1976) J Int Med Res 4 (Suppl 1):5–7
Böcker K, Köhler E, Seipel L, Loogen F (1982) Z Kardiol 71:839–845
Bryson SM, Whiting B, Lawrence JR (1978) Br J Clin Pharmacol 6:409–419
Hinderling PH, Garrett ER (1976) J Pharmacokin Biopharmac 4:199–230
Brogden RN, Todd PA (1987) Drugs 34:151–187
Norris RLG, Ahokas JT, Ravenscroft PJ, Henry M (1984) J Pharm Sci 73:824–826
Bonde J, Graudal NA, Pedersen LE, Balslov S, Angelo HR, Svendsen TL, Kampmann JP (1986) Eur J Clin Pharmacol 31:73–77
Karim A (1975) Angiology 26:85–98
Burk M, Peters U (1983) Clin Pharmacol Ther 34:331–340
Ilett KF, Madsen BW, Woods JD (1979) Clin Pharmacol Ther 34:331–336
Landmark K, Bredesen JE, Thaulow E, Simonsen S, Amlie JP (1981) Eur J Clin Pharmacol 19:187–192
Baumann JL, Gallastegui J, Strasberg B, Swiryn S, Hoff J, Welch WJ, Bauernfeind RA (1986) Am Heart J 111:654–660
Smith WS (1978) Herz 3:399–406
Kumana CR, Rambihar VS, Tanser PH, Cairns JA, Gupta RN, Wildeman RA, Johnston M, Johnson AL, Gent M (1982) Br J Clin Pharmacol 14:519–527
Porterfield JG, Antman EM, Lown B (1980) N Engl J Med 303:584
Podrid PJ, Schoeneberger A, Lown B (1980) New Engl J Med 303:614–617
Riccioni N, Castiglioni M, Bartolomei C (1983) Am Heart J 105:870–871
Nicholson WJ, Martin CE, Gracey JG, Knoch HR (1979) Am J Cardiol 43:1.053–1.055
Camm J, Ward D, Spurrell RAJ (1979) Br J Clin Pharmacol 8:441–449
Desai JM, Scheinman MM, Hirschfeld D, Gonzales S, Peters RW (1981) Chest 79:545–551
Kg/gl
Dibbern HW (1991) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf, S. 1438
Harvey CS, Withrow CD (1990) Cardiovascular Drugs. In: Remington’s Pharmaceutical Sciences, 18. Aufl., Mack Publishing Company, Easton Pennsylvania, S. 849
WP
Miller KW, Paton WDM, Smith EB, Smith RA (1972) Anesthesiol 36:339–351
Gillman MA (1986) Life Sci 39:1.209–1.221
Gillman MA (1986) Am J Med 81:97–102
Koblin DD (1990) Semin Surg Oncol 6:141–147
Yagiela JA (1991) Anesth Progr 38:1–11
Ruprecht J, Erdmann W, Dzoljic M, van Stolk MA (1989) Anaesthesiol Reanim 14:251–259
Yasuda N, Lockhart SH, Eger EI, Weiskopf RB, Johnson BH, Freire BA, Fassoulaki A (1991) Anesthesiol. 74:489–498
Smiley RM (1992) Anesth Anaig 75:Suppl 4, S38–S44
Koren G, Sloan I (1985) Res Commun Chem Pathol Pharmacol 49:95–108
Brodsky JB, Cohen EN (1986) Med Toxicol 1:362–374
Meulenbelt J, Sangster B (1990) Neth J Med 37:132–138
Schumann D (1990) Int Nurs Rev 37:214–217
Aldridge LM, Tunstall ME (1986) Birt J Anaesth 58:1.348–1.356
Johnson RA (1979) Practitioner 222:681–683
Ermens AA, Schoester M, Spijker LJ, Lindemans J, Abels J (1989) Cancer Res 49:6.337–6.341
vB
Schmid O (1957) US 2789981, zit. nach CA (1958) 52:2090b
Kuhnert-Brandstätter M, Kofier A, Kramer G (1974) Sci Pharm 42:150–163
Kracmar J, Kracmarova J, Stejskal Z (1987) Pharmazie 42:18–22
Daltrup T, Michalke P, Boehme W (1982) Chromatogr Newsl 10:1–7
Abdelkader MA, Taha AM, Abdelfattah S (1980) Pharmazie 35:30–32
Dessouky YM, Gad el Rub LN (1980) Pharm Weekbl Sci Ed 2:153–156
Tokuji S, Yuichi T (1970) Yakugaku Zasshi 90:762–770, zit. nach CA (1970) 73:592600v
Goldstein A (1944) J Gen Physiol 27:529–580
Grob D (1958) J Chron Dis 8:536–566
Grob D (1963) Therapy of myasthenia gravis. In: Koelle GB (Hrsg.) Handbuch der experimentellen Pharmakologie. Ergänzungswerk XV, Springer, Berlin Göttingen Heidelberg, S. 1028–1050
Herzfeld E, Kraupp O, Pateisky K, Stumpf C (1957) Wien Klin Wschr 69:245–248
Eyirik K, Taniguchi H, Ishihara K, Hara Y, Baba S (1990) Diabetes Res Clin Pract 8:193–199
Hampf G, Bowsher D, Nurmikko T (1989) Anesth Prog 36:58–62
Yamaba H, Yasue H, Okumura K, Ogawa H, Obata K, Oshima S (1990) Am Heart J 120:211–213
GA
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, 2nd Ed., The Pharmaceutical Press, London
Gupta VD (1981) Am J Hosp Pharm 38:363–364
Agarwal RP, McPherson R, Phillips M (1983) Res Commun Chem Pathol Pharmacol 42:293–310
LA
Kitson TM (1977) J Stud Alcohol 38:96–113
Sauter AM, Boss D, von Wartburg J-P (1977) J Stud Alcohol 38:1.680–1.695
Anonym (1991) Disulfiram. In: Henschler D (Hrsg.) Gesundheitsschädliche Arbeitsstoffe, VCH Verlagsgesellschaft Weinheim, 1.-17. Lieferung, S. 1–11
Jacobsen E (1967) Med Welt 18(N.F.):2.169–2.173
Brien JF, Loomis CW (1983) Drug Metab Rev 14:113–126
Kwentus J, Major LF (1979) J Stud Alcohol 40:428–446
Jacobsen E (1967) Med Welt 18(N.F.):2.230–2.234
Deutsche Forschungsgemeinschaft (1992) MAK-und BAT-Werte-Liste 1992, Maximale Arbeitsplatzkonzentrationen und Biologische Arbeitsstofftoleranzwerte, Mitteilung 28 der Senatskommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe, VCH Verlagsgesellschaft, Weinheim, S. 42
Fk
Klem EB (1978) J Invest Dermatol 70:27–32
Reichert U, Jaques Y, Grangeret M, Schmidt R (1985) J Invest Dermatol 84:130–134
Jaques Y, Reichert U (1981) Brit J Dermatol 105 (Suppl20):45–48
Fisher LB, Maibach HI (1975) J Invest Dermatol 64:338–341
Fuchs J, Zimmer G, Wölbing RH, Miklbradt R (1986) Arch Dermatol Res 279:59–65
Morlière P, Dubertret L, Sae Melo T, Salet C, Fosse M, Santus R (1985) Brit J Dermatol 112:509–515
Swanbeck G, Lindquist P (1972) Acta Derm Venerol 52:94–98
Morlière P, Dubertret L, Sae Melo T, Salet T, Santus R (1983) J Invest Dermatol 80:350
Steigleder KG, Schumann H, Lennartz KJ (1973) Arch Derm Forsch 246:231–235
Schäfer H, Schalla W, Shroot B (1981) Zbl Haut-Geschl Krankh 146:273–282
Schalla W, Bauer E, Schaefer H (1981) Brit J Dermatol 105(Suppl20):104–108
Selim MM, Goldberg LH, Schaefer H, Bishop SC, Farber EM (1981) Brit J Dermatol 105 (Suppl 20):101–103
Shroot B, Schaefer H (1989) Anthralin. In: Greaves MW, Shuster S (Eds.) Pharmacology of the skin II, Heffter-Heubner Hdbch exper Pharmak 87/II, Springer, Berlin Heidelberg New York
Kammerau B, Zesch A, Schaefer H (1975) J Invest Dermatol 64:145–149
Krebs A, Schaltegger H, Schaltegger A (1981) Brit J Dermatol 105 (Suppl 20):6–11
Farber EM, Nall L (1984) Drugs 28:324–346
Ippen H (1981) Brit J Dermatol 105 (Suppl 20):72–75
Schaefer H, Farber EM, Goldberg L, Schalla W (1980) Brit J Dermatol 102:571–573
Runne U, Kunze J (1982) Brit J Dermatol 106:135–140
Ingram JT (1953) Brit Med J 2:591
Schauder S, Mahrle G (1982) Hautarzt 33:206–209
Gay MW, Moore WJ, Morgan JM, Montes LF (1972) Arch Dermatol 105:213–215
Lawlor F, Hindson C (1982) Contact Dermatits 8:137–138
Mar 29, S. 919–920
Green PG (1985) Brit J Dermatol 113 (Suppl 29):26
Gs
Sycheva TP, Savitskaya NV, Shchukina MN (1953) Sbornik Statei Obshchei Khim Akad Nauk S.S.S.R 1:568–71, zit. nach CA (1955) 49:955c
Tashika Y, Nitta Y, Yomoda J (1954) J Pharm Soc Japan 74:1193–1195
Dunstan S, Henbest HB (1957) J Chem Soc 4:4905–4908
Laboratoires Lumiere and Institut Merieux, Fr. M 2587 (C1.A 61k,C07c) 1964, Appl. 1963, zit. nach CA (1965) 62:489f
Singer GM, Lijinsky W, Rainey WT (1975) Org Mass Spectrom 10:473–479
MA
Ruigh WL, Major RT (1931) J Am Chem Soc 53:2662–2668
Clague ADH, Danti A (1967) J Mol Spectroscopy 22:371–382
Hull LA (1978) J Org Chem 43:2776–2780
Martin RW (1949) Anal Chem 21:921–922
EK
Mar 29, S. 1.127
vB
Barany G, Schroll AL, Mott AW, Halsrud DA (1983) J Org Chem 48:4750–4761
Beil Hauptwerk Bd. 3, S.215; Beil Erg. Werk 1, Bd. 3, Teil 4, S.85 Beil Erg. Werk 2, Bd. 3, Teil 4, S. 154 Beil Erg. Werk 3, Bd.3, Teil 1, S.349 Beil Erg. Werk 4, Bd. 3, Teil 1,S. 416
PA
Morren HG (1958) Belg Pat 566958, zit. nach CA (1960)54:594d
Clarke’s Isolation and Identification of Drugs, (1986) The Pharmaceutical Press, London
Ebel S (1977) Handbuch der Arzneimittel-Analytik, Verlag Chemie, Weinheim
Kreyenbühl B, Joshi RK, Perlia X (1979) Pharm Acta Helv 54:197–205
Eigene Messung
Musumarra G, Scarlata G, Cirma G, Romano G, Palazzo S, Clementi S, Giulietti G (1985) J Chromatogr 350:151–168
MP
Larsson S, Hagerdal M, Lundberg D (1988) Acta Anaesthesiol Scand 32:131–134
Kivalo I, Rosenberg P (1976) Ann Chir Gynaecol 65:28–29
Berg S, Dehlin O, Falkheden T, Gatzinska R, Nordquist P (1977) Scand J Soc Med Suppl 14:85–96
Sorbe B, Hallen C, Skare NG, Underskog I (1989) Radiother Oncol 15:161–167
Goransson AM (1979) Scand J Gastroenterol 14:961–967
Westergren I, Johansson BB (1991) Acta Neurochir Wien 113:171–175
Liedholm J, Liden A, Kroon L, Melander A, Wahlin-Boll E (1985) Drug Nutr Interact 3:87–92
Poulsen J (1981) Acta Derm Vernereol Stockh 61:85–88
EH
Tuttle R R, Mills J (1973) French Patent 2, 182, 947; Ger Offen 2, 317, 710; (1976) U S Patent 2.987, 200, zit. nach CA (1977) 86:72167
Gb
Goldberg LT, Hsieh YY, Resnekov L (1977) Prog Cardiovasc Dis 19:327–340
Lipman J, Plit M (1984) S afr Med J 65:506–509
Majerus TC, Dasta JF, Mauman JL, Danzinger LH, Ruffolo RRjr (1989) Pharmacotherapy 9:245–259
Rude RE (1983) Adv Shock Res 10:35–49
Sonnenblick EH, Fristman WH, LeJemtal TH (1979) N Engl J Med 300:17–22
Adams HR (1984) J Am Vet Assoc 185:966–974
Ruffolo RR jr (1987) Am J Sci 249:244–248
Sharp DN (1984) Methods Fin Exp Clin Pharmacol 6:215–218
Ruffolo RR, Kopia GA (1986) Am J Med 80:67–72
Colucci WS (1990) Circulation 82(Suppl.): 144–151
Driscoll DJ (1987) Clin Perinatol 14:931–949
Andersson KE (1986) Acta Med Scand (Suppl.)707:65–73
Dixon DW, Loeb HS, Gunnar RM (1979) Herz 4:385–396
Bhatt-Mehta V, Nahata MC (1989) Pharmacotherapy 9:303–314
Mauro VF, Mauro LS (1986) Drug Intell Clin Pharm 20:919–924
Thomas LR, Watson D, Marshall LE (1987) Pharmacotherapy 7:47–53
Lö
Moffat AC, Jackson JV, Moss MS, Widdop B (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London S. 568–569
Mills III T, Roberson JC (1987) Instrumental Data for Drug Analysis, 2. Aufl., Elsevier, New York Amsterdam London, S. 780–781
Hardee GE, Lai JW (1983) Analyt Lett (Part B) 16:69–75
Gb
Handbook of Pharmaceutical Excipients (1986) American Pharmaceutical Association, Washington, USA, S. 106–107
BK
Gilman AG, Rall TW, Nies AS, Taylor P (1990) Goodman and Gilman’s The pharmacogical basis of therapeutics, 8. Aufl., Pergamon, New York, S. 922
Mar 29, S. 1088
Tedesco FJ (1985) Am J Gastroenterol 80:303–309
Chapman RW, Sillery J, Fontana DD, Matthys C, Saunders DR (1985) Gastroenterology 89:489–493
Goodman J, Pang J, Bessmann AN (1976) J Chron Dis 29:59–63
Mar 28, S. 1441
Lish PM (1961) Gastroenterology 41:580–584
Gaginella TS, Stewart JJ, Gullikson GW, Olsen WA, Bass P (1975) Life Sci 16:1595–1606
Bretagne JF, Vidon N, L’Hirondel CH, Bernier JJ (1981) Gut 22:264–269
Moriarty KJ, Kelly MJ, Beetham R, Clark ML (1985) Gut 26:1008–1013
Saunders DR, Sillery J, Rachmilewitz D (1975) Gastroenterology 69:380–386
Beubler E, Juan H (1979) J Pharm Pharmacol 31:681–685
Nell G, Rummel W (1984) Action mechanisms of secretagogue drugs. In: Handb Exp Pharmacol 70/II Csaky TZ (Hrsg.), Springer, Berlin, S. 482–487
Rachmilewitz D, Karmeli F, Okon E (1981) Isr J Med Sci 17:28–35
Donowitz M, Binder HJ (1975) Gastroenterology 69:941–950
SimonB,KatherH(1980) Eur J ClinInvest 10:231–234
Gullikson GW, Cline WS, Lorenzsonn V, Benz L, Olsen WA, Bass P (1977) Gastroenterology 73:501–511
Gaginella TS, Lewis JC, Phillips SF (1977) Am J Dig Dis 22:781–790
Landsverk T, Oltedal E, Sund RB (1984) Acta Pharmacol Toxicol 54:22–32
Anonymus (1974) Dioctyl sodium sulphosuccinate-Biological data. WHO food additives, series No. 6
DujovneCA, Shoeman DW (1972) Clin Pharmacol Ther 13:602–608
Ammon HPT (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 382–384
Schindler AM (1984) Lancet 2:822
Jodhka GS, Gouda MW, Medora RS, Khalil SA (1975) J Pharm Sci 64:1858–1862
Jodhka GS, Gouda MW, Medora RS, Khalil SA (1976) J Pharm Sci 64:1319–1332
Ammon HPT (1981) Arzneimittelneben-und Wechselwirkungen, Wissenschaftliche Verlagsgesellschaft, Stuttgart, S. 10
Khallafallah N, Gouda MW, Khalil SA (1975) J Pharm Sci 64:991–994
PK
Mar 29, S. 1.360
vB
Negwer M (1989) Organisch-chemische Arzneimittel und ihre Symptoma, 5. Aufl., Bd. 11, Akademie Verlag, Berlin, S. 1.018
ak
USA Patent (USP) 1976 Nr. 4066772
Vandenberk J, Kennis LEJ, Van der AMJMC, Van Heertum AAMTh (1977) Ger. Offen.:101–110, zit. nach CA (1984) 101:23274c
Zarapkar SS, Salunkhe BB (1990) Indian Drugs 27(10):537–540, zit. nach CA (1992) 116:28304q
Shah Y, Khanna S, Jindal KC, Dighe VS (1990) Indian J Pharm Sci 52(2):100–101, zit. nach CA (1991) 114: 109049w
Rao GR, Kini GR, Avadhanulu AB, Vatsa DK (1990) East Pharm 33(389):133–135, zit. nach CA (1991) 113: 218365w
Al-Khamis KI, Hagga MEM, Al-Khamees HA, Al-Awadi M (1990) Anal Lett 23(3):451–460, zit. nach CA (1991) 113:103520a
mh
Wienbeck M, Barnert J (1990) Z Gastroenterol 28(Suppl. l):22–26
Champion MC (1988) Gen Pharmacol 19:499–505
Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP (1986) J Clin Pharmacol 26:628–632
hr
Waser E, Sommer H (1923) Helv Chim Act 6:54–61
Schöpf C, Bayerle H (1934) Liebigs Ann Chem 513:190–202
Hahn G, Siehl K (1936) Chem Ber 69:2627–2654
NE
KohliJD, Glock D, Goldberg LI (1982) Adv Biochem Psychopharmacol 35:97–108
Stoof JC, Kebabian JW (1984) Life Sci 35:2.281–2.296
Dawson TM, Gehlert DR, Wamsley JK (1986) Adv Exp Med Biol 204:93–118
Beart PM (1989) Clin Exp Pharmacol Physiol 16:511–515
Brodde OE (1982) Life Sci 31:289–306
Goldberg LI (1972) Pharmacol Rev 24:1–29
Farah AE, Alousi AA, Schwarz RP jr (1984) Annu Rev Pharmacol Toxicol 243:275–328
Scholz H (1984) J Amer Coll Cardiol 4:389–397
Colucci WS (1989) Cardiol Clin 7:131–144
Kleinschmidt R, Spannbrucker N, Vogel F (1985) Dtsch med Wochenschr 110:598–603
Lee MR (1982) Clin Sci 62:439–448
Smit AJ (1989) Neth J Med 34:47–58
Lokhandwala MF, Barrett RJ (1982) J Auton Pharmacol 2:189–215
Crexells C, Bourassa MG, Biron P (1973) Cardiovasc Res 7:436–445
Balakumaran K, Hugenholtz PG (1986) Drugs 32:372–382
Pop T, Erbel R, Henrichs KJ, Esser MJ, Meyer J (1986) Dtsch Med Wochenschr 111:1.118–1.120
Smith CB, Jacobson JA (1986) Dis Mon 32:77–118
Schwarz R, Aviado DM (1976) J Clin Pharmacol 16:88–98
Loeb HS, Winslow EBJ, Rahimitoola SH (1971) Circulation 44:163–173
Goldberg LI, Hsieh YY, Resnekov L (1977) Prog Cardiovasc Dis 19:327–340
Rajfer SI, Goldberg LI (1982) Eur Heart J 3:103–106
Dasta JF, Kirby MG (1986) Pharmacotherapy 6:304–310
Horn AS (1976) Postgrad Med J 52:25–32
Mt
Waser E, Sommer H (1923) Helv Chim Act 6:54–61
Hahn G, Siehl K (1936) Chem Ber 69:2627–2654
Carter JE, Johnson JH, Baaske DM (1982) Dopamine Hydrochloride. In Ana, Bd. 11, S. 257–272
Dibbern H W, Wirbitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor Aulendorf
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
NE
Dahl LE, Dencker SJ, Lundin L (1981) J Int Med Res 9:103–107
Blacker R, Shanks NJ, Chapman N, Davay A (1988) Psychopharmacology 95:S18–S24
Deering RB, Vallè-Jones JC (1974) Curr Med Res Opin 2:471–473
Dorman T (1980) J Int Med Res 8:286–292
Lambourn J, Rees JA (1974) J Int Med Res 2:210–213
Mendlewicz J, Linkowski P, Rees JA (1980) Br J Psychiatry 136:154–160
Eilenberg D (1980) New Zealand Med J 91:92–93
Evans L, Cox J (1981) Med J Australia 2:147–148
General Practitioner Research Group (1976) Practitioner 216:581–583
Shopsin B, Cassano GB, Conti L (1981) An overview of new „second generation“ antidepressant compounds: research and treatment implications. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 219–251
Lancaster SG, Gonzalez JP (1989) Drugs 38:123–147
Lipsedge MS, Linford Rees W, Pike DJ (1971) Psychopharmacologia 19:153–162
Takahashi R, Tsuiki D, Hironaka I, Kusumoto S, Kurihara M (1983) Clin Evaluations 11:201–228
Ishikawa K, Shibanoki S, Kubo T, Watanabe S, Matsumoto A, Kogure M (1986) Eur J Pharmacol 120:63–68
Richelson E, Pfenning M (1984) Eur J Pharmacol 104:277–286
Shein K, Smith SE (1978) Br J Pharmacol 62:567–571
Richelson E, Nelson A (1984) J Pharmacol Exp Ther 230:94–102
Sulser F (1983) Psychopharmacol Bull 19:300–304
Yu DK, Dimmitt DC, Lanman RC, Giesing DH (1986) J Pharm Sci 75:582–585
Maguire KP, Burrows GD, Norman TR, Scoggins BA (1981) Br J Clin Pharmacol 12:405–109
Nakra BRS, Glass RC, Rees JA (1977) J Int Med Res 5:391–397
Rees JA (1981) J Int Med Res 9:98–102
Ogura C, Kishimoto A, Mizukawa R, Hazama H, Honma H (1983) Eur J Clin Pharmacol 25:811–814
Sieberns S (1985) Therapiewoche 35:5.805–5.815
RM
DFG (1985) Gas Chromatographic Retentions Indices of Toxicologicaly Relevant Substances, Verlag Chemie
Ab
Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2.Aufl., Noyes Publications, Park Ridge, New Jersey, USA, S. 536
Lunsford CD, Cale AD jr, Ward JW, Franko BV, Jenkins H (1964) J Med Chem 7:302
Tamada M, Morita K, Ishii S, Arikawa S (1975) Iyakuhin Kenkyu 6:17, zit. nach CA (1975) 88:141592y
RE
Locke RG, Salvia JV (1990) J Am Osteopath Assoc 90:602–604 und 607–612
hr
Sittig M (1988) Pharmaceutical Manufacturing Encyclopedia, 2. Aufl., Noyes Publications, Park Ridge New Jersey, USA, S. 536
Salim EF, Martin AE (1967) J Pharm Sci 56:748
Masumarra G, Scarlata G, Cirma G, Romano G, Palazzo S, Clementi S, Giulietti G (1985) J Chromatogr 350:151
Daldrup T, Susanto F, Michalke P (1981) Fresenius’ Z Anal Chem 308:413
RE
Goodman LS, US-Pat. 2,744,852 (1956), zit. nach CA (1957)51:487d
PA
Negwer M (1987) Organic-chemical Drugs and their Synonyms, Akademie-Verlag, Berlin
vB
Ribbentrop A, Schaumann W (1965) Arzneim Forsch 15:863–868
Pinder RM, Brogden RN, Speight TM, Avery GS (1977) Drugs 13:161–218
Sieberns S (1985) Therapiewoche 35:5.805–5.815
Sugrue MF (1981) Chronic antidepressant administration and adaptive changes in central monoaminergic systems. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 13–30
Richelson E, Pfenning M (1984) Eur J Pharmacol 104:277–286
Baldessarini RJ (1989) J Clin Psychiatry 50:117–126
Baldessarini RJ (1982) McLean Hosp J 7:1–27
Richelson E (1981) Tricyclic antidepressants: Interaction with histamine and muscarinic acetylcholine receptors. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 53–73
Peroutka SJ, Snyder SH (1981) Interactions of antidepressants with neurotransmitter receptor sites. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 75–90
Møller-Nielsen I (1980) Tricyclic antidepressants: General pharmacology. In: Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychotropic agents Part I: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New York, S. 399–414
Shein K, Smith SE (1978) Br J Pharmacol 62:567–571
Schönhöder PS, Schwabe U (1989) Therapeutischer Einsatz von Psychopharmaka. In: Fülgraff G, Palm D (Hrsg.) Pharmakotherapie. Klinische Pharmakologie. Gustav Fischer Verlag, Stuttgart New York, S.232–251
Mobley PL, Sulser F (1981) Down regulation of central noradrenergic receptor system by antidepressant therapies: Biochemical and clinical aspect. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 31–51
Sulser F (1983) Psychopharmacol Bull 19:300–304
Babington RG (1981) Neurophysiologic techniques and antidepressive activity. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 157–173
Ziegler VE, Biggs JT, Wylle LT, Rosen SH, Hawf DJ, Coryell WH (1978) Clin Pharmacol Ther 23:573–579
Abernethy DR, Todd EL (1986) J Clin Psychopharmacol 6:8–12
Baldessarini RJ (1990) Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P (Hrsg.) Goodman and Gilman’s The pharmacological basis of therapeutics, 8th edition. Macmillan, New York, S. 383–435
Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE (1983) Clin Pharmacol Ther 34:509–515
Pollock BG, Perel JM (1989) Can J Psychiatry 34:609–617
Friedel RO, Raskind MA (1975) Relationship of blood levels of Sinequan® to clinical effects in the treatment of depression in aged patients. In: Mendels J (Hrsg.) Sinequan: A monograph of recent clinical studies. Elsevier, New York, S. 51–53
Sutherland DL, Remillard AJ, Haight KR, Brown MA, Old L (1987) Eur J Clin Pharmacol 32:159–164
Scheinin M, Virtanen R, Iisalo E (1985) Int J Clin Pharmacol Ther Toxicol 23:38–42
Hobbs CD (1969) Biochem Pharmacol 18:1.941–1.954
Kimura Y, Kume M, Kageyama K (1972) Pharmacometrics 6:955–971
Biggs JT, Preskom SH, Ziegler VE, Rosen SH, Meyer DA (1978) J Clin Psychiatry 39:740–742
Risch SC, Janovsky DS, Huey LY (1981) Plasma levels of tricyclic antidepressants and clinical efficacy. In: Enna SJ, Malick JB, Richelson E (Hrsg.) Antidepressants: Neurochemical, behavioral, and clinical perspectives. Raven Press, New York, S. 183–217
Möller HJ, Kissling W, Wendt G, Stoll KD (1989) Psychopharmakotherapie. Kohlhammer Verlag, Stuttgart, S. 143–169
Haase HJ (1982) Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten, 5.Aufl., Schattauer Verlag, Stuttgart New York
Baker CE (1985) (Hrsg.) Physicians desk reference, 39. Aufl., Medical Economics Comp., Oradell NJ
Thomann P, Hess R (1980) Toxicology of antidepressants. In: Born GVR, Farah A, Herken H, Welch AD (Hrsg.) Handbook of experimental pharmacology, Vol. 55/I. Hoffmeister F, Stille G (Hrsg.) Psychotropic agents Parti: Antipsychotics and antidepressants. Springer-Verlag, Berlin Heidelberg New York, S. 527–549
Vohra J, Burrows G, Hunt D, Sloman G (1975) Eur J Cardiol Excerpta Medica 3:219–227
Elonen E (1974) Med Biol 52:415–423
Elonen E, Mattila MJ, Saarnivaara L (1974) Eur J Pharmacol 28:178–188
RM
Vigevani A, Williamson MJ (1980) Doxorubicin In: Florey K (Hrsg.) Ana 9:245–274
Aleksandrova LG, Rubasheva LM, Zbarskii VB, Salimova EI, Brazhnikova MG (1986) Antibiotiki i Meditsinskaya Biotekhnologiya 31:851– (1987) 106:56004d
WM
Seeber S (1981) Molekulare, zelluläre und klinische Pharmakologie von Adriamycin. In: Füllenbach D, Nagel GA, Seeber S (Hrsg.) Adriamycin Symposion.Ergebnisse und Aspekte, Beitr Onkol, Karger, Basel 9:1–15
Peterson C, Paul C (1983) Pharmacokinetics of doxorubucin and daunorubicin. In: Hansen HH (Hrsg.) Anthracyclines and cancer therapy. Excerpta Medica, Elsevier Science Publishers BV, Amsterdam, S.7–12
Di Marco A (1894) Epirubicin: mechanism of action at the cellular level. In: Bonadonna G (Hrsg.) Advances in anthracycline chemotherapy: epirubicin, Masson Italia Editori, Milano, S. 41–50
DiMarco A, Acarmone F (1975) Adriamycin and its mechanism of action. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent,Belgium, S. 11–24
Bachur NR (1983) Mechanism of action of doxorubicin. In: Hansen HH (Hrsg.) Anthracyclines and cancer therapy. Excerpta Medica, Elsevier Science Publishers BV, Amsterdam, S. 2–5
Pigram WJ, Fuller W, Hamilton LD (1972) Nature (New Biol) 235:17–19
Harteel JC, Duarte-Karim MM, Karim OS, Arlandini E (1975) Some physicochemical properties of adriamycin and adriamycin-DNA complex. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin Review, European Press Medikon, Ghent, Belgium, S. 27–36
Ward DC, Reich E, Goldberg IH (1965) Science 149:1.259–1.263
Schwartz HS (1975) Res Commun Chem Pathol Pharmacol 10:51–64
Dasdia T, Di Marco A, Goffredi M, Minghetti A, Necco A (1979) Pharmacol Res Commun 11:19–29
Carafoli E (1983) Effect of anthracyclines on calcium and phosphate transport membrane systems of heart cells. In: Abstr of the Fourth NCI-EORTC Symposion on new drugs in chemotherapy, Brüssel, Abstr. 13
Casazza AM, Isetta AM, Giuliani M, Di Marco A (1975) Immunodepressive activity of daunomcin and adriamycin. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin Review, Eurpean Press Medikon, Ghent, Belgium, S. 121–131
Benjamin RS, Riggs CE, Bachur NR (1977) Cancer Res 37:1.416–1.420
Ehninger RG, Stocker H, Wilms K (1981) Metabolisierung und Ausscheidung von Adriamycin. In: Füllenbach D, Nagel GA, Seeber S (Hrsg.) Adriamycin Symposion. Ergebnisse und Aspekte, Beitr Onkol, Karger, Basel 9:16–25
Dorr RT, Alberts DS (1982) Pharmacology of doxorubicin. In: Jones SE (Hrsg.) Current concepts in the use of doxorubicin chemotherapy, Farmitalia Carlo Erba, Milano, Italy, S. 3–20
Wilkinson PM (1978) Clinical pharmacology of adriamycin. In: Pinedo HM (Hrsg.) Clinical pharmacology of anti-neoplastic drugs, Elsevier North-Holland Biomedical Press, S. 209–223
Bachur NR, Hildebrand RC, Jaenke RS (1974) J Pharmac Exp Ther 191:331–340
Liss RH, Jesair DW, Schepis JP (1977) Proc Am Ass Cancer Res 18:221
Lee YTN, Chan KK, Harris PA, Cohen JL (1980) Cancer 45:2.231–2.239
Lenaz L, DiFronzo G, Molinari R (1975) Distribution of daunomycin and adriamycin in man. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 89–99
Rosso R, Ravazzoni C, Esposito M, Sala R, Santi L (1972) Europ J Cancer 8:455–459
Riggs CF, Benjamin RS, Serpik AA, Bachur NR (1977) Clin Pharmacol Ther 22:234–238
Takanshi S, Bachur NR (1976) Drug Metab Disp 4:79–87
Dorr RT, Alberts TS (1982) Brit J Cancer 45:35–43
Chan KK, Chlebowski RT, Tong M, Chen HSG, Gross JF, Bateman JR (1980) Cancer Res 40:1.263–1.269
Benjamin RS, Wiernik PH, Bachur NR (1974) Cancer 33:19–27
Goldin A, Johnson RK (1975) Antitumor effect of adriamycin in comparison with related drugs, and in combination chemotherapy. In: Staquet M, Tagnon H, Kenis Y (Hrsg.) Adriamycin and its mechanism of action. Adriamycin Review, European Press Medicon, Ghent, Belgium, S. 7–54
Davis HL, Davis TE (1979) Cancer Treat Rep 63:809–815
Dedrick RL, Myers CE, Bungay PM, De Vita VT Jr (1978) Cancer Treat Rep 62:1–11
Ozols RF, Young RC, Speyer JL, Weltz M, Collins JM, Dedrick RL, Myers CE (1980) Proc AACR/ASCO 21:C-423
Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Cancer Treat Rep 64:47–51
Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich E (1982) Ann Intern Med 96:133–139
Creasey WA, Mcintosh LS, Brescian T, Odujinrin O, Aspnes ST, Murray E, Marsh JC (1976) Cancer Res 36:216–221
Bristow M, Thompson PD, Martin RP, Mason J, Billingham M, Harrison DC (1978) Am J Med 68:823–832
Höfling B (1984) Die Anthracyclin Kardiotoxizität, Kehrer, Freiburg
Couch RD, Loh KK, Sugino J (1981) Cancer 48:38–39
Worthman JE, Lucas VS, Schuster E, Thiele D, Logue GL(1979) Cancer 44:1.588–1.591
Toussaint R, Löser H, Stuppenreich E, Bachour G (1979) Herz/Kreisl 11:363
LeFrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) Cancer 32:302–314
Mikkelsen RB, Lin PS, Wallach DFH (1977) J Molec Med 2:33–40
Minow R, Benjamin R, Gottlieb J (1975) Cancer Chemother Rep 3:195–201
Minow RA, Benjamin RS, Lee ET, Gottlieb JA (1977) Cancer 39:1.397–1.402
Marzin D, Jasmin C, Maral R, Mathe G (1983) Eur J Cancer Clin Oncol 19:641–647
Mw
Vigevani A, Williamson MJ (1980) In: Florey K (Hrsg) Ana 9:245–274
Clarke EGC (1974) Isolation and Identification of Drugs, The Pharmaceutical Press, London S. 575
WM
Stephens CR et al. (1963) J Am Chem Soc 85:2643–2652 Gd
Popov N (1982) Z Ärztl Fortbild 76:624–633
Witte W, Klare I, Halle E, Spencker FB, Böhme G (1990) Z Klin Med 45:1389–1393
Münnich D (1988) Ther Hung 36:47–50
Walther H, Meyer FP (1987) Klinische Pharmakologie antibakterieller Arzneimittel, Urban & Schwarzenberg, München Wien Baltimore, S.245–262
Fabre J, Milek E, Kalfopoulos P, Merier G (1971) Schweiz Med Wochenschr 101:593
Meyer FP, Specht H, Quednow B, Walther H (1988) Zentbl Pharm Pharmakother Lab Diagn 127:2–5
Keller M, Bezler H, Nieder M (1988) Dtsch Apoth Ztg 128:1565–1571
Campistron G, Coulais Y, Caillard C, Mosser J, Pontagnier H, Houin G (1986) Arzneimittelforschung 36:1705–1707
Weingärtner L, Weigel W, Patsch R, Radzuweit H (1970) Zentbl Pharm Pharmakother Lab Diagn 109:477–482
Bocker R, Mühlberg W, Platt D, Estler CJ (1986) Eur J Clin Pharmacol 30:105–108
Heaney D, Eknoyan G (1978) Clin Pharmacol Ther 24:233–239
Ludwig E, Arr M, Deutsch T, Graber H (1976) Zentbl Pharm Pharmakother Lab Diagn 118:193–196
Meyer FP, Specht H, Quednow B, Walther H (1989) Infection 17:245–246
Rüinzi J, Gikalov I, Durand R (1987) Muench Med Wochenschr 129:163–164
Hoigné R, Keller H, Sonntag R (1988) Penicillins, cephalosporins and tetracyclines. In: Dukes MNG (Hrsg.) Meyler’s side effects of drugs, Elsevier, Amsterdam New York Oxford, S. 501–542
Hummel S, Müller W (1990) Medikamentum 31:59–61
Neuvonen PJ, Penttilä O (1974) Eur J Clin Pharmacol 7:361–363
Venho VMK, Salonen RO, Mattila MJ (1978) Eur J Clin Pharmacol 14:277–280
Pentillä O, Neuvonen PJ, Aho K, Lahtovaara R (1974) Br Med J:470–472
Neuvonen PJ, Penttilä O, Lehtovaara R, Aho K (1975) Eur J Clin Pharmacol 9:147–154
Garaffo R, Dellamonica P, Fournier JP, Lapalus P, Bernard E (1988) Infection 16:297–298
Neuvonen PJ, Penttilä O, Roos M, Tirkkonen J (1976) Int J Clin Pharmacol 14:303–307
fm/Wh
McCormick JRD et al. (1960) J Am Chem Soc 82:3381–3386
Stephens CR (1963) J Am Chem Soc 85:2643–2652
Casy AF, Yasin A (1985) Magn Res Chem 23:767–770
Asleson GL, Frank CW (1975) J Am Chem Soc 97:6246–6248
Jäger H et al. (1980) Arzneim-Forsch 30:1932–1943
Gd
McCormick JRD et al. (1960), J Am Chem Soc 82:3381–3386
Gd
Jap Pat 80 10,576 (TokkyoKoho), zit. nach CA (1980) 93:168021b
Gd
Tilford CH, Shelton RS, Van Campen MG (1948), J Am Chem Soc 70:4001–4009
Sperber N, Papa D, Schwenk E, Sherlock M (1949), J Am Chem Soc 71:887–890
Beil Erg. Werk 3/4, Bd. 21, Teil 2, S. 1434
Fricke FL (1972), J Assoc Off Anal Chem 55:1162–1167
Musumarra C, Scarlata G, Cirma G, Romano G, Palazzo S, Clementi S, Giulietti G (1985), J Chromatogr 350:151–169
Beil Erg. Werk 5, Bd. 21, Teil 3, S.508
MP
Feinberg SM, Bernstein TB (1948) J Lab clin Med 33:319–324
Haas H (1951) Histamin und Antihistamine, Aulendorf i. Württ, Editio Cantor
Brown BB, Werner HW, Peters EL (1948) J Lab clin Med 33:325–331
Marsh DF, Davis AJ jr (1947) J Pharmacol Exp Ther 89:234–246
Sjoqvist F, Lasagna L (1967) Clin Pharmacol Ther 8:48–54
Snyder FH, Klahm GR, Werner HW (1948) J Am Pharm Assoc 37:420–423
Favis GR (1976) New Engl J Med 294:730
sw
Dibbern HW (1978) UV- und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Edito Cantor, Aulendorf
Eigene Messung
MP
Miescher K, Hoffmann K (1941) Helv Chim Acta 24:458–462
Mndzhoyan OL, Bagdasaryan ER, Asratyan SN (1968) Arm Khim Zh 21:981–984 CA (1969) 70:106.150j
Gb
Blicke FF (1944) Ann Rev Biochem 13:549
Lands AM, Luduena FP (1956) J Pharmacol Exp Ther 117:331–346
Weston AW (1946) J Org Chem 68:345–348
Meier R, Hoffmann K (1940/41) Helv Med Acta 7, Suppl. 6:106–125
Necheles H, Olson HW, Neuwelt F, Spier E (1944) Gastroenterology 2:46–59
Fleisch A, Formanek K, Habicht E, Weis W (1961) Arzneim Forsch 11:1119–1126
Gilman A, Goodman L, Thomas JM, Hahn GA, Prutting JM (1942) J Pharm Exper Ther 74:290–298
Geigy (1990) Fachinfo zu Spasmo-Cibalgin S und Spasmo-Cibalgin compositum S
Wiegand UW, Weder HG, Haller R (1975) Arzneim Forsch 25:839–843
KC
Dibbern HW, Wirlitzki E (1978) UV-und IR-Spektren wichtiger pharmazeutischer Wirkstoffe, Editio Cantor, Aulendorf
Facchini G, Zaccheo F, Nannetti M (1983) Boll Chim Farm 122:405–411
Longree R, Bosly J (1975) Michrochim Acta 1975:321–336
Cieszynski T (1974) Acta Pol Pharm 31:99–107
Gb
Ruenitz PC, Bagley JR, Mokker CM (1982) J Med Chem 25:1056–1060
AE
Aubry U, Carignan G, Charette D, Lavallee JP (1966) Canad Anaesth Soc J 13:263–271
Corssen G, Chodoff P (1965) Neuroleptanalgesia. In: Orkin L (Hrsg.) Clinical management of the patient in shock, F. A. Davis Comp., Philadelphia, S. 137–154
Cressman WA, Plostnieks J, Johnson PC (1973) Anesthesiology 38:363–369
Etschenberg E (1973) Anaesthesie mit Droperidol und Fentanyl, Editio Cantor, Aulendorf
Heininger K, Siebers S (1992) Pharmakologie. In: Riederer P, Laux G, Pöldinger W (Hrsg.) Neuro-Psychopharmaka, Bd.4, Springer-Verlag, Wien, S. 17–43
Janssen PAJ, Niemegeers CJE, Schellekens KH, Verbruggen FJ, van Neuten JM (1963) Arzneim Forsch 13:205–211
Janssen PAJ, Allewijn FTN (1969) Arzneim Forsch 19:199–208
Janssen PAJ, van Bever WFM (1983) Butyrophenone and Diphenylbutylamine. In: Hippius H, Klein HE (Hrsg.) Therapie mit Neuroleptika, perimed Fachbuch-Verlagsgesellschaft mbh, Erlangen, S. 13–53
Hyttel J, Larsen J-J, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. In: Casey DE, Chase TN, Christensen AV, Gerlach J (Hrsg.) Dyskinesia-Research and Treatment, Springer-Verlag, Berlin Heidelberg, S. 9–18
Kuemmerle H-P (1989) Klinisch-Pharmakologische Arzneimittelprofile. Droperidol, ecomed
Soudijin W, van Wijngaarden I, Allewijn F (1967) Eur J Pharmacol 1:47–57
OT
Morren HG (1961) Belg. Pat. 601394, zit. nach CA (1962) 56:2460d
Moffat AC, Jackson JV, Moss MS, Widdop B (Hrsg.) (1986) Clarke’s Isolation and Identification of Drugs, 2. Aufl., The Pharmaceutical Press, London
Cavazutti G, Gagliardi L, Amato A, Profili M, Zagarese V, Tonelli D, Gattavecchia E (1983) J Chromatogr 268:528–534
Musumarra G, Scarlata G, Cirma G, Romano G, Palazzo S, Clementi S, Giulietti G (1985) J Chromatogr 350:151–168
Bourdais J (1968) Bull Soc Chim France: 3246–3249
KU
Bossi R, Lavezzo A (1988) Preliminary data: levodropropizine prevent fog induced bronchospasm in asthmatic allergic hyperreactive patients, 2nd Int Meeting on Respiratory Allergy, Sorrento, Italy 21–23 April, S. 96
Malandrino S, Melillo G, Bestetti A, Borsa M, Guiliani P, Tonon GC (1988) Arzneim Forsch 38:1141–1143
Melillo G, Malandrino S, Rossoni G, Caselli G, Bestetti A, Borsa M, Tonon GC, Berti F (1988) Arzneim Forsch 38:1144–1150
Bastos-Ramos WP, Fortes VA, Ramos AC (1984) Rev Ciènc Bioméd 5:27–32
Kurz H (1989) Antitussiva und Expektoranzien, Wissenschaftliche Verlagsgesellschaft, Stuttgart
SZ
Ringold HJ, Batres E, Halpern O, Necoechea E (1959) J Am Chem Soc 81:427–432
WM
Ringold HJ, Batres E, Halpern O, Necoechea E (1959) J Am Chem Soc 81:427–432
WM
Cooperative Breast Cancer Group (1961) Cancer Chemother Rep 11:119
Dorfman RJ, Baba S, Abe O et al. (1968) The influence of drostanolone on a rat mammary fibroadenoma and carcinogen-induced adeno-carcinoma. In: Jarett AS (Hrsg.) The treatment of carcinoma of the breast, Exerpta Medica, Amsterdam, S. 15
Deshpande N, Jensen V, Bulbrook RD (1967) Steroids 10:219
Trams G (1977) Europ J Cancer 13:149
Thomas AN, Gordan GS, Goldman L et al. (1962) Cancer 15:176
OJ
Seki I, Kitami M (1967/1968) S. African Pat. 03407, zit. nach CA (1969) 71:39247b
KU
Profft F (1952) Chem Tech 4:241–246, zit. nach CA (1953) 47:10531d
TR
Mar 29, S. 1.215
vB
Jager FC, Michielsms PMLJ, Minter B, Post LC, De Wachter AM, Williams JGC, Zwagenmakers JMA (1988) Summary of the properties of dydrogesterone, Duphar BV, Weesp, The Netherlands
Boris A, Stevenson RH, Trmal T (1966) Steroids 7:7–10
Neumann F (1968) Chemische Konstitution und pharmakologische Wirkung. In: Junkmann K (Hrsg.) Handbuch der experimentellen Pharmakologie, BandXXII/1, Die Gestagene, Teil 1, Springer-Verlag, Berlin Heidelberg New York
Lauritzen C (1989) Stellungnahme zur klinischen Indikation on Dydrogesteron, 15.12.1989, Duphar BV, Weesp, The Netherlands
Kupfermic MJ, Lessing JB, Amit A, Yoel J, Daid MP, Peyser MR (1990) Human Reproduction 5:271–279
Coutts JR, McNally EM, McEwan HP (1983) Br J Clin Pract 24:27–33
De Cleyn K, Buytaert P, Delbeke L, Gerris J (1986) Eur J Obstet Gynecol Reprod Biol 23:201–209
Jesinger DK (1987) The effects of endometrial histology and blood lipids of 10 or 20 mg dydrogesterone for the first 12 days per month to counteract unopposed oestrogen therapy in postmenopausal women, Duphar report No.H. 102.913/M, Duphar Laboratories Ltd., Gaters Hill, Southampton
Lacey RW, Howson GL, Sampson GA (1983) Br J Clin Pract 24:4–10
Lane G, Siddle NC, Ryder TA, Pryse-Davies J, Endacott J, Whitehead MJ (1982) Int Med 2, 1:13
Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MJ (1986) Br J Obstet Gynecol 93:55–62
Lane G, Whitehead MJ, King RJB (1982) Int Med 2:13–18
Serfaty D, Bestaux Y, Brun JP, Malgonyat J, Sally F, Legal M (1986) Contraception-fertilité-sexualité 14:641–648
Soutoul JH, Rozenbaum H, Racinet C, Pauchet H, Netter A (1983) Gynécologique 34:473–470
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
von Bruchhausen, F. et al. (1993). D. In: von Bruchhausen, F., et al. Hagers Handbuch der Pharmazeutischen Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57995-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-57995-0_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63429-1
Online ISBN: 978-3-642-57995-0
eBook Packages: Springer Book Archive